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Synthetic materials have been successful in applications requiring large-diameter 
(>5 to 6 mm) vascular substitutes. However, in smaller diameter applications such as 
peripheral vascular repair below the knee or coronary bypass are not effective due to 
serious thrombosis and hemostasis. It has been recognized that established paradigms 
based on natural systems provide strategies to design functional biomaterials ad hoc to 
improve the performance of synthetic grafts. Particularly, the biological membrane has 
been used as a model system for the development of biosensors, drug delivery systems, 
and surface modified medical devices. We postulate that membrane-mimetic systems, 
incorporating with biologically functional substances, may offer a useful approach to 
improve the long- term efficacy of the synthetic grafts by modulating surface-mediated 
blood coagulation. 
The membrane-mimetic construct contains polymeric phospholipid monolayer on 
an alkylated polyelectrolyte multilayer supported by planar substrate such as glass or 
silicone. When incorporated with thrombomodulin (TM), a transmembrane protein 
constitutively expressed by endothelial cells, the model platform exhibited the biological 
function by facilitating activation of protein C, which is a potent anticoagulant. Surface 
TM-medicated protein C activation was extensively studied under flow conditions by 
perfusion of protein mixture at 50 and 500 sec-1, the physiologic venous and arterial shear 
rates, respectively. Significantly, surface TM activity was limited in the presence of TM 
surface density more than 800 fmole/cm2 due to a transport limitation. By storing the 
surface in human plasma and investigating surface activity under the same flow 
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conditions periodically, we found the stability of TM bioactivity can retain up to two 
months. In addition to creating a TM- incorporated membrane-mimetic thin film, we also 
immobilized heparin based on the same membrane-mimetic construct as an alternative 
for potential antithrombogenic system. The heparinized surface was fabricated by 
anchoring biotin-conjugated heparin onto biotinylated phospholipid membrane through 
biotin-streptavidin binding interactions. Surface heparin activity was investigated to 
determine its catalytic efficiency for thrombin inactivation by perfusion of thrombin and 
antithrombin at shear rates of 50 and 500 sec-1. The efficiency on thrombin decay can not 
be improved significantly in the presence of heparin surface density more than 4.4 
pmole/cm2, indicating mass transport of reactants onto catalytic surface is the rate-
limiting factor.  
We designed a membrane-mimetic-system-based tissue factor (TF)-coated surface as a 
vascular injury-mimetic system to initiate thrombin generation. The purpose of this 
design was to determine antithrombogenic capacity of the above two surface 
anticoagulants. We investigated thrombin responses by perfusion of  a mixture of 
relevant coagulation proteins and inhibitors over a composite surface system containing 
TF positioned at the upstream and TM and/or heparin at the downstream of the flow. 
Although initial thrombin generation cannot be completely inhibited in the presence of 
TM and heparin, they have potential to shut down thrombin generation completely at the 
end of perfusion. Due to the complexity of intertwined effects of transport and surface 
reactions on regulation of thrombin generation, we attempt to work on a mathematical 
model to provide in depth analyses of the experimental results as a future work. In 
addition, we will try  to investigate the capacity of the surface anticoagulants to inhibit 
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coagulation in vitro using human plasma or blood. Ultimately, we are looking forward to 











Atherosclerosis remains a serious source of morbidity and death despite advances in 
preventive measures and pharmacological therapeutics. Surgical treatment of vascular 
disease has become a common medical procedure. Nearly 700,000 vascular surgical 
procedures are performed annually in the United States along with several hundred 
thousand peripheral and coronary angioplasties(1). Prosthetic bypass grafts and, more 
recently, arterial stents and other endovascular prostheses have been utilized in 
association with these reconstructive procedures. Although vascular grafts have been 
successfully developed from polymers such as polytetrafluoroethylene (PTFE) and 
polyethylene terephthalate, the use of synthetic materials is limited to large diameter 
grafts (> 6 mm internal diameter) due to the frequency of occlusion observed with 
synthetic vessels of small caliber. Consequently, significant efforts in the past 20 years 
have focused on improving clinical durability of small caliber vascular prostheses. 
Surface modification has become one of proposed approaches, which here particularly 
involves introducing biological materials that are actively antithrombogenic.  
It is recognized that the adverse events leading to the failure of many vascular 
prostheses are related to maladaptive biological reactions at the blood-material and 
tissue-material interface. Attempts to improve performance of grafts have been made by 
coating with clotting inhibitor such as albumin and prostacyclin analogues, or inert 
materials like polyethylene oxide (2, 3), which turned out to be a failure due to 
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overwhelming platelet activation and coagulation. An alternative approach has been used 
to design materials which support the in situ regeneration of an endothelial cell lining in 
order to create a functional arterial substitute with a durable thromboresistant interface (4, 
5), which ironically led to a more thrombogenic surface due to incomplete coverage or 
loss of cells.   
Endothelial cells lining the blood vessels and regulating biological mechanisms in 
blood leads to the hypothesis that the cell membrane establishes an important paradigm 
for the design of an antithrombogenic surface because of its capacity to participate in 
molecular recognition processes that are physiologically relevant to the control of blood 
coagulation. Based on mechanisms of regulation of blood coagulation, we consider 
heparin and thrombomodulin, which respectively facilitate inactivation of several 
coagulation factors and protein C anticoagulant pathway, as critical factors for 
antithrombogenicity. Consequently, we believe that a membrane-mimetic assembly 
serving as a platform for the presentation of biological regulators provides a rational 
design strategy for surface modification of synthetic prostheses.  
 
1.2 GOAL AND SPECIFIC AIMS 
Our central hypothesis is that a membrane-mimetic system will provide a route for 
generating an actively antithrombogenic surface thereby enhancing the patency of small-
caliber arterial bioprostheses. In this regard, our goal was to create a well-characterized 
membrane-mimetic construct featuring immobilized functional anticoagulants and 
determine their antithrombogenic capacities. 
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Specific aims of the thesis were (1) Characterizing the catalytic capacity of surface 
bound TM to catalyze protein C activation, (2) Characterizing surface bound heparin to 
facilitate thrombin inactivation by antithrombin, (3) characterizing surface bound TF-
induced thrombin generation as a vascular injury model, and  4) Determining 
antithrombogenic capacities of surface bound TM and heparin to inhibit surface TF-
induced thrombin generation. 
In this thesis, general background information including a membrane-mimetic surface 
containing physiologically significant regulators for thrombus formation and the effect of 
flow on surface enzyme activity was introduced in CHAPTER 2. There are four distinct 
topics presented in CHAPTERS 3-6. Characterization of surface bound thrombomodulin 
(TM) and heparin based on membrane-mimetic assemblies are presented in CHAPTER 3 
and 4, respectively. Specifically, we determined surface densities of both surface 
anticoagulants and studied surface bioactivity under flow conditions. In CHAPTER 5, we 
designed a membrane-mimetic construct containing tissue factor (TF), which is a 
physiologic trigger for blood coagulation, as a vascular injury model. We observed that 
surface TF can exhibited activity by inducing thrombin generation, which provides 
strategies for determining antithrombogenic capacities of surface TM and heparin, which 
is described in CHAPTER 6. A composite system was designed by combining TF, TM 
and/or heparin on a membrane-mimetic surface in order to investigate effects of surface 
bound TM and/or heparin on TF-induced thrombin generation. Following these four 
chapters, applications and limitations of current model systems are discussed in 
CHPATER 7. Significant outcomes from the results of this research are summarized in 
CHAPTER 8 and recommendations for future work are in CHAPTER 9.   
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The use of synthetic materials to fabricate a blood vessel substitute began in the 
1950s and has led to vascular prostheses made from a wide variety of materials, including 
nylon, Teflon, Orlon, Dacron, polyethylene, and polyurethane (4). Among them, 
expanded poly(tetrafluoroethylene) (e-PTFE), and Dacron remain the most widely used 
synthetic materials. Although these materials have been very successful in the use of 
large-diameter (> 5 to 6 mm) substitutes (6), their use in small-caliber vascular substitutes 
remains ineffective (7, 8). Graft failure is associated with thrombogenicity (9-11). Natural 
blood vessels have endothelial cells (ECs) lining the interior of the vessel wall and these 
cells synthesize several inhibitors of clot formation such as plasminogen activators, 
heparin, and thrombomodulin (12). Since ECs are not present in synthetic grafts, no 
inhibitors are released to stop the clot formation once the coagulation cascade is triggered. 
This has led to the impetus for developing composite devices incorporating biological 










         
TF: Tissue Factor 
Intrinsic Pathway PL: phospholipid 
PK: Prekallikrein 
HMWK K: Kallikrein 
Figure 1  The blood coagulation cascades. The intrinsic cascade is initiated when 
contact is made between blood and surfaces. The extrinsic pathway is 
initiation upon vascular injury which leads to exposure of tissue factor (TF) 
(also identified as factor III), a subendothelial cell-surface glycoprotein that 
binds phospholipid. The two pathways converge at the activation of factor X 
to Xa. Factor Xa has a role in the further activation of factor VII to VIIa as 
depicted by the dashed arrow. Active factor Xa hydrolyzes and activates 
prothrombin to thrombin. Thrombin can then activate factors VIII and V 
furthering the cascade. Ultimately the role of thrombin is to convert fibrinogen 
to fibrin and to activate factor XIII to XIIIa. Factor XIIIa cross-links fibrin 
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2.2 REGULATION OF BLOOD COAGULATION 
It is commonly accepted that the blood coagulation cascade (Figure 1) is initiated in 
vivo when subendothelial tissue factor (TF) is exposed and/or expressed to the blood flow 
following vascular injury (13-17).  Tissue factor functions in coagulation by serving as a  
protein cofactor for the plasma serine protease, factor VIIa, already present in blood (18, 
19). The formation of TF-VIIa enzyme complex in turn activates two zymogens, factor 
IX and factor X (20-23). The serine protease factor Xa induces generation of trace 
amounts of thrombin (in picomolar scale (14, 24, 25)) in the initial phase of coagulation. 
Generated thrombin triggers positive feedback reactions by activating coagulation factors 
V and VIII to form Va and VIIIa (24, 26, 27), which serve as cofactors of Xa to form 
prothrombinase complex and cofactor of IXa to form tenase (intrinsic factor Xase), 
respectively. Since tenase and prothrombinase are primary activators of factor X and 
prothrombin (28-30), the generation of thrombin is quickly and largely amplified due to 
activation of factors V and VIII (24, 31) and continuous positive-feedback reactions. 
Moreover, thrombin activates factor XIII and cleaves fibrinogen (32, 33) to generate 
insoluble cross-linked fibrin clot (34, 35) and activates platelets by cleaving thrombin 
receptors on the platelet surface.  
In order to attenuate the procoagulant processes, there are two major mechanisms 
involved: serine protease inhibitors and protein C pathway. Serine protease inhibitors, 
also called “serpins”, function by formation of stable 1:1 complex with their target 
enzymes and neutralize them. Antithrombin has been one of classic serpins by being the 
major inhibitor of several serine proteases produced during the blood coagulation (36), 
including thrombin, factor IXa and Xa, and some noncoagulation serine proteases, such 
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as plasmin, kallikrein and the complement enzyme C1. Specifically, thrombin 
inactivation by antithrombin can be significantly enhanced in the presence of heparin (37, 
38), a type of glycosaminoglycan (GAG). To date, the catalysis of the ATIII-thrombin 
reaction by heparan sulfate has been most thoroughly characterized (39-43). Tissue factor 
pathway inhibitor (TFPI), another example of stoichiometric inhibitor, serves as an 
important regulator of serine proteases by inhibiting its principle targets including factor 
Xa and factor VIIa-TF-factor Xa complex (44-46).  
The protein C anticoagulant pathway has emerged as a dynamic inhibitory 
mechanism for blood coagulation. This “on demand” physiologic anticoagulant pathway 
is initiated when thrombin binds to thrombomodulin (TM) (47). Thrombomodulin (TM), 
a 60 kD type I transmembrane protein (human) providing high affinity binding sites for 
thrombin with dissociation constant (Kd) about 0.7 nM (12), forms a 1:1 molar complex 
which affects the biological function of thrombin by changing its activity (47). The 
thrombin-TM complex exhibits dramatically altered macromolecular specificity and 
rapidly cleaves the plasma zymogen, protein C, to form activated protein C by releasing 
12 residue peptides from the heavy chain of the zymogen (48). Activated protein C serves 
as a robust anticoagulant by interacting with its cofactor protein S on membrane surfaces 
to catalyze the inactivation of factor Va and VIIIa, thus preventing the generation of Xa 






2.3 THE EFFECT OF FLOW ON BLOOD COAGULATION 
The coagulation of blood on damaged tissue surfaces has been long recognized to 
involve the nature of the surface, the blood elements and local flow conditions (50). The 
processes of hemostasis and its pathological correlate, thrombosis, are dynamic events in 
nature, meaning they primarily occur in the presence of flow. In a flow regime, the 
transfer of fluid phase reactants, to a catalytic surface and the removal rate of formed 
products depends upon the kinetics of molecular adsorption and desorption processes, 
intrinsic surface reaction rate constants, convection by the fluid flow, and diffusion 
within the boundary layer region. Therefore, local flow conditions likely have a 
significant effect on such a surface catalytic reaction in the presence of competing 
substrates for a given cofactor or an enzyme active site.  
The overall reaction rate at which proteins or cells react with an enzymatically 
active surface usually depends on a combination of kinetics of chemical reactions at the 
interface and the rate at which molecules arrive at the interface through convection and 
diffusion. In most cases, fluid dynamics and the kinetic reaction processes are coupled or 
interdependent. In the presence of solute-interface reaction, the flow pattern in the 
vicinity of the surface may be altered such that there is a finite velocity component in a 
direction vertical to the surface, which leads to a net transfer of solutes in this direction 
required by the reaction. Therefore, both equations of fluid dynamics and mass transfer 
must be solved simultaneously, which would be exceedingly complex especially when 
further simultaneous equations are required for each additional reactant and product 
involved in the reaction. To simplify the above situation, it is commonly assumed that the 
surface enzymatic reaction is transport-limited. 
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2.4 SURFACE MODIFICATION OF VASCULAR SUBSTITUTES 
To develop a clinically durable small-caliber arterial substitute, modification of a 
blood-contacting surface to reduce thrombogenicity has been pursued. Affixing 
antithrombogenic substances experimentally to synthetic materials has been one of the 
proposed strategies. Heparin binding Dacron prostheses, for example, transiently reduces 
its thrombogenicity in some models (51). Some animal studies (52) have also 
demonstrated that heparin is able to improve graft patency rates by immobilizing onto 
polyurethane and poly(dimethylsiloxane). Besides applying onto synthetic grafts, 
covalent bonding of nitrite-degraded heparin by end-point attachment applied on 
membrane oxygenators and tubings makes it possible to maintain a long-lasting 
extracorporeal circulation without systemic heparinization (53). Direct coating of 
thrombomodulin onto polymer-based surfaces has been investigated. TM has been 
conjugated to both aminated and carboxylated surfaces (54-57) and immobilized onto 
poly(acrylic acid) surface-grafted PTFE (58, 59). In vitro studies showed that both 
clotting time and protein C activation were enhanced.  
While immobilization of biologically functional materials has been strategized for 
medical application, loss of surface bioactivity remains the major issue (54-59). For 
immobilization of TM through direct covalent binding, TM surface bioactivity in terms 
of protein C activation rates was increased by only 10 fold compared with 20,000-fold 
enhancement previously observed when TM is a component of either lipid vesicles or the 
endothelial cell surface. Since TM’s biological properties are closely related to a variety 
of structural features, including three distal epidermal growth factor (EGF)-like modules 
that are able to recognize thrombin and a covalently associated chondroitin sulfate moiety 
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that increases the affinity of thrombin binding to TM (60), altering these properties would 
lead to the loss of cofactor activity, which may have been due to the protein 
immobilization by the direct covalent binding procedure. Moreover, random-site 
reactions to any accessible functional group on the TM surface, including those within 
the thrombin-binding site, may have inactivated the catalytic domain of TM. 
Enhancement of TM catalytic activity on lipid surface possibly results from interactions 
of proteins and lipid, such as protein C through a C-terminal 4-carboxyglutamic acid 
(Gla) domain binds to the cell membrane and thereby increases its local concentration by 
confining it to the two-dimensional plane of the lipid bilayer (61-63). In addition, the 
electrostatic and hydrophobic interactions between protein C and cell membrane may 
also induce conformational changes that help align the protein C cleavage site with 
thrombin's proteolytically active domain. Consequently, the inherent strength of a 
membrane-mimetic based approach may be the capacity to incorporate a variety of 
physiologically significant processes relevant to the control of blood coagulation, which 
leads to developing biological regulator-incorporated membrane-mimetic systems. 
 
2.5 BIOMEMBRANE-MIMETIC MODELS  
Lipid membranes, as self-organizing noncovalent aggregates, offer a model for 
molecular engineering in which the constituent members can be controlled, modified, 
precisely defined, and easily assembled. During the past decade, phospholipids differing 
in chemical composition, saturation, and size have been utilized as building blocks in the 
design of a variety of structures of complex geometry.  Lipid-based cylinders, cubes, and 
spheres have found applications in both drug delivery and as templates for composite 
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molecularly engineered structures (64).  Surface-coupled bilayers for biosensor 
applications have also been produced by assembling a layer of closely packed 
hydrocarbon chains onto an underlying substrate followed by exposure to either a dilute 
solution of emulsified lipids or unilamellar lipid vesicles (65-67).  In addition, Langmuir-
Blodgett techniques have been used as an alternate strategy to construct supported 
bilayers via a process of controlled dipping of a substrate through an organic amphiphilic 
monolayer (68). Remarkably, these noncovalent molecular assemblies exhibit a high 
degree of stability. Israelachvili and others have determined that 26 kT is required to 
remove a double chained C-16 phosphatidylcholine molecule from a bilayer into water 
(69, 70). This nearly approximates the biotin-streptavidin bond energy of 35 kT and is 
several orders of magnitude greater than the affinity of typical monoclonal antibody-
antigen interactions.  Thus, the significance of these design methodologies lies in the 
ability to engineer relatively robust materials with an unparalleled level of reproducibility 
and molecular control over surface order and chemistry. 
Membrane-mimetic systems have also had a direct impact on efforts aimed at 
understanding the mechanisms of blood coagulation at sites of vascular wall injury and 
on artificial surfaces.  In a series of investigations using planar membrane models, 
Thompson and colleagues (71, 72) have characterized the molecular requirements for 
prothrombin binding to phospholipid membranes.  Most intriguing has been the 
observation by other investigators that the phosphorylcholine head group appears to limit 
the induction of blood clot formation on synthetic surfaces (73-75).  Although not well 
understood, it has been speculated that this biological property may be related to the large 
amount of water bound to this zwitterionic head group, or conceivably, the selective 
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adsorption to phosphorylcholine of specific plasma proteins that inhibit the blood clotting 
process (76).  
Given the fact that lipid bilayers serve as a critical factor for protein bioactivity by 
locally concentrating and coordinating appropriate alignment of reacting substrates, we 
propose that a substrate-supported membrane-mimetic assembly provide a rational design 
for generating an actively antithrombogenic blood contacting interface. The model 
construct (Figure 2) coated onto a supporting substrate is composed of polyelectrolyte 
multilayer of poly-(L-lysine)-alginate as a base layer, an amphiphilic alkylated 
terpolymer (3-acryloyl-3-oxapropyl-3-(N,N-dioctadecyl-carbamoyl)-propionate))3:(2-
hydroxyethyl acrylate)6:sodium styrene sulfonate1 (AOD3:HEA6:SS1), and lipid 
monolayer comprised of monoacrylate-phospholipids (77-80). Based on such a system, 
additional substances can be incorporated with the model surface, which provides a high 
level of molecular control over surface order and chemistry and, as a consequence, 
facilitates the examination of surface molecular determinants, which are required for 
efficient antithrombogenicity. In the following parts of the thesis, fabrication and 
characterization of TM and heparin functionalized surfaces are presented and their 
potential individual and combined antithrombogenic capacities are investigated using TF-
presented surface as a vascular injury model. The mechanisms governing TM-initiated 
APC generation, heparin-enhanced thrombin inactivation, and their capacities to inhibit 






















Figure 2  Schematic representation of a polymeric phospholipid monolayer composed 
of 1-palmitoyl-2-[12-(acryloyloxy) dodecanoyl]-sn-glycero-3-
phosphorylcholine supported on an alkylated polyelectrolyte multilayer (Not 








CHAPTER 3   
 
 







The protein C anticoagulant pathway generates an “on demand” physiologic 
anticoagulant response, which is initiated when thrombin binds to thrombomodulin (TM), 
a transmemebrane protein constitutively expressed by endothelial cells. A stable, protein 
C activating membrane-mimetic film was produced on a polyelectrolyte multilayer (PEM) 
by in-situ photopolymerization of a phospholipid assembly containing TM. The 
monoacrylated phospholipid monomer was initially synthesized and prepared as 
unilamellar vesicles with varying molar concentrations of TM. Membrane-mimetic films 
were constructed on planar substrates with predictable surface concentrations of 
catalytically active TM. 125I-labeled TM demonstrated little change in TM surface 
concentration over periods of up to 4 weeks. We have utilized a continuous parallel plate 
flow reactor to investigate effects of physiologic shear rates (50 sec-1 and 500 sec-1) and 
TM surface concentration (0 - 1400 fmole per cm2) on activation of protein C. In 
agreement with an analysis of reaction kinetics and mass transfer, experimental results 
demonstrated that reaction rates became saturated when TM surface density was equal to 
or greater than 800 fmole per cm2. Moreover, steady state rate of activated protein C 
generation increased with shear rate and TM surface content. Stability tests of TM 
activity showed that surface TM activity in terms of protein C activation can be preserved 
for at least a short-term period. We believe that the design of membrane-mimetic films 
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that have the capacity to activate the protein C pathway will provide a useful strategy for 
generating “actively” antithrombogenic surfaces. 
 
3.2 INTRODUCTION 
It has been postulated that a clinically durable vascular prosthesis may be achievable 
by controlling thrombus formation on molecularly engineered surfaces through the 
incorporation of physiologically relevant antithrombogenic mechanisms that are normally 
operative at the blood-material interface under a range of hemodynamic conditions. The 
inhibition of blood coagulation is primarily achieved by two complementary mechanisms 
- serine proteinase inhibitors (serpins) and the protein C pathway (81). Despite the 
presence of serpin binding sites on heparan sulfates and the well characterized 
anticoagulant properties of these glycosaminoglycans, the physiological significance of 
the anticoagulant/antithrombotic functions attributed to heparan sulfates at the endothelial 
cell surface have not been conclusively established. For example, high affinity 
antithrombin binding sites have not been localized to heparan sulfates that are in direct 
contact with blood (82). Moreover, Lollar et al. (83) could not confirm the alleged 
catalytic effect of heparan sulfate on the ATIII-thrombin reaction in recirculating rabbit 
Langendorff heart preparations. In contrast, there is growing evidence that 
thrombomodulin (TM), as a critical regulator of the protein C pathway, represents the 
major anticoagulant mechanism that is operative in both normal and injured blood vessels 
under physiologic conditions in vivo (84).  
TM is a transmembrane glycoprotein of the endothelium of blood and lymphatic 
vessels and the basis of a major natural anticoagulant system (60). TM has high affinity 
 15
for thrombin to form 1:1 stoichiometric complex and in the process turns all known 
procoagulant/proinflammatory functions of thrombin into anticoagulant/anti-
inflammatory activities of the enzyme complex, which initiates protein C anticoagulant 
system. TM-facilitated protein C activation shows robust physiologic anticoagulant 
response due to three distinct substrate dependent mechanisms. While free thrombin 
efficiently converts fibrinogen to fibrin, thrombin bound to TM is no longer capable of 
cleaving fibrinogen, nor is it able to act on platelets (61). In addition, TM not only 
enhances the rate of thrombin inactivation by ATIII but also dramatically accelerates the 
ability of thrombin to activate protein C. APC together with its cofactor protein S 
inactivates coagulation factors Va and VIIIa (49) which are generated by thrombin-
catalyzed activation of factor V and VIII and serve as critical cofactors for generation of 
thrombin and factor Xa, respectively. Inasmuch as APC functions as a potent inhibitor of 
blood clot formation by preventing the generation of factor Xa and thrombin which are 
critical for the amplification of the coagulation cascade, TM apparently plays a key role 
to regulation of blood coagulation. 
Several investigators have described the direct immobilization of thrombomodulin 
onto polymeric surfaces in order to generate thromboresistant materials for blood 
contacting applications. Kishida et al. (54-57) have conjugated TM to both aminated and 
carboxylated surfaces, including poly(vinyl amine) and poly(acrylic acid) surface-grafted 
polyethylene and a surface-hydrolyzed poly(ether urethaneurea). Similarly, Vasilets et al. 
(59) have reported the immobilization of TM onto poly(acrylic acid) surface-grafted 
PTFE. Recently, Li at al. (85) have reported the immobilization of TM onto expanded 
PTFE utilizing carbodiimide-based coupling reaction. Han et al. (86) have documented 
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the immobilization of TM onto the cover glass substrates using trichlorotriazine (TCT) 
and amino-terminated silane as new coupling agents with or without the aid of PEG 
between TM and substrate. Sperling et al. (87) have reported TM was covalently 
anchored onto thin films of poly(octadecene alt maleic anhydride) covering planar glass 
substrates, which was achieved by active ester formation at the carboxylic acid terminus 
of the PEG spacers. While the conjugation schemes in these reports vary TM is always 
coupled to the substrate via freely available amino or carboxyl functionalities on the 
protein surface. Characteristically, in vitro studies demonstrated that both clotting time 
and protein C activation are enhanced and this activity appears to be directly proportional 
to TM surface density, as determined by a ninhydrin assay. However, the ability to 
control TM surface concentration was substrate dependent with reported TM densities 
ranging between 0.15 and 0.45 µg/cm2.  Furthermore, TM bioactivity was significantly 
reduced after surface coupling, as evident by protein C activation rates, which were 
increased only 5 to 10-fold compared with an observed 20,000-fold enhancement when 
TM is evaluated as a component of either lipid vesicles or the endothelial cell surface.   
Furthermore, the impact of local flow conditions on the effectiveness of this strategy was 
not investigated.  
These studies confirm that substrate bound TM has the potential to limit 
thrombus formation on synthetic surfaces that are otherwise thrombogenic. However, the 
observed reduction in TM bioactivity serves to emphasize that TM’s biological properties 
are intimately tied to a variety of structural features which may be lost upon direct 
covalent coupling to a biomaterial surface, possibly due to random-site reactions to any 
accessible functional group on the TM surface, including those within the thrombin 
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binding site. For example, TM’s ability to accelerate the thrombin-dependent activation 
of protein C requires three tandemly repeated EGF-like domains that serve as a thrombin 
binding site; a serine/threonine-rich 65 Å spacer between the EGF-like domains and the 
transmembrane domain (88), a distance similar to the location of the active site of APC 
above the membrane surface (89), which optimally align thrombin’s active site with the 
critical scissile bond in protein C; and a covalently associated chondroitin sulfate moiety 
that increases the affinity of thrombin binding to TM by 10- to 20-fold and catalyzes 
ATIII inactivation of thrombin (60, 90). Furthermore, while some activity is retained 
even after the solubilization of TM with detergents, membrane association significantly 
accelerates protein C activation by TM. This is mediated, in part, by the ability of the 
membrane to locally concentrate and coordinate the appropriate alignment of reacting 
cofactors and substrates with TM (91). For example, protein C has a C-terminal 4-
carboxyglutamic acid (Gla) domain which binds to the cell membrane and presumably 
increase its local concentration by confining it to the two-dimensional plane of the lipid 
bilayer (61-63).  In addition, the binding of protein C to the plasma membrane may also 
induce conformational changes that help align the protein C cleavage site with thrombin's 
proteolytically active domain. Furthermore, direct interaction of the Gla domain of 
protein C with the phospholipids is augmented by calcium and negatively charged 
phospholipids are the most active type of lipid (92). Analysis of the membrane binding 
properties of protein C indicates that this interaction with negatively charged 
phospholipids probably involves insertion of the very hydrophobic loop of the protein C 
Gla domain into the hydrophobic regions of the bilayer (93). Presumably, this membrane 
binding concentrates protein near the activation complex accounting for the observed 
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decrease in the Km (92). In addition, orientation of the scissile bond on protein C with the 
active site of thrombin in the thrombin-TM complex probably plays an important role in 
this process (88). Thus, the lipid bilayer serves as an essential ‘cofactor’, which in 
concert with TM accelerates protein C activation and subsequently optimizes APC 
anticoagulant activity. Given this framework, a membrane-mimetic design strategy not 
only facilitates the formation of chemically heterogeneous and biologically active thin 
films through a process of self-assembly, but provides a useful scheme for incorporating 
TM into blood-contacting interfaces in a manner that provides for optimal anticoagulant 
activity. 
Phospholipid membrane surfaces accelerate TM-facilitated protein C activation 
by acting as an essential mediator which locally concentrates and coordinate the 
appropriate alignment of reacting cofactors and substrates (88, 89, 92, 93). Given the 
molecular basis of protein C activation on the membrane surface, we have postulated that 
a substrate-supported membrane-mimetic assembly that contains TM provides a rational 
design for generating an actively antithrombogenic blood contacting interface. We have 
recently described the formation of a stabilized, membrane-mimetic film containing 
reconstitution of TM into lipid assemblies composed of 1-palmitoyl-2-[12-(acryloyloxy) 
dodecanoyl]-sn-glycero-3-phosphorylcholine (monoacrylate-PC) (78, 79, 94, 95) through 



































Figure 3 Schematic representation of TM functionalized polymeric phospholipid 






Although TM containing membrane-mimetic films have been studied under a variety 
of static conditions (79), the catalytic efficiency of this system under well defined flow 
conditions has not been previously investigated. In this regard, an analytical model is 
used to define the mass-transfer limited regime under simulated arterial (500 sec-1) and 
venous (50 sec-1) conditions in which increases in TM surface concentration do not 
further enhance local APC production.  This was confirmed experimentally in a parallel 
plate flow chamber (Figure 4). Moreover, preserved TM bioactivity was documented 
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igure 4  Schematic of parallel plate flow reactor (not to scale). The gasket (plastic 
shim) creates height of the flow channel. TM containing membrane-mimetic 
construct is immobilized onto a glass substrate. The surface is perfused with 
reactants and the perfusate is collected at the outlet to determine product 
concentration. 
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3.3 MATERIALS AND METHODS 
3.3.1 Materials 
Rabbit lung thrombomodulin (single chain containing NH2-terminal hydrophobic 
domain, six EGF domains, one O-glycosylation rich domain, one transmembrane domain, 
COOH-terminal cytoplasmic domain, 74 kD, in 0.02 M Tris, 0.15 M NaCl, pH 7.4 
containing 0.05% lubrol PX), human protein C, and human thrombin were obtained from 
Haematologic Technologies, Inc. Human antithrombin III and Spectrozyme PCa 
substrate (H-DLys (γ-carbobenzoxy)-Pro-Arg-pNA•2AcOH) were obtained from 
American Diagnostica Inc. Eosin Y (EY, 5% in water), triethylamine (TEA), 1-vinyl-2-
pyrrolidinone (VP) were obtained from Aldrich. Nucleopore polycarbonate filters, 
circular glass coverslips (15 mm diameter, 0.17 mm thickness) and Contrad 70 detergent 
were obtained from Fisher. Alginate (ALG; low viscosity, ca. 60% mannuronic acid) was 
obtained from Pronova Biomedical (Norway). Poly (L-lysine) (PLL, MW > 300 kD) and 
all buffer salts were obtained from Sigma. Normal pooled human plasma was purchased 
from George King Biomedicals, Inc. Sodium azide (NaN3) was purchased from Sigma. 
Monoacrylate-PC (AcPC, 1-palmitoyl-2-[12-(acryloyloxy) dodeca-noyl]-sn-glycero-3-
phosphocholine) was synthesized as described previously (77).  The synthesis of the 
terpolymer that consists (3-acryloyl-3-oxapropyl-3-(N,N-dioctadecyl-carbamoyl)-
propionate))6:(2-hydroxyethyl acrylate)3:sodium styrene sulfonate1 (AOD6:HEA3:SS1) 
has been described elsewhere (96). 
Instrumentation: Irradiation was performed using a DynaLume quartz halogen 
illuminator equipped with a heat shield (Scientific Instruments). Light intensity was 
measured using a radiometer model IL 1400A equipped with a SL021 photodetector and 
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FQI filter (International Light). Radioactive materials were detected using Gamma 
counter. All spectrophotometric measurements were executed on a Cary 50 Bio UV-
Visible spectrophotometer (Varian) equipped with a temperature-regulated cell 
compartment.   
3.3.2 Layer-By-Layer Assembly of an Alkylated Alginate/Poly-L-Lysine (ALG/PLL) 
Multilayer on a Glass Surface 
 
Microscope glass slides were cleaned by 30 minutes of sonication in 10% Contrad 
70 detergent solution followed by extensive washing and sonication in deionized water. 
The substrate was then immersed in a solution of 0.10% PLL in 20 mM PBS for 30 
seconds and then washed with water. The procedure was repeated using a solution of 
0.15% ALG in 20 mM PBS. This process was repeated until a total of 11 layers (six PLL 
and five alginate layers) were coated, with the top layer comprised of PLL. Samples were 
then immersed in a 0.1 mM (in [SS]) terpolymer (AOD6:HEA3:SS1) solution in 1% (v/v) 
DMSO/PBS buffer for 1 minute. After extensive rinsing with water, samples were air-
dried. Advancing contact angles of > 100° were characteristic of these substrates. 
Comprehensive surface analysis of these films with or without a supported lipid assembly, 
including contact angle goniometry, ellipsometry, external reflectance infrared 
spectroscopy, and high resolution scanning electron microscopy, has been detailed 
elsewhere (96). 
3.3.3 Reconstitution of Thrombomodulin into Lipid Vesicles 
Large unilamellar vesicles (LUV) of 12 mM lipid solution in 20 mM sodium 
phosphate buffer, pH 7.4, were prepared by four successive freeze/thaw/vortex cycles 
using liquid N2 and a 45°C water bath. Thrombomodulin was then added to obtain the 
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desired thrombomodulin/lipid molar ratio, which ranged in these investigations from 
1:4000 to 1:200,000. The lipid/thrombomodulin solution was gently vortexed for 1hr at 
room temperature before it was extruded 21 times; each through two back-to-back 2000 
nm and then 600 nm polycarbonate filters (Avanti Polar Lipids, Inc.). It has been 
confirmed that 95% of the TM activity was associated with the lipid vesicles (79). 
3.3.4 Formation of a Thrombomodulin Containing Membrane-Mimetic Thin Film 
Extruded lipid vesicles were diluted to 1.2 mM with 20 mM sodium phosphate 
buffer containing 150 mM NaCl, pH 7.4. This solution was then purged with argon for 20 
minutes.  A terpolymer-coated glass slide was completely immersed in 4 mL of vesicle 
solution, faced upwards, and maintained overnight at 40°C. Photopolymerization of 
acrylate-PC was carried out as described previously (78) with some modifications. A 
stock solution of co-initiators was prepared as 10 mM Eosin Y, 225 mM TEA, and 37 
mM VP in water, and was stored in an opaque amber bottle. In a glove box purged with 
argon, the desired amount of initiator stock solution was added to the vial containing the 
substrate fused with vesicles so that a 12:1 ratio of [AcPC]:[Eosin Y] was achieved. The 
sample was irradiated for 30 minutes under ambient conditions from above at a distance 
of approximately 6 cm (light intensity ~ 40 mW/cm2). Following the 
photopolymerization period, the sample was removed from the polymerization media and 





3.3.5 Determination of Thrombomodulin Surface Density and Stability within a 
Polymeric Lipid Membrane 
 
Rabbit lung thrombomodulin at a concentration of 1 mg/mL was radiolabeled with 
125I using Iodobeads (Pierce Chemical Co., Rockford, IL) according to the manufacture’s 
protocol. The concentration of radiolabeled TM was determined by a modification of the 
Bradford Protein Assay (Bio-Rad) using a TM standard curve. Specific activity of the 
protein solution averaged 1.8 x 107 cpm/µg (1330 cpm/fmole). Cleaned supporting 
substrates (5x5 mm2 Si chip) were coated with TM containing membrane-mimetic thin 
film as described previously.  125I-TM and unlabeled TM were mixed to form 1:16 molar 
ratio solution, and TM was then added to obtain the desired TM/lipid molar ratio. Planar 
photopolymerized lipid/TM assemblies were produced as described above and washed 
extensively with water prior to measuring surface radioactivity in a gamma counter. TM 
surface density (fmol/cm2) was calculated as {cpm/(specific activity x sample area)} and 
specific activity corrected for decay. For stability analysis, samples were stored in PBS at 
37 °C and radioactivity periodically measured after extensive washing in water over a 1-
month period. Test samples were generated in quadruplicate. 
3.3.6 Analysis of TM Catalytic Activity 
Activity of TM was accessed via the activation of human protein C by human 
thrombin-rabbit lung TM complex, as described in the literature with some modification 
(61). Activation was performed at 37 °C in 20mM Tris-HCl buffer, pH 7.5, containing 
100 mM NaCl, 0.1% BSA, and 5 mM Ca2+. A typical activation mixture contains 0.5 nM 
of TM as a component of LUVs, 5 nM of thrombin, and 0.1 µM of protein C. Incubation 
periods were adjusted such that less than 10% of protein C was converted to activated 
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protein C. Activation was terminated by the addition of antithrombin III (300 µg/mL final 
concentration). Activated protein C concentration was determined using the Spectrozyme 
PCa substrate (absorbance 405 nm). Km and kcat values were calculated assuming 
Michaelis-Menton reaction kinetics.  
Thrombomodulin activity on glass coverslips coated with a membrane-mimetic thin 
film was determined in similar fashion in a shaking water bath at 37 °C. For stability tests, 
samples were incubated in PBS at 4 °C or human plasma at 37 °C for specified time 
periods prior to measuring TM activity. Fresh samples were used for all stability tests, 
and a total of six samples were assayed to obtain each data point. 
3.3.7 Continuous Flow Reactor Assays on Thrombomodulin Containing Membrane-
Mimetic Surface 
 
 Microscope glass slides were cleaned and coated with TM-incorporated 
membrane-mimetic thin film. A parallel plate flow system (0.6 cm (width) x 0.01 cm 
(height) x 4.5 cm (length), 27µL volume) containing the coated sample was flushed with 
20mM Tris-HCl buffer for 1 hours at γw = 2000 sec-1. The reaction was started by 
perfusing the sample with the Tris-BSA (20mM Tris-HCl + 100 mM NaCl + 0.1 wt% 
BSA, pH 7.5) containing 5 mM Ca2+, 2 nM of thrombin and 0.1 µM of protein C at 37oC. 
The entrance length (i.e., the distance from the inlet over which the laminar flow profile 
becomes fully developed) for the current flow system was estimated by Le/H = 1 + 0.1Re, 
where Le is entrance length, H is the height of the channel, and Re is the Reynolds 
number (97). As the Reynolds numbers in this system were less than 10, the entrance 
length was less than 0.5% of the total reactor length. Protein C activation was 
investigated at shear rates of 50 and 500 sec-1, which correspond to flow rates of 0.031 
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and 0.31 mL/min and residence times over the reactive surface of 53 and 5.3 sec, 
respectively. The perfusate was collected at timed intervals (every 10 minutes for 50 sec-1 
and every 5 minutes for 500 sec-1) and quenched by antithrombin III (120 µg/mL, final 
concentration) for 5 minutes, and assayed by adding Spectrozyme PCa substrate (0.2 mM, 
final concentration). The concentration of activated protein C (APC) was determined by 
converting measured absorbance (at 405 nm) from UV-VIS spectrophotometer via a 
standard curve (see Appendix A1). 
3.3.8 Stability Tests on Bioactivity of Thrombomodulin Incorporated Membrane-Mimetic 
Surface  
 
TM-incorporated membrane mimetic surfaces were incubated with daily fresh 
phosphate-buffered saline (PBS, 1X) or normal pooled human plasma (replace with fresh 
plasma every 2~3 days) at 37 °C. The model surface was tested using the same 






















3.4 RESULTS AND DISCUSSION 
 
The lipid membrane has been considered as an essential cofactor in blood coagulation, 
mainly due to the central role it plays in assembly of the activation complexes. For 
example, the formation of the enzyme complex prothrombinase on membrane surface  
provides a platform for its substrate prothrombin to bind effectively (71, 72). In the 
absence of membrane, the formation of the complex is either abolished or impaired (29, 
98-100). In contrast, catalytic activity of integral membrane proteins is largely enhanced 
by orders of magnitude comparing to that of pure enzyme (22, 98). Specifically, the 
assembly of thrombin-TM complex on membrane leads to > 104 fold in the proteolytic 
efficiency of activation of protein C (60, 91). 
It have been noted that the phosphorylcholine headgroup appears to limit the 
induction of blood clot formation on synthetic surfaces (73-75). While our group has 
observed limited thrombus formation and neointimal hyperplasia on phospholipids 
functionalized surfaces using short-term in vivo assays (77, 101), we believe that the 
inherent strength of a membrane-mimetic-based approach is the capacity to incorporate 
within these systems a variety of physiologically significant processes relevant to the 
control of blood coagulation. As a critical regulator of the protein C pathway, TM 
represents the major anticoagulant mechanism that is operative under physiologic 
conditions in vivo and thereby provides an appropriate target for functionalizing blood 




3.4.1 Robust Membrane-Mimetic Films can be Constructed on Planar Substrates with 
Predictable Surface Concentrations of Catalytically Active TM.  
 
A schematic representation of the membrane-mimetic construct is illustrated in 
Figure 3, and a detailed description of the surface physiochemical properties of this 
system have been published elsewhere (96). The molar ratio of TM:phospholipids was 
systematically varied from 1:4000 to 1:200000 with an observed linear relationship 
between the concentration of TM in the lipid mixture and the rate of activated protein C 






Figure 5  The relationship between the rate of surface mediated protein C activation 
(nM/min/cm2) and the concentration of TM in the fusion mixture. Adopted 
with permission from (79).  
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Moreover, TM activity was unchanged over a 5-day incubation period in PBS at 
4°C (Figure 6A). Incubation of films in plasma at 37 °C revealed a small decrease in TM 
activity (~20%) within 30 min. Nonetheless, continued incubation for an additional 3 
days was not associated with any further loss of TM activity (Figure 6B).  
125I-protein labeling was used to determine the absolute surface density of TM on 
planar-supported membranes as a function of its molar concentration in the vesicle 
solution (Figure 7). A linear relationship was observed over a wide range of TM 
concentrations. A small decrease in surface concentration was noted within the first 3 
days on incubation at 37 °C in PBS with relatively little change observed over a period 
extending up to 28 days. We speculate that the small decrease TM concentration soon 
after the initiation of PBS incubation may be related to the loss of partially adsorbed lipid 
vesicles. Notably, samples were removed from the bathing media on multiple occasions 
during the incubation period, which emphasizes the relative stability and robustness of 
this system.  
 However, for the highest TM concentration, i.e. [TM] = 300 nM in fusion 
solution, the behavior of TM stability was observed to be a bit more drastic than lower 
TM concentration (Figure 8). It appears to have more initial loss during the first week of 













Figure 6  (A) Serial measurements (mean ± S.D.) of the rate of protein C activation for 
a TM containing lipid film incubated in PBS at 4 °C. (B) Serial measurements 
(mean ± S.D.) of the rate of protein C activation for a TM containing lipid 
film incubated in plasma at 37 °C. All values are normalized with respect to 



































































































































Figure 7  TM surface density and stability within a polymeric lipid membrane. TM was 
radiolabeled with 125I and reconstituted into lipid vesicles, and surface 
concentration was determined after the formation of a polymeric lipid 
assembly. The stability of this system was assessed in PBS at 37 °C over a 28-
day period. Films were transferred to fresh PBS at indicated time points and 







































Figure 8  Stability of TM surface concentrations for [TM] = 300nM for lipid fusion. 
The surface samples were incubated with PBS at 37oC and radioactivity was 









3.4.2 Theoretical Considerations of the Surface TM-Catalyzed Flow Reactor   
 
Under flow conditions, the production of TM-catalyzed activated protein C depends 
upon an intrinsic reaction rate constant, as well as the transport of protein C and thrombin 
to TM and the subsequent removal of APC.  The latter processes are governed by 
convection in fluid flow and diffusion within the boundary layer region.  To simplify the 
analysis of this system, we have assumed that TM and thrombin for a stable protein C 
activating complex and that the reaction of protein C with this complex acts as a two-
component system consisting of an enzyme and substrate.  In addition, we have assumed 
that TM-catalyzed activation of protein C occurs at the catalytic site within the boundary 
layer and the bulk concentration of protein C remains constant.  
The reaction kinetics for an immobilized enzyme (thrombin-TM complex) bound 
on the surface of a parallel plate reactor and exposed to substrate (protein C) flowing past 
under laminar flow conditions has been considered in a similar fashion to a tubular 
reactor (102, 103) because a parallel plate flow system is highly analogous to a tubular 
system in terms of fluid dynamic properties (104). The hydrodynamic properties of such 
a flow system are presented (Figure 9). The flow profile is parabolic across the height and 
uniform across the width of the flow chamber due to the aspect ratio (W/H > 10) of the 
channel cross section. The substrate concentration behaves in a boundary layer-like 
fashion base on the following assumptions: (a) steady state and (b) diffusion and 
convection are radially (y-direction) and axially (z-direction) dominant. The governing 

































yvvz   (2) 
 
The appropriate boundary conditions at the surface and in the bulk fluid are: 
 
B.C. 1: C = C0      at   z = 0 (at entrance) for all y (3)  
 
B.C. 2: )( wCfy
CD =
∂
∂    at y = ±B for all z (4) 
  
B.C. 3: C = C0 everywhere but at y ≈ ±B   (5) 
 
 
where Co is the bulk substrate concentration, C is the substrate concentration within the 
boundary layer, vz is the local fluid velocity in the axial direction (z) as a function of the 
position in the height of the reactor (y), and vmax is the maximum fluid velocity. 
The first condition describes the initial substrate concentration at the entrance of the 
flow. The third condition represents the boundary layer-like nature of the mass transport 
for which changes in substrate concentration occur only in the vicinity of the surface. The 
second boundary condition indicates diffusive flux is exactly balanced by rate of reaction 
at the catalytic surface. Under flow conditions in which diffusional transport to the 
surface is rate-limiting relative to the enzyme kinetics, eq.(4) becomes  









The average rate of reaction per unit area at the surface can be shown to be  
 

























=  (8) 
where 
(rp)diff  = rate of surface reaction (flux, pmole/min/cm2) 
D: diffusion coefficient (cm2/min) 
L: length of the reactor (cm) 
H: height of the reactor (= 2B) (cm) 
k: mass transfer coefficient (cm/min) 
W: width of the reactor (cm) 
Q: volumetric flow rate (mL/min)  
 
wγ : wall shear rate = WB
Q
22
3  (sec-1)  (9) 
 




























      
 
Figure 9  Schematic of fluid dynamic profiles in a parallel plate flow system for surface 











Details about solving the above partial differential equation are shown in Appendix 
B for readers unfamiliar with the field. Given the flow chamber geometry, the wall shear 
rates of 50 and 500 sec-1 require flow rates of 0.031 and 0.31 mL/min, which result in 
residence time of 53 and 5.3 seconds respectively. The diffusion coefficient of protein C 
was estimated 7.36 X 10-7 cm2/sec at 37oC using semiempirical equation of Polson (105) 







=       (10) 
where D is diffusion coefficient in cm2/sec, Mw is the molecular weight of the molecule 
in g/gmol, T is temperature in K, and µ is viscosity of solution in g/(cm·sec).  For 0.1 µM 
protein C, theoretical rates of reaction due to transport effect are 0.88 and 1.90 
pmole/(min·cm2) at 50 and 500 sec-1, respectively. 












avδ                    (11) 
 
The average thicknesses of boundary layer in our system are 55 and 25 µm for shear 
rates of 50 and 500 sec-1, respectively. According to the above analytical results (eq. (7) 
and (11)), both rate of reaction and average thickness of concentration boundary layer are 
a function of shear rate, given the other fixed parameters including diffusivity, and 
geometry of reactor vessel, the similar expressions to previous studies (102, 109). Steady 
state rate of reaction is expected to be higher due to faster transport of materials through a 
thinner boundary layer. 
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In order to optimize catalytic surface design in a manner that appropriately matches 
the enzymatic capacity of a surface with the anticipated level of substrate delivery, it is 
often useful to define a mass transfer limited regime in which the rate of product 
formation is dictated by the transport of the substrate to surface reactive sites rather than 
by insufficient surface catalytic activity. Given that the physiologic concentration of 
protein C is ~ 0.1 µM and varies little, this analysis requires a consideration of both 
surface reaction kinetics and the rate of substrate transport to the reactive surface at a 
given shear rate. Assuming Michaelis-Menten kinetics and that all surface sites are 
catalytically primed through full complexation of TM with thrombin, the relative effects 
of these parameters can be assessed in a ratio referred to as a Damköhler number (Da). Da 
is a dimensionless number and its physical significance is emphasized as the ratio of 
maximum rate of reaction kinetic to maximum rate of transport (110): 
 Da = Vmax / kCo
where Vmax (Michaelis-Menten kinetics) = kcat[E]t , [E]t is the TM surface density, kcat is 
23 min-1  for TM-reconstituted polymerized lipid vesicles (79), k is the mass transfer 
coefficient, C0 is the initial substrate concentration of protein C.  
According to the above analytical model (eq. (6)), theoretical calculations of kC0 are 0.88 
and 1.90 (pmole/min/cm2) for 50 sec-1 and 500 sec-1 respectively  
Characteristically, at a Da >> 1 a transport-limited regime exists, while conversely a 
reaction-limited regime occurs at a Da << 1.  Thus, Damköhler numbers as a function of 
TM surface density can be determined and are summarized in Table 1. At TM 
concentrations between 66 and 800 fmol/cm2, Da varies between 1 and 10, which 
suggests that both diffusive transport and surface kinetics dictate product formation and 
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that maximum protein C activation would not be achieved.  However, if surfaces were 
designed at a TM surface density > 800 fmole/cm2, our analysis predicted that a 
transport-limited regime (Da > 10) would be attained at both target shear rates. In 
addition, at the same TM surface concentration, Da is smaller at higher shear rate due to 
higher rate of transport effect. Since no Da is much less than unity in all given TM 





Table 1  Damköhler number (Da) at a series of TM surface concentration under flow 
conditions. Da is defined as the ratio of maximum rate of kinetic reaction 
(Vmax) over maximum rate of transport (kC0). Vmax is obtained from the 
product of kcat (79) and TM surface concentration ([E]t), while kC0 is obtained 
from analytical expression shown in equation (6). 
 
TM (fmole/cm2) Vmax = kcat [E]t Da (50 sec-1) Da (500 sec-1) 
1351 31.05 35.22  16.35  
764 17.57 19.93  9.25  
488 11.22 12.73  5.91  
344 7.91 8.98  4.17  
162 3.73 4.23  1.96  
82 1.89 2.14  0.99  
















 3.4.3  Experimental Analysis of TM-Mediated Activated Protein C Production Under 
Laminar Flow Conditions 
 
Activated protein C production as a function of TM surface density at shear rates 
of 50 and 500 sec-1 are shown in Figure 10. APC generation increased with increasing 
perfusion time until a steady-state concentration of APC was observed.  After initiating 
perfusion at shear rate of 50 and 500 sec-1, the time to reach steady-state level was 
approximately 40 min and 5 min, respectively. Of note, the concentration of APC 
measured at the outlet varied inversely with wall shear rate, which is consistent with what 
equations (6)-(9) reflect.  As summarized in Figure 11, the rate of protein C activation 
increases with TM surface concentration and reaches a maximum at a TM surface density 
equal to or greater than 800 fmole/cm2, which is also in agreement with Da analysis. The 
TM density plots (Figure 3) were fit to the equation for a hyperbola, thereby defining two 
parameters, K1/2 E, the density required for half-maximal rates, and Vmax E, the predicted 
maximal rate of reaction, both are summarized in Table 2. Values of K1/2 E reflect the 
activation rates of protein C with 106 and 127 fmol/cm2 TM were 0.23 and 0.69 
pmole/(min·cm2) respectively. These values are equivalent to a turnover of 2.17 and 5.43 
molecules per min per TM-thrombin complex at shear rates of 50 and 500 sec-1 
respectively.  In contrast, within a regime characterized by excess TM, as exemplified by 
a TM surface concentration of 1350 fmol/cm2, respective turnover rates were 0.33 and 
1.01 molecules per min per TM-thrombin complex., showing the excess catalytic 
capacity at high TM densities. The average steady-state rates of APC generation in the 
presence of TM surface density = 1350 fmole/cm2 were 0.44 (n = 5) and 1.35 
pmole/(min·cm2) at shear rates of 50 and 500 sec-1, respectively, which are close to the 
Vmax E value determined by the curve fitting. The ratio of Vmax E at 50:500 sec-1 is 
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approximately 1:3, while theoretical ratio based on transport limitation is 1: 2.2 (= 501/3 
:5001/3).  
Although the empirical rate of APC as a function TM surface density indicates 
that the rate of reaction is higher at higher shear rate and the system reaches the limit of 
catalytic efficiency at high TM surface content, there is discrepancy between theoretical 
and experimental values. Compared to theoretical values of rate of APC generation, 
experimental results show approximately 50% (0.45/0.88 pmole/(min·cm2)) and 72% 
(1.37/1.90 pmole/(min·cm2)) of those anticipated (k.Co) at wall shear rates of 50 and 500 
sec-1, respectively. The analytical model assumes that the substrate concentration in the 
center core of the chamber remains constant and only substrate molecules in the substrate 
boundary layer, which is typically quite small compared to the chamber thickness, are 
involved in the reaction. However, calculated average boundary layer thicknesses at shear 
rates of 50 and 500 sec-1 are approximately one-half and one-quarter of the flow chamber 
height, respectively. Thus, the theoretical flux may be overestimated due to a greater 
level of transport resistance than otherwise anticipated providing one possible 
explanation for the observed discrepancy between measured and predicted rates of APC 
production. It is also plausible that these differences may be related to a disparity in 
estimated and actual kcat values, as well as the possibility that the local shear environment 
induces a conformational change in the catalytic site of TM and, as a consequence, kcat.  
More detailed studies will be required to address these issues. Nevertheless, it is 
consistent with the hydrodynamic theory that the rate of the reaction is higher at higher 
shear rate due to less transport resistance (smaller δ), which also has been observed in 
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Figure 10  Kinetics of APC generation ([APC] vs. perfusion time) at a wall shear rate of 
(A) 50 sec-1 and (B) 500 sec-1 with TM surface concentrations of 1351 (●), 
764(○), 488 (■), 344 (□), 162 (▲), 82 (∆), 66 (▼) fmole/cm2. Each data point 
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Figure 11 Rate of steady state protein C activation as a function of TM surface 
concentration at two different shear rates 50 (■) and 500 (□) sec-1. Each data 
point represents the mean ± standard deviation (n = 5). Note: rate of APC 
generation (pmole/min/cm2) = APC generation (nM) x flow rate (mL/min) / 
reactor surface area (cm2) 
 
 
Table 2 Parameters of TM Density Titrations. The TM density plots (Lineweaver-
Burk plot) of figure 10 were fit to a hyperbola. The maximal APC production 
rate (Vmax E) and the TM density resulting in half-maximal rate of reaction 
(K1/2 E) are shown. 
 
γw (sec-1) K1/2 E (fmole/cm2) Vmax E (pmole/min/cm2) 
50 105.65 ±11.80 0.45 ±0.05 









3.4.4 Stability of Surface TM Activity 
The biostability of TM containing membrane-mimetic films was assessed using test 
samples containing TM at a density of 1350 fmole/cm2. Films were stored in PBS or 
human plasma at 37 °C and APC generation measured under flow over a three month 
period. Upon incubation in PBS, TM activity appeared to be relatively stable after 1-
week with little change over a subsequent four week period (Figure 4). In plasma, TM 
activity decreased during the first two-weeks, but displayed little change over a 
subsequent 3 month observation period (Figure 5). A prior report from our group, 
reported the stability of these assemblies  using 125I-TM  (79). Consistent with the current 
set of bioactivity studies a decrease in surface concentration was observed within the first 
3 days of incubation in PBS with relatively little change observed thereafter. Since high 
shear flow (2000 sec-1 for 1 h) was applied to wash away non-fused, loosely associated 
surface TM/lipid vesicles before conducting activity tests, we have assumed that the 
effect of TM/vesicle desorption can be largely neglected and the loss in activity primarily 
reflects direct enzyme inactivation. As anticipated, a greater loss of TM activity was 
noted for test samples stored in plasma. We suspect that this effect is due, at least in part, 
to the existence of plasma protein inhibitors of TM. For example, the protein C inhibitor 
(PCI), known as an inhibitor of activated protein C, is also a potent inhibitor of the 
thrombin-thrombomodulin complex (113, 114). In addition, homocysteine, a sulfur 
containing amino acid in plasma that plays an important role in methionine and folate 
metabolism, has been reported as a possible factor of inactivating the cofactor activity of 
thrombomodulin by reducing the disulfide-bond rich epidermal growth factor-like 
structures of thrombomodulin (115).  
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There is growing evidence that immobilized proteins and enzymes have been found 
useful in many bioanalytical and biomedical applications (116). Among those enzyme-
immobilized systems, enzyme-incorporated lipid membrane constructs have been broadly 
used for biosensors and bioreactors (116-118), such as liposome-encapsulated enzymes  
for disease treatment. While the stability of the immobilized enzyme as an application for 
biosensors in medicine can retain months in most cases (116), the current model system 
































































































Figure 12  Stability of TM activities. Surface samples were incubated in phosphate-
buffered saline (PBS, 1X) at 37oC (A) steady-state APC generation (nM) and 
(B) rate of steady state APC generation (pmole/min/cm2) at shear rates 50 (●) 




































































Figure 13 Stability of TM activities. Surface samples were incubated within normal 
pooled human plasma at 37oC. (A) steady-state APC generation (nM) and (B) 
rate of steady state APC generation (pmole/min/cm2) at shear rates 50 (●) and 









Conclusively, membrane-mimetic films can be constructed on planar substrates with 
predictable surface concentrations of catalytically active TM. Under flow conditions, 
APC production increased with increasing TM surface density, but the catalytic capacity 
of TM was exceeded when TM surface density is greater than 800 fmole per cm2, 
indicating that a transport limit takes effect on the rate of reaction. The persistence of TM 
activity was investigated by incubating test films in human plasma at 37oC with periodic 































CHAPTER 4   
 
 
 FABRICATION AND CHARACTERIZATION OF HEPARINIZED SURFACE 





A functional heparinized surface based on biomimetic assemblies was fabricated as a 
potential system to improve hemocompatibility of blood contacting devices. Heparin was 
chemically modified by end-point conjugation of biotin. Soluble biotinylated heparin was 
tested for catalytic activity on thrombin inactivation by antithrombin (ATIII). 
Significantly, catalytic efficiency of biotin-heparin increased with increasing heparin 
concentration in a range of 10 nM to 1 µM (Mw ~ 14kDa). Immobilization of biotin-
heparin onto membrane-mimetic surfaces was achieved through biotin-streptavidin 
binding interactions. 3H-Heparin was used to determine surface concentration of heparin 
and the results showed that correlation between surface concentration and biotin content 
within membrane-mimetic assemblies were fit to binding isotherm. Activity of surface 
heparin was investigated under well-defined flow conditions by the use of a parallel plate 
flow chamber at wall shear rates of 50 sec-1 and 500 sec-1.  Significantly, rate of thrombin 
decay becomes saturated at surface heparin concentrations equal to or greater than 4.4 
pmole per cm2, indicating catalytic efficiency of surface heparin is exceeded due to a 






Clinically used since 1930s (119), heparin has become a common anticoagulant for 
preventing blood clotting during surgery and in the treatment of postoperative thrombosis 
and embolism. Heparin is a strongly negatively charged glycosaminoglycan (GAG) and a 
polymer of alternating hexuronic acid residues, which can be either D-glucuronic acid or 
L -iduronic acid, and D-glucosamine residues (Figure 14A). The resulting polysaccharide 
chain is highly sulfated, with N-sulfate groups on the glucosamine residues and O-sulfate 
groups in various positions on both the hexuronic acid and glucosamine residues. Both 
the distribution of glucuronic acid and iduronic acid unit and the sulfation pattern are 
variable, which results in a considerable structural heterogeneity (120, 121). Heparin has 
been found in mast cells in a large number of mammalian and nonmammalian vertebrates 
and is located mainly in tissues/organs that are in direct contact with the environment (i.e. 
lung, skin and intestine) (122).  
Pharmacologically, the well-known anticoagulant activity of heparin is due 
predominantly to the ability of the polysaccharide to accelerate greatly the rate by which 
antithrombin inactivates clotting proteinases including thrombin, factor Xa, and factor 
IXa (81, 123). The mechanism is primarily through initial binding of a unique 
antithrombin-binding pentasaccharide sequence (Figure 14B) in a heparin GAG chain to 
antithrombin, which induces a conformational change in the antithrombin molecule, and 
then greatly facilitates the antithrombin inhibition of its target enzymes (124, 125). The 
reaction for the inactivation of thrombin is accelerated 2000- to 4000- fold: the apparent 
second-order rate constant increases from 0.7 to 1.4 x 104 M-1s-1 at 25 to 37oC in the 
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absence of heparin to 1.5 to 4 x 107 M-1s-1 in the presence of optimal concentrations of 






























Figure 14  Heparin is a heterogeneous mixture of polysaccharides, which chains are 
made up of alternating 1 to 4 linked, sulfated monosaccharide residues of L-
iduronic acid and D-glucosamine. The most frequent types of disaccharide 
unit represent up to 90% of the structure of beef-lung heparin, and up to 70% 
of pig-mucosa heparin (A). The unique pentasaccharide binding site for 








Heparinization of artificial surfaces has been studied and shown to be a successful 
way to prevent surface-induced thrombus formation and improve the hemocompatibility 
of blood-contacting surfaces in a variety of studies. Among those studies, heparin 
immobilized onto surfaces using spacer groups has been largely reported. Covalent 
bonding of nitrite-degraded heparin by end-point attachment applied on membrane 
oxygenators and tubings makes it possible to maintain a long-lasting extracorporeal 
circulation without systemic heparinization (53). Heparin immobilized through 
poly(ethylene oxide) (PEO) spacer groups onto polyurethane surfaces consistently 
enhanced bioactivity in in vitro, ex vivo, and in vivo experiments (52, 131). It was 
demonstrated that the activity of immobilized heparin increased with increasing length of 
the alkyl spacer group (132). Heparin coupled to surface through a spacer system was 
found to be more active than direct coupling due to accelerated antithrombin binding to 
heparin, leading to enhanced inactivation of coagulation protease. Specifically, the 
dominant mechanism for spacer-immobilized heparin was binding to antithrombin, 
followed by thrombin binding to the heparin-antithrombin complex (133, 134).  
Our group has recently reported cytomimetic biomaterials as model platforms which 
can potentially improve the clinical performance characteristics of blood-contacting 
artificial organs and other implantable medical devices by modulating maladaptive 
processes at the blood material and tissue-material interfaces (77-80, 95, 96). Such a 
model construct provides strategies for generating biologically functional systems by 
incorporating transmembrane protein (79), as well as peptide or carbohydrate lipophilic 
conjugates (80). In addition, we have recently described and characterized a membrane-
mimetic thin film composed of mixed polymerizable lipids containing 
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phosphatidylcholine or biotin headgroups (80, 94), which leads to fabrication of 
heparinized surface based on membrane-mimetic assemblies (Figure 15). 
Heparin was chemically modified by oxidation and lactonization at the terminal 
position, followed by conjugation of biotinylated linker which was synthesized by 
reacting 2-(4-aminophenyl) ethylamine with N-biotin succinimide. Before applied for 
coating, biotinylated heparin was characterized by determining the extent of biotinylation 
and the catalytic efficiency on thrombin inactivation by antithrombin in a solution form. 
The results showed that there was more than 90% of biotinylation and the activity was 
comparable to that of original heparin extracted from porcine intestinal mucosa. 
Heparinized surface was then fabricated by coupling biotinylated heparin to biotinylated 
lipid thin film bridged by streptavidin. Surface concentration of heparin was determined 
and found to be a function of biotinylated lipid surface content. A parallel plate flow 
reactor containing heparin-coated surface was used to investigate heparin-mediated 
thrombin inactivation by antithrombin at shear rates of 50 sec-1 and 500 sec-1. Under such 
circumstances, the kinetics of thrombin inactivation at a heparinized surface is not only 
dependent on inherent reactions among thrombin, antithrombin, and heparin, but also 
influenced by the transport of reactant toward and removal of products from the catalytic 
surface, which is determined by convection in bulk and diffusion within boundary layer 
under laminar flow conditions. Steady-state rates of thrombin decay were higher at higher 
shear rate and became saturated in the presence of heparin surface content equal to or 
greater than 4.4 pmole/cm2, indicating that capacity of surface heparin to facilitate 
thrombin neutralization can not be further enhanced by increasing heparin surface density 







Figure 15  Schematic representation of immobilized heparin on the basis of polymeric 
phospholipid monolayer supported on an alkylated polyelectrolyte multilayer. 







4.3 MATERIALS AND METHODS 
4.3.1 Materials  
Human thrombin and antithrombin III (ATIII) were obtained from Haematologic 
Technologies, Inc. Heparin (sodium salt, porcine intestinal mucosa, Mw: 12,000-14,000) 
and streptavidin was obtained from Calbiochem. N-hydroxysuccinmido biotin (active 
ester) and polybrene (1,5-Dimethyl-1,5-diazaundecamethylene polymethobromide) were 
obtained from Sigma. Tritiated heparin (Heparin sodium salt,[3H(G)]- M.W. 6,000-
20,000) was purchased from PerkinElmer. Chromogenic substrate for thrombin 
Spectrozyme TH: H-D-hexahydrotyrosyl-L-alanyl-L-arginine-p-nitroanilide-diacetate 
salt was purchased from American Diagnostica, Inc. Eosin Y (EY, 5% in water), 
triethylamine (TEA), 1-vinyl-2-pyrrolidinone (VP) were obtained from Aldrich.  
Nucleopore polycarbonate filters, circular glass coverslips (12 mm diameter, 0.17 mm 
thickness from Fisher) and Contrad 70 detergent are obtained from Fisher.  Alginate 
(ALG; low viscosity, ca. 60% mannuronic acid) was obtained from Pronova Biomedical 
(Norway). Poly (L-lysine) (PLL, MW > 300 kD) and all buffer salts were obtained from 
Sigma. Synthesis of monoacrylate-PC (AcPC, 1-palmitoyl-2-[12-(acryloyloxy)dodeca-
noyl]-sn-glycero-3-phosphocholine), monoacrylate-PE (AcPE, 1-palmitoyl-2-(12-
(acryloyloxy)dodecanoyl)-sn-glycero-3-phosphoethanolamine) and its biotin derivative 
(biotin-AcPE, mono-acryl PE-biotin) have been described previously (77, 94).  The 
synthesis of the terpolymer that consists (3-acryloyl-3-oxapropyl-3-(N,N-dioctadecyl-
carbamoyl)-propionate))6:(2-hydroxyethyl acrylate)3:sodium styrene sulfonate1 
(AOD6:HEA3:SS1) has been described elsewhere (135).  
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Instrumentation. Biotinylated heparin was characterized by NMR spectroscopy for 
component analysis. 1H NMR spectra was recorded on a Varian INOVA 400 MHz or on 
600 MHz NMR spectrometer. For 1H NMR spectra recorded in CDCl3, D2O and CD3OD 
chemical shifts (δ) are given in ppm relative to solvent peaks (for CDCl3, 1H δ = 7.26, for 
D2O 1H δ = 4.85, for CD3OD 1H δ = 4.87 & 3.32) as internal standard. Coupling 
constants (J) are reported in Hertz (Hz). Size exclusion chromatography/laser light 
scattering (SEC/LLS) was used to determine molecular weight and polydispersity. 3H-
labeled materials were detected using a scintillation counter (Beckman LS 6000IC). UV-
Visible spectrophotometric measurements were executed on a Cary 50 Bio 
spectrophotometer (Varian) equipped with a temperature-regulated cell compartment. 
4.3.2 Synthesis of Biotin-Conjugated Heparin  
The procedure for the preparation of biotinylated heparin is illustrated in the Figure 
16.  Three reaction steps were sequentially conducted:  
Step I: Oxidization of Heparin 
Heparin sodium salt 1, was dissolved in water and passed through the protonated Dowex 
resin (50X8 H+) and eluted with water. The eluate was dialyzed and lyophilized to obtain 
Heparin (protonated form). The heparin-lactone was then prepared by oxidizing the 
reducing end of HMW protonated heparin (0.0392 mmol, 550 mg) by iodide (20 eq.) in 
20% aqueous MeOH solution (100 mL) for 6–8 h at room temperature. The completion 
of the oxidation process was assessed by 3,5-dinitrosalicylcic acid method.* The reaction 
solution was then added to a ethanolic 4% KOH solution (100 mL). The mixture was 
allowed to stand for 30-45 min and then the supernatant solution was decanted and 
centrifuged. The collective white residue obtained was dissolved in water and subjected 
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to dialysis (MWCO ∼ 3500) for 24 h. The sample solution was freeze dried and 
lyophilized to obtain the oxidized heparin product 2 (370 mg) [*3,5-dinitrosalicylcic acid 
method: 3 mL of sugar solution + 3 mL of DNS reagent. Heat the mixture for 5 – 15 min 
at 90 °C. The color of the solution changes from orange to reddish brown. 3,5-
dinitrosalicylcic acid reagent (1%) was prepared by dissolving 10 g of 3,5-DNSA, 2 g of 
Phenol, 0.5 g of Sodium sulfite Na2SO3, and 10 g of NaOH  in 1 L of deionized water]. 
Step II: Preparation of Heparin-lactone 
The oxidized heparin product 2 was subsequently dissolved in distilled water and passed 
through a protonated Dowex resin (50X8 H+) and stirred for 30 min. The eluant was then 
filtered and washed with water several time (the eluant was checked regularly with litmus 
paper to ensure that the washing is complete). The sample solution was freeze dried and 
lyophilized to obtain the heparin lactone 3 (300 mg).  
Amine-terminated biotin linker 6 was synthesized before conjugated with the heparin-
lactone: to a solution of 2-(4-aminophenyl)-ethylamine 4 (1.2 eq., 3.51 mmol, 478 mg) in 
dry DMF was added triethylamine Et3N (1.25 eq., 3.662 mmol, 510 µl) and the solution 
was stirred at room temperature for 20 min under Argon atmosphere. To this mixture, N-
biotin succinimide 5 (2.93 mmol, 1.0 g) dissolved in DMF was added and the reaction 
was allowed to stir at room temperature for 24 h. Removal of the solvent under vacuum 
afforded a residue which was purified by silica gel column chromatography using 10% 
CHCl3 + MeOH mixture as the eluent. The lyophilized product was orange yellow solid 
(510 mg, yield: 45 – 50%); TLC: 20% MeOH/CHCl3. 1H NMR (400 MHz, 9:1 CD3OD + 
CDCl3) δ 6.93 (d, 2 H, J = 5.6 Hz), 6.63 (d, 2 H, J = 5.6 Hz), 4.43 (dd, 1H, J = 3.2 Hz, 
NH-CH), 4.21 (m, 1H, J = 3.2 Hz, NH-CH), 3.1 (m, 1H, S-CH), 2.86 (dd, 1H, J = 3.2 
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Hz), 2.67 - 2.59 (5H, Ar-CH2 + NH-CH2 + S-CH), 2.09 (t, 2H, J = 4.4 Hz, CO-CH2), 
1.68-1.52 (m, 4H, (CH2)2), 1.15 (m, 2H, CH2).  
Step III: Coupling of aminated biotin with heparin Lactone 
Amine terminated biotin 6 (10 eq., 0,22 mmol, 75 mg) dissolved in DMF was added to a 
solution of heparin-lactone 3 (0.022 mmol, 300 mg) in DMF containing 
diisopropylethylamine (10 eq., 40 µl). The reaction mixture was stirred for 8 h at 55 – 60 
°C. The reaction mixture was concentrated and washed with CHCl3/MeOH mixture to 
remove the excess aminated biotin. The subsequent residue was dissolved in water, 
dialyzed (36 h, MWCO ∼ 3500) and freeze dried to obtain the biotinylated heparin. 
Finally, the biotinated heparin was purified by Gel permeation chromatography 
(Sephadex G-25) using water as an eluant. The water fractions containing the product 
were pooled together and lyophilized to afford a pale yellow biotin-functionalized 
heparin derivative 7 (180 mg, yield: 60%). 1H NMR of 7 (600 MHz, D2O) δ 7.6 – 7.2 (m, 
ArH), 5.72 – 4.91 (m, ring protons), 4.75 – 4.1 (m, ring protons + NH-CH), 4.08 – 3.35 
(m, ring protons), 3.06 – 2.76 (m, Ar-CH2 + NH-CH2 + S-CH), 2.09 (s, CO-CH2), 2.01 ( 






























Figure 16. Sequential procedure for the synthesis of biotinylated heparin. Adopted with 








4.3.3 Purification of Biotin-Conjugated Heparin. 
ImmunoPure® Immobilized Monomeric Avidin, a commercially available kit 
obtained from Pierce, was used for purification. The principle of the kit is using 
immobilized polymeric forms of avidin with strong binding characteristics to biotinylated 
molecules (137-139). In brief, these high affinity biotin-binding sites are first blocked 
with a biotin-containing buffer. Biotin molecules are eluted from the monomers with a 
glycine solution revealing only the reversible binding sites. The biotinylated molecule of 
interest may then be applied to the support for purification and then eluted by ligand 
competition using a biotin-containing buffer. Since the final eluted materials contain 
biotin, extraneous sources of biotin were removed by dialysis in order to obtain optimal 
binding capacity.   
4.3.4 Determination of Biotin Content From Biotin-Conjugated Heparin 
 
Biotin content from biotinylated heparin was determined using HABA assay 
which has been considered suitable for the spectrophotometric determination of the 
extent of biotinylation. The assay reagent, HABA/Avidin, contains 0.3 mM HABA (4-
Hydroxyazobenzene-2-carboxylic acid), 0.45 mg/ml avidin, 0.3 M NaCl, 0.01 M HEPES 
(N-[2-Hydroxyethyl] piperazine-NN-[2-ethanesulfonic acid], a buffer with pKa = 7.5), 
0.01 M MgCl2, 0.02% sodium azide (as a preservative), pH 7.3 when reconstituted with 
10 mL deionized water. The assay was run by following the manufacture protocols 
(Sigma). Briefly, the following samples were measured at 500 nm by UV-VIS 
spectroscopy: (a) 900 µL HABA reagent, (b)100 µL biotinylated heparin + 900 µL buffer 
(50 mM NaH2PO4/150 mM NaCl, pH 7.4), and (c) 900 µL HABA reagent + 100 µL 
biotinylated heparin. Then the absorbance difference ∆A500 defined as 0.9(a) + (b) – (c) 
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(0.9 is dilution factor of HABA reagent upon addition of sample) was calculated. The 
amount of biotin is defined as µmole biotin/mL, which is equal to (∆A500/34) X 10 (34 is 
mM extinction coefficient at 500nm, 10 is dilution factor of sample into cuvette). Biotin 
content of biotinylated heparin is defined as mole biotin/mole heparin, which is equal to 
(µmole biotin/mL sample)/(µmole heparin/mL sample) (140).  
4.3.5 Analysis of Biotin-Heparin Activity 
The heparin activity test was conducted based on its catalytic capacity to facilitate 
thrombin inactivation by antithrombin in a solution form, and activity of biotinylated 
heparin was investigated and compared to that of heparin (porcine mucus heparin, 
Calbiochem) in order to determine the effect of biotinylation on heparin activity. To 
perform thrombin inactivation assay, Hepes buffer (20 mM Hepes + 100 mM NaCl + 0.5 
wt% BSA) containing heparin was incubated with 10 nM human ATIII at 37oC for 5 min, 
followed by adding 10 nM human thrombin to start the reaction. At timed intervals, 
aliquots were withdrawn and assayed by adding to Tris buffer (50 mM Tris-HCl + 175 
mM NaCl + 0.05 wt% BSA, pH 7.9) containing 1 mg/mL Polybrene (141, 142) and 
chromogenic substrate Spectrozyme TH (0.2 mM final). The residual thrombin was 
determined by converting measured absorbance from UV-VIS spectrophotometer via a 





4.3.6 Fabrication of Biotin-Functionalized Membrane-Mimetic Thin Films 
Preparation of a (PLL-ALG)5-PLL Terpolymer Film on Circle Coverglass. Circle 
coverslip substrates (12 mm dia., Fisher) was cleaned by 30 minutes of sonication in 10% 
Contrad 70 detergent solution followed by extensive washing and sonication in deionized 
water. PLL and ALG were prepared at concentrations of 0.10 and 0.15 w/v % in 
phosphate-buffered saline (PBS; 20 mM NaH2PO4, 0.9 w/v % NaCl, pH 7.4), 
respectively.  The cleaned substrates were then coated by PLL and ALG alternating 
monolayers to form 11 layers (six PLL and five alginate layers) were coated, with the top 
layer comprised of PLL. The (PLL-ALG)5-PLL-coated substrates were then exposed to a 
0.1 mM solution of terpolymer (AOD6:HEA3:SS1) dissolved in a mixture of 20 mM 
NaH2PO4/DMSO (99:1 v/v), pH 7.4 for 90 s. The (PLL-ALG)5-PLL terpolymer coated 
samples were then rinsed 7-10 times with deionized water.  
Vesicle Fusion. Large unilamellar vesicles (LUVs) totaling 12 mM lipid (in either 0, 
2, 5, 10, 20, or 50 mol % biotin-AcPE) in 20 mM sodium phosphate buffer (pH 7.4) were 
prepared by four successive freeze/thaw/vortex cycles using liquid N2 and a 65 °C water 
bath. The LUVs were then extruded 21 times each through 2.0 µm and 0.6 µm 
polycarbonate filters (Millipore), and the solution was diluted to 1.2 mM with 20 mM 
sodium phosphate buffer (pH 7.4) and 150 mM NaCl. The (PLL-ALG)5-PLL terpolymer 
coated substrates were then incubated with the vesicle solution at 43 °C overnight for 14 
to 16 hours. 
In Situ Photopolymerization of a Supported Lipid Film. Details of the 
photopolymerization of lipid films on alkylated glass and silicon have been reported 
elsewhere (78, 135). Briefly, a stock solution of coinitiators was prepared as 10 mM 
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Eosin Y (EY), 225 mM triethanolamine (TEA), and 37 mM VP in water. A 10:1 
(mol/mol) monomer/EY ratio was used for photopolymerization. After lipid fusion, the 
samples were placed into an Ar-purged atmosphere at 30% relative humidity and 10 µL 
of initiator was added per 1 mL of sample solution. The initiator was gently mixed by 
slowly rotating the vial in a horizontal circular motion without lifting it from the bench 
surface. The sample was then irradiated with a Dynalume visible light lamp at an 
intensity of approximately 40 mW/cm2. Following photopolymerization, the samples 
were washed with deionized water 6-8 times and stored for further processes.  
4.3.7 Fabrication of a Heparinized Surface Based on a Membrane-Mimetic Thin Film  
Streptavidin binding onto a biotin-functionalized lipid membrane. Streptavidin was 
prepared in PBST (50 mM NaH2PO4 and 150 mM NaCl, pH 7.4) at a concentration of 
5µg/mL. Streptavidin-containing solutions were incubated with biotin-functionalized 
substrates for 15 min on a horizontal rotating platform, followed by rinsing with 
deionized water extensively (~ 10 times). 
Biotinylated heparin binding to a streptavidin-functionalized surface. Streptavidin-
coated lipid membranes were incubated with biotin-conjugated heparin at a concentration 
of 0.1 mg/mL in PBST overnight at 4oC on a horizontal rotating platform. The membrane 
was then rinsed with deionized water extensively (~ 10 times). 
4.3.8 Determination of Heparin Surface Density 
3H-heparin and unlabeled heparin were mixed to form a mass ratio of 1: 160 for 
biotinylation as described previously (4.3.2). The biotinylated compound was purified 
(4.3.3) and determined the extent of biotinylation with more than 95%. Specific activity 
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(cpm/µg or cpm/pmole) of 3H-heparin was determined by measuring radioactivity of 5, 
10, 15, 20, and 30 µL (5 replicates each) from a mixed 3H-heparin and unlabeled heparin 
solution prepared in  PBST at a concentration of 1 mg/mL. Surface density of heparin 
was determined by incubating streptavidin-coated membrane-mimetic thin films with the 
3H-heparin solution. Briefly, circle cover glasses (12 mm diameter) were cleaned and 
coated with membrane-mimetic constructs as described previously. A series of biotin 
contents in mixed lipids, 2, 5, 10, 20, 50 mole% of biotin-AcPE mixed with AcPC, were 
prepared for heparinization as described previously (4.3.7). The heparinized samples 
were placed in scintillation vials filled with scintillation liquid (BD Biosciences) and 3H 
activity was counted by scintillation counter (Beckman LS 6000IC). Heparin surface 
density (pmol/cm2) was calculated as (cpm/specific activity/sample area) and specific 
activity corrected for decay. Test surface samples were fabricated in six replicates for 
each lipid composition. 
4.3.9 Continuous Flow Reactor Assays on Heparinized Surface 
Heparinized surface was fabricated on a microscope glass slide (2.6 cm x 4.6 cm, 
Fisher) by anchoring biotinylated heparin onto streptavidin-coated membrane-mimetic 
thin film as previously described. In order to accommodate different surface amount of 
heparin, we selected 5, 10, 20, and 50 mol% of biotin-AcPE functionalized membrane-
mimetic surfaces for heparinization. Surface heparin activity was investigated under 
unidirectional flow conditions with shear rates 50 sec-1 and 500 sec-1. A parallel plate 
flow system  (0.6cm (width) x 0.01 cm (height) x 3.6 cm (length), 22 µL volume, Figure 
17) containing coated samples was flushed with 20 mM Hepes buffer for 1 hours at γw  = 
2000 sec-1. The reaction was started by perfusing the surface with HBSA (20 mM Hepes 
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+ 190 mM NaCl + 0.05 wt% BSA, pH 7.5) (143) containing thrombin (30 nM, final) and 
antithrombin (30 nM, final) in two syringes separately at 37oC. At pre-selected timed 
points, aliquots were withdrawn from the outlet of the reactor and assayed by adding to 
Tris buffer/EDTA (50 mM Tris-HCl + 175 mM NaCl + 0.05 wt% BSA + 20 mM EDTA, 
pH 7.9) containing Spectrozyme TH substrate (0.2 mM final) (143). The residual 
thrombin was determined by converting measured absorbance from UV-VIS 
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4.4 RESULTS AND DISCUSSION 
4.4.1 Synthesis of Biotin-Conjugated Heparin  
The rationale behind biotinylated Heparin is that biotin bound to an oligosaccharide 
moiety is available for noncovalent high affinity interaction with avidin or streptavidin. 
The affinity constant between biotin and the glycoprotein avidin is one of the largest free 
energies of association known for noncovalent binding of a protein and a small ligand in 
aqueous solution. This complex is extremely stable over a wide range of temperature and 
pH.  
Three reaction steps were sequentially conducted: I) iodide cleavage of the terminal 
reducing end, II) Lactone ring formation, and finally II) bioconjugation of the amine-
functionalized biotin with Heparin lactone via ring opening of the terminal pyranose ring 
to generate terminal biotin-tagged heparin construct. Heparin sodium salt was passed 
through the protonated Dowex resin (50 X 8 H+), eluted with water, dialyzed and 
lyophilized to obtain the protonated form of heparin. The heparin-lactone was prepared 
by oxidation of the aldehyde at the reducing end by iodide, which cleaves the pyranose 
ring at the C-O bond resulting in the formation of acid (COO−). The completion of the 
oxidation process was assessed by 3,5-dinitrosalicylcic acid. The acid so formed, reacts 
with the 5-hydroxyl group of the reducing end sugar in presence of an H+ ion exchange 
Dowex resin to form the cyclic lactone. The lactonized heparin was analyzed by NMR 
(Figure 18). It was noticed that although the purity of the lactone could not be determined 
by NMR, size exclusion chromatography (SEC, gel permeation) analyses (Figure 21) 
before and after the modification showed that there was little significant change between 
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the GPC pattern of lactone and heparin, indicating that oxidative cleavage of glycosidic 
bonds in the main backbone did not occur.  
 Generating a biotin terminated spacer-arm capable of conjugating to heparin 
necessitated the utilization of a linker possessing two functional groups. Based on our 
initial assessment, we devised a simple strategy which involved regioselective amide 
bond formation at one end of a diamine with the active ester of biotin. As such a diamine 
derivative having a free aliphatic and aromatic amine group at opposite ends (para- 
positions) of the aromatic skeleton was thought to be the ideal candidate for the coupling 
reaction. For example, based on the preferential selectivity of the two amines, reaction of 
N-hydroxysuccinmido biotin (active ester) with the diamine 2-(4-aminophenyl)-
ethylamine (NH2-Ar-R-NH2, where R = -CH2-CH2) resulted in regioselective amide bond 
formation at the aliphatic end of the primary amine (R-NH2) affording the desired free 
amine terminated biotin spacer (Yield 50%). The expected product was confirmed by 
NMR analysis (Figure 19). 
Subsequent reaction of the lactone with the amine-terminated biotin was carried out 
in presence of a base triethylamine (Et3N) and dry dimethylformamide (DMF) at 55 ºC 
for 10 h under Argon atmosphere. Anhydrous solvents and condition are required for this 
reaction considering the hygroscopic and water labile nature of the lactone. In order to 
drive the reaction and to ensure that the amide bond coupling between the lactone and the 
amine is complete, a 10 molar excess of amine is added. On completion, the crude 
mixture was concentrated in vacuum and washed with 10% CHCl3/MeOH mixture in 
order to remove the excess of biotin linker. The orange-brown residue obtained was 
dissolved in distilled water, dialyzed extensively (MWCO 6000-8000) for a period of 48 
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h and lyophilized. Final purification by gel permeation chromatography (Sephadex G25) 
of the product using distilled water as eluant followed by lyophilization furnished the 
biotinylated-heparin as a fluffy pale yellow solid. Analyses of the 1H NMR (Figure 20) of 
the product indicated the characteristic presence of aromatic protons at 7.2 ppm, keto-
methyl (COCH2) group from the spacer arm at around 2.1 ppm. Additionally, the 
aliphatic methylene protons (CH2, 1.4–1.6 ppm) while the resonance signals of other 
methylene protons attached to N-CH2, S-CH2, Ar-CH2 could be observed between 2.8-3.2 
ppm. Though the anomeric protons could be observed between 5.0–5.8 ppm, a 
characteristic peak at 2.00 ppm was assigned to the N-acetyl group (NH-COCH3) from 
heparin. In order to determine the coupling efficiency of the process, integration values of 
the peak heights between the aromatic protons and the N-acetyl resonance signal was 
calculated. The yield of the reaction was ∼60% while the conversion efficiency 
(calculated from 1H NMR) of the coupled product was found to be more than 90%. 
Moreover, in order to ascertain that incorporation of amine-terminated biotin via covalent 
functionalization of native heparin does not afford degraded byproducts due to competing 
side reactions resulting in loss of glycosidic moiety sequence (responsible for its 
antithrombogenic activity) from the parent polysaccharide chain, the molecular weight of 
the resultant biotinylated heparin was assessed by size-exclusion chromatography (SEC) 
coupled with refractive index (RI) and laser-light scattering (LLS) detectors (Figure 21 
and Table 3). To this end, analysis of heparin-lactone and biotinylated heparin in 
comparison with that of native heparin on the basis of its molecular weight demonstrated 
that covalent biomolecular modification of the heparin backbone resulted in significant 










Figure 18  1H NMR spectrum of heparin-lactone (600 MHz/D2O). Adopted with 

















Figure 19  1H NMR of amine terminated biotin spacer arm in CD3OD/CDCl3 mixture 






























Figure 20   1H NMR spectra of biotin-functionalized heparin D2O (600 MHz). Adopted 























Figure 21 Size Exclusion Chromatography (SEC)/ Laser Light Scattering (LLS) profiles 




Table 3 Polydispersity and molecular weight of heparin and biotin-heparin from SEC 
and LLS. Adopted with permission from (136). 
 
 Polydispersity Index 
(PDI) 
Molar Mass Moments (g/mol) 
Mw (kDa)                  Mz (kDa) 
Heparin 1.084 14.3 15.1 







The biotinylated heparin was purified by running through an avidin column (4.3.3) 
to assure optimal binding capacity. The process of purification was monitored by 
measuring absorbance of eluted substances at wavelength of 500 nm (see Appendix D). 
After purification, the extent of biotinylation of the compound was determined by HABA 
assay following the manufacture protocols (Sigma). The results (n = 5) are shown in the 
following: 
(a) A500 of HABA reagent  = 1.074 ± 0.008  
(b) A500 of biotinylated heparin + buffer = 0.067 ± 0.005  
(c) A500 of HABA + biotinylated heparin = 0.892 ± 0.012  
(d) ∆A500 (biotinylated heparin) = 0.9(a) + (b) +(c) = 0.229 ± 0.016  
(e) µmole biotin/mL (biotinylated heparin) = (∆A500/34 X 10) = 0.067 ± 0.005 
(f) 1mg/mL heparin solution = 0.072 (µmole/mL) (Mw = 13,800). 
 
Biotin levels from biotinylated-heparin, defined as mole biotin/mole heparin = (e)/(f) = 
0.92 ± 0.03,  showing extent of biotinylation was 92%. 
4.4.2 Analysis of Biotin-Heparin Activity 
 Activity of biotinylated heparin was analyzed based on its catalytic capacity to 
facilitate thrombin inactivation by ATIII. The results showed that thrombin decay was 
dependent on the heparin or biotinylated heparin concentration ranging from 10 nM to 1 
µM. A linear relationship between the reciprocal of the residual thrombin concentration 
and the incubation time (Figure 22) was found and the kinetic analysis demonstrated that 
thrombin decay fits the second order reaction (130). The slope of the curve represents the 
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second order rate constant (kapp). By comparing the second order rate constants between 
heparin and biotin-heparin (Table 4), heparin activity was considered well preserved after 
biotinylation. 
It was postulated that the reaction mechanisms include direct inactivation of 
thrombin by ATIII, formation of heparin-ATIII complex, and inactivation of thrombin by 
the complex. When heparin concentration varied from 1 nM to 1 µM, we assume that any 
heparin-thrombin complex formation would be negligible (144): 
 
 
ATIII + T    →   ATIII-T                     k0: 2nd – order rate constant without heparin 
0 k
 
b-H-ATIII + T   →   ATIII-T + b-H      k: 2nd- order rate constant with heparin 
k
 
b-H + ATIII     ↔     b-H-ATIII  KHI:  the dissociation constant of the b-H- 
KHI
ATIII complex                  
 
 
The apparent rate constant kapp is a function of k0, k, KHI, and Cb-H (130): 
 
kapp = (k0 KHI + k Cb-H)/(KHI + Cb-H)   Cb-H : concentration of biotin-heparin  
 
After rearrangement, kapp can expressed as:   
kapp = -KHI (kapp – k0)/Cb-H + k  
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KHI and k can be determined by experimental kapp values obtained at the 
corresponding Cb-H values, i.e. plotting kapp vs. (kapp – k0)/Cb-H. The two parameters, kapp 
and (kapp – k0)/Cb-H, were found to be linearly correlated, which determined the values of 
KHI and k as (2.30 ± 0.55) x 10-7 M and (2.42 ±0.17) x 109 M-1min-1, respectively. In the 
absence of heparin, k0 (= kapp) is 2.2 x 106 M-1min-1 which is three orders of magnitude 
less than k. The good correlation observed between the kinetic model and experimental 
data suggests that the heparin-accelerated thrombin-inhibitor reaction be a two-step 
mechanism when heparin concentration ranges from 10 nM to 1 µM, including the rapid 
formation of a heparin-inhibitor complex and the complex reacts with free thrombin. The 
reaction occurs more rapidly than that of the free inhibitor with the free protease in the 
absence of heparin. Comparing KHI and k with other studies (Table 5), we found there is 
no significant difference between the values computed from current experimental results 
and those from previous research, despite using different types of heparin (low molecular 






















































Figure 22  Thrombin inactivation by antithrombin in the presence of various (A) heparin 
or (B) biotin-heparin concentrations. Results for heparin concentrations 
ranging from 10 nM to 1 µM are presented: 0 (○),10 nM (■), 40 nM (□), 0.1 
µM (▲), 1 µM (∆). Each data point represents a mean value at each reaction 














Table 4  Comparison of experimental values of the second order rate constant between 
heparin and biotin-heparin. 
 
concentration Heparin Biotin-heparin 
µg/mL µM kapp (M-1min-1) kapp (M-1min-1) 
14 1 (2.69±0.30) x 109 (2.01±0.38) x 109
1.4 0.1 (7.11± 0.99) x 108 (6.50±0.14) x 108
0.56 0.04 (3.58±0.81) x 108 (3.13±0.32) x 108
0.14 0.01 (1.08±0.30) x 108 (1.03±0.24) x 108
0.014 0.001 (2.87±0.12) x 107 (6.87±1.88) x 106





Table 5  Comparison of dissociation constants of heparin-antithrombin (KHI) and the 
second order rate constants with heparin (k) between current and previous 
studies. 
 
  KHI (M) k (M-1 min-1) 
Maaroufi  et al. (130) (UFH1)a 3.7 x 10-7 1.3 x 109
Jordan et at. (144) (LMWH2)b 1.0 x 10-7 1.9 x 109
Olson (145) (LMWH3)b 2.3 x 10-7 N/A 
Griffith (128, 141)(UFH1)b 1.0 x 10-7 N/A 




1. UFH (unfractionated heparin,): Mw ~ 15 kDa  
2. LMWH (low molecular weight heparin): Mw ~ 6.5 kDa  
3. LMWH: ~ 8 kDa 
a. KHI  was computed from experimental data 
b. KHI  was determined directly from the change in the intrinsic fluorescence of 










4.4.3 Determination of Heparin Surface Density 
Mixed 3H-heparin and unlabeled heparin was biotinylated and its specific activity of 
the heparin solution averaged 324.6 CPM/µg. The extent of biotin levels was determined 
using HABA assay and the result showed that the biotin level is 0.975 ± 0.025 mole 
biotin/mole heparin (n = 5), approximately 1:1 molar ratio of biotin to mixed heparin. 
According to specific activity, surface mass of heparin was determined based on 
radioactivity from surface 3H-heparin and was found to be a function of surface biotin 
content (mol% of biotin-AcPE). The corresponding heparin surface concentration to 
biotin content within membrane-mimetic thin film is summarized in Table 6. Surface 
heparin content became saturated when biotin content within membrane-mimetic surface 
is larger than 50% (Figure 23).  Heparin surface concentration as a function of biotin 
content within membrane-mimetic construct was expressed in a double reciprocal plot 
(Lineweaver-Burke plot), i.e. 1/[heparin surface concentration] vs. 1/[biotin mole%] 
(Figure 24) and a linear relationship was found. From intercept of the fitted equation, the 
saturated heparin surface concentration is approximately 6.6 pmole/cm2, or equivalent to 
92.4ng/cm2 (Mw = 13.8 kDa).  
Previous studies about binding kinetics between streptavidin (SA) and biotin-
containing alkylated monolayers (146-148) which constructs were similar to current 
model systems showed that the amount of SA adsorption increases with surface mole 
fraction of biotin at low surface biotin concentrations, which provides more binding sites 
for anchoring biotin or biotinylated molecules. The amount of SA adsorption maximizes 
at ~230 ng/cm2 (~ 4 pmole/cm2) in the presence of 50 mole% of surface biotin (146). The 
gradual saturation of surface heparin possibly results from saturating surface SA. This 
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phenomenon may be explained by two reasons: the conformational and orientational 
disorder of the lipid hydrocarbon chains and the formation of biotin microdomains 
increase with increasing mole fraction of biotinylated lipids (80), and crowding biotin 
molecules on the surface may become less accessible to protrude deep enough into the 
binding site of SA (146). Indeed, it was observed that saturation coverage of SA 
decreases at high surface biotin concentrations (146, 149). 
Given the fact that streptavidin binding to biotin-containing monolayer normally 
exposes two of its binding sites away from the surface (149-151), the maximum surface 
content of biotinylated heparin onto streptavidin-biotinylated membrane-mimetic surface 
could double the amount of SA surface concentration. The accessibility for biotin-heparin 
to streptavidin binding sites and desorption of surface streptavidin by biotin-heparin 
could lower the maximum surface content of heparin, indicating the current experimental 



























































Figure 23  Surface density of biotin-heparin as a function of mole% of biotin-AcPE 
within membrane-mimetic construct. Each data point represents mean ± 




Table 6  Characterization of heparin surface concentration (mean ± standard deviation, 
n = 6) resulted from biotin-AcPE mole% within membrane-mimetic thin film.   
 
Biotin-AcPE mole% b-heparin (pmole/cm2) 
2 1.93 ± 0.26 
5 3.47 ± 0.41 
10 4.36 ± 0.44 
20 5.34 ± 0.51 











































y = 0.7446x + 0.1522
R2 = 0.9984
 
Figure 24  Lineweaver-Burke plot of data points from Figure 21. The linear relationship 










4.4.4 Flow Effect on Catalytic Efficiency of  Heparinized Surface 
After characterizing the surface concentration of heparin by altering biotin-AcPE 
content within membrane-mimetic construct, we further investigated how heparin density 
would affect thrombin inactivation by antithrombin under flow conditions. 
Thrombin decay curves in the presence of different surface densities of biotinylated 
heparin are shown (Figure 25). In the absence of surface heparin, thrombin responses at 
both shear rates of 50 sec-1 and 500 sec-1 stabilized after 20 min of perfusion showed 1.9-
2.5 nM of thrombin was inactivated, which were 6-8% of initial thrombin concentration 
(30 nM). In the presence of surface heparin, 35 to 50 % and 15 to 21 % of thrombin was 
inactivated at shear rates of 50 sec-1 and 500 sec-1, respectively, demonstrating surface 
heparin was catalytically active. In addition, time to reach the steady state level of 
thrombin decay (Figure 26 & 27) was shorter for higher shear rate, which were 
approximately 20 and 15 min after starting the flow at shear rates 50 sec-1 and 500 sec-1 
respectively). Moreover, the results revealed that no discernible effect on rate of thrombin 
decay when surface heparin was equal to or greater than 4.4 pmole/cm2, corresponding to 
immobilization of biotinylated heparin onto 10 mole% of biotin-AcPE within membrane-
mimetic thin film, indicating possible mass transfer limitation for thrombin and 
























































Figure 25 Thrombin inactivation at timed points during the perfusion of thrombin and 
antithrombin over heparinized surface with surface concentrations of 0 (○). 
3.47 (●), 4.36 (□), 5.34 (■), and 5.94 pmole/cm2 (∆) at shear rates of (A) 50 






























































Figure 26 Kinetic data of levels of thrombin decay over perfusion time as a function of 
heparin surface concentrations (3.47 (●), 4.36 (□), 5.34 (■), and 5.94 
pmole/cm2 (∆)) at shear rates of (A) 50 sec-1and (B) 500 sec-1. Each data point 
represents a mean value (n = 4). Note: the level of thrombin decay as the 
difference between the initial thrombin concentration, i.e. 30 nM, and a 
















































































Figure 27 Rate of thrombin inactivation (= level of thrombin decay x flow rate / flow-
exposed heparinized surface area) as a function of heparin surface 
concentrations (3.47 (●), 4.36 (□), 5.34 (■), and 5.94 pmole/cm2 (∆)) at shear 
rates of (A) 50 sec-1and (B) 500 sec-1. Each data point represents a mean value 
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Figure 28  Steady state rate of thrombin inactivation as a function of heparin surface 
concentration. Saturated rates of thrombin inactivation were 0.20 ± 0.01 and 
0.82 ± 0.03 pmole/min/cm2 (mean ± standard deviation) in the presence of 
surface heparin equal to or greater than 4.36 pmole/cm2 at shear rates of 50 
(○) and 500 (●) sec-1. Data points represent the mean values ± standard 











Heparin was chemically modified by conjugation of biotin spacer group at the 
terminal position without significantly compromising its catalytic capacity of thrombin 
inactivation by ATIII. Biotinylated heparin was further utilized for the fabricating the 
heparinized surface by immobilizing the compound onto streptavidin functionalized 
membrane-mimetic thin films. Surface concentration of heparin was characterized using 
3H-labeled heparin and found to be directly related to the surface density of biotin-
conjugated AcPE.  Significantly, surface concentration of heparin increases with 
increasing surface content of biotinylated lipids and tends to reach saturation in the 
presence of biotinylated lipids more than 50 mole% of the total surface lipids.  
In the absence of surface heparin, limited thrombin inactivation by antithrombin at a 
concentration of 30 nM was observed.  However, it is anticipated that thrombin activity 
will be tremendously diminished in a short period of time in the presence of physiologic 
concentration of antithrombin, ranging from 1.5 to 2.5 µM (152-154), hence the 
contribution of the heparinized surface to the inactivation of thrombin might be negligible. 
Nevertheless, the current system shows that surface heparin is catalytically active under 
flow conditions, yet its catalytic efficiency is limited by transport rates of reactants and 
products toward and removal from the surface. Inasmuch as membrane-mimetic 
assemblies can be easily controlled and modified as previously described (78-80, 94-96), 
we may create a potentially robust antithrombogenic environment by immobilizing 









   FABRICATION AND CHARACTERIZATION OF TISSUE FACTOR-COATED 





Tissue factor (TF), an integral membrane protein located on subendothelial cells, is 
the physiologic trigger of the blood coagulation during normal hemostasis when it is 
exposed to the blood following vascular injury. A TF-coated surface based on membrane-
mimetic assemblies, which have been developed from our laboratory, was fabricated as a 
model that functions to activate coagulation proteins. A continuous flow parallel plate 
enzyme reactor was used to  investigate the effects of shear rate, surface density of tissue 
factor, and mass transport on the activation of factor X and thrombin generation initiated 
by the complex of TF-factor VIIa. For factor X activation, production of factor Xa at the 
outlet of the reactor was monitored with time during perfusion of the flow chamber with 
160 nM factor X in the presence of 10 nM VIIa at physiologic shear rates of 50 and 500 
sec-1 in vein and artery, respectively. The results showed that time to reach steady-state 
factor Xa generation was shorter and the reaction rates are higher at higher shear rate. In 
addition, rate of factor X activation becomes saturated in the presence of more than 50 
fmole of TF per cm2, indicating the activation of factor X is controlled by the transport of 
reactants toward as well as removal of the products from the catalytic surface . For 
thrombin generation, the reaction is initiated by perfusing the TF-coated surface with 
coagulation factors V, VII, VIIa, VIII, IX, X, and prothrombin prepared at mean plasma 
concentrations. Kinetic behavior of thrombin production showed that the steady-state 
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levels were reached more rapidly at the higher shear rate and increased with increasing 
TF surface concentration. In contrast to thrombin generation in a static well mixed model 
studied by many researchers, the experimental results confirm that as anticipated local 
hemodynamic conditions play a key role in tissue factor induced Xa and thrombin 
generation. The reaction rates of thrombin generation became saturated at higher TF 
surface density in a manner similar to Xa generation, consistent with previous studies that 




































The blood coagulation process in vivo is initiated when subendothelial tissue factor is 
exposed to the blood flow following either the damage or activation of the endothelium 
(155). Tissue factor, a critical mediator in hemostasis and thrombosis, is an integral 
membrane glycoprotein that is normally presented on the surface of certain cell types 
located outside the vasculature. Since the appropriate spatial and temporal expression of 
TF is essential for thrombosis and hemostasis, TF expression in vivo is highly cell type-
specific (156). Instead of constitutive expression by endothelium or by cellular 
components of blood, TF is expressed strongly in the tunica adventitia, which ensures 
prompt initiation of coagulation in the event of vascular injury. In addition, induction of 
TF synthesis in vivo can occur during activation of endothelial cells and 
monocytes/macrophages by cytokines such as interleukin-1 and tumor necrosis factor, 
endotoxin, and anoxia (157-160) and is implicated in the onset of thrombosis in 
conditions as diverse as atherosclerosis (161), disseminated intravascular coagulation 
(DIC), malignancy (162) and hyperacute rejection of xenografts (163).  
Tissue factor functions in coagulation by serving as a protein cofactor for a plasma 
serine protease, factor VIIa. Although the vast majority of factor VII in plasma circulates 
as a zymogen, all normal individuals have been found to have low levels of factor VIIa in 
their plasma (~1% or less of the total VII) (164). At the site of a vascular injury, factor 
VII and VIIa bind TF and form a TF-factor VIIa complex (TF:VIIa), which triggers the 
blood clotting cascade in two ways. One is to directly activate factor X to Xa. The other 
is to activate factor IX to IXa which can, in turn, activate factor X in the presence of its 
protein cofactor, factor VIIIa, on a phospholipids surface. Interestingly, factor X appears 
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to be the preferred substrate for TF:VIIa under in vitro conditions, although which 
mechanism predominates in vivo may depend on local factors, which are not entirely 
understood (16). Newly formed Xa assembles on phospholipid surfaces with its protein 
cofactor, factor Va, to catalyze the conversion of prothrombin to thrombin, which is 
responsible for fibrin clot formation and serves as a potent platelet activator.  
Additional details regarding the initiation and propagation phases of the coagulation 
phases are worth noting. During the “initiation phase” (26) of the blood coagulation 
process, limited activation of the coagulation zymogens such as IX and X occurs in the 
absence of their cofactors. Nonetheless, trace amounts of initial thrombin can be 
produced (~ picomolar concentration). Significantly, the newly formed thrombin 
accelerates further thrombin generation by feedback activation of cofactors V and VIII, 
which leads to explosive generation of thrombin during the “propagation phase” (26) of 
the process. In addition , factor VII can be further activated by factors IXa, Xa, XIIa, 
thrombin and plasma (165-171) to enhance the amplification of coagulation protease 
generation. 
TF-initiated blood coagulation has been well investigated using several in vitro 
models under nonflow conditions (20-27, 172), which has revealed much about the 
biochemistry of coagulation. However, several reports have documented that shear flow 
is a critical regulator of surface TF reactivity (109, 112, 173-175). Specifically, it has 
been demonstrated that Km decreased and Vmax increased with increasing shear rate in 
TF:VIIa-catalyzed activation of factor X (112, 175), indicating enzymatic efficiency is 
enhanced by flow. In addition, the rate of the surface reaction is limited at an upper level 
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of TF surface density, suggesting that a transport-limited effect plays a dominant role in 
determining the maximum levels of local thrombin production.  
As a transmembrane protein, TF can maintain its activity only when incorporated into 
phospholipid vesicles or supported membranes (176). Significantly, TF activity in terms 
of catalyzing activation of factor X is maximal when relipidated TF contains 20 mole% 
of phosphatidylserine, a negatively charged phospholipid (164). Previous studies have 
shown that a TF containing phospholipid bilayer can be immobilized on a glass surface 
and thereby utilized as a continuous flow enzyme reactor for simulating TF-initiated 
blood coagulation (50, 109, 112, 174). Inasmuch as we consider TF to be the major 
trigger of coagulation and neighboring lipid membranes as an essential cofactor for such 
surface reactions, a TF-coated surface based on the membrane-mimetic assembly 
described in the previous chapters was developed. The main purpose of creating such a 
system was to determine the antithrombogenic capacity of anticoagulants incorporated 
into membrane-mimetic thin film, such as surface heparin and thrombomodulin. In this 
chapter, TF-coated surfaces are described and surface TF activity in the absence of 
anticoagulants is characterized.  
TF-reconstituted lipid vesicles, composed of phosphatidylcholine, phosphatidylserine, 
and phosphatidylethanolamine, were anchored via biotin-streptavidin binding interactions 
on membrane-mimetic constructs containing a mixture of polymerizable phospholipids, 
monoacrylate-phosphatidylcholine and biotin-conjugated monoacrylate-
phosphatidylethanolamine (Figure 29). Instead of varying surface biotin content within 
membrane-mimetic thin film, we characterized TF surface concentration by changing 
molar ratios of TF to lipid (TF:PL)vesicles at fixed surface biotin content of 10 mol%. TF 
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surface concentration was found to increase with increasing TF:PL at fixed lipid vesicle 
concentration. TF-coated surfaces were fabricated as a continuous flow enzyme reactor in 
a parallel plate flow chamber and the catalytic efficiency of TF-mediated factor X 
activation and thrombin generation was defined under wall shear rates of 50 and 500 sec-1. 
Our studies revealed that the capacity of TF to induce factor Xa and thrombin was 
dependent upon shear rate and TF surface concentration. Saturated levels of factor Xa 
and thrombin were reached at surface TF concentrations equal to or greater than 50 fmole 
of TF per cm2. As compared to previous studies under nonflow conditions, flow studies 
confirm that thrombin is not only dependent on inherent reactions among zymogens and 
their enzyme complexes, but also influenced by the transport of macromolecules from the 




































Figure 29   Schematic representation of immobilized relipidated tissue factor on the basis 
of polymeric phospholipid monolayer supported on an alkylated 













5.3 MATERIALS AND METHODS 
5.3.1 Materials  
Human coagulation factors V, VII, VIIa, IX, X, prothrombin, human antithrombin 
III, and human protein C were obtained from Haematologic Technologies, Inc. Human 
coagulation factor VIII, tissue factor ( full length recombinant human tissue factor, TF, 
43 kD, lyophilized from 0.01 M Tris, 0.15 M NaCl, pH 8.0 containing 0.01% CHAPS 
and 200 mM mannitol), and Spectrozyme TH substrate for thrombin (H-D-
hexahydrotyrosyl-L-alanyl-L-arginine-p-nitroanilide-diacetate salt) were obtained from 
American Diagnostica Inc. S-2222 substrate for factor Xa (Bz-IIe-Glu(γ-OR)-Gly-Arg-
pNA•HCl) was purchased from Chromogenix.  Eosin Y (EY, 5% in water), triethylamine 
(TEA), 1-vinyl-2-pyrrolidinone (VP) were obtained from Aldrich.  Nucleopore 
polycarbonate filters and Contrad 70 detergent were obtained from Fisher. Detergent OG 
(n-octyl-β-D-glucopyranoside) was obtained from Sigma. Chicken egg PC (L-α-
Phosphatidylcholine), porcine brain PS  (L-α-Phosphatidylserine, sodium salt), N-
Biotinyl Cap-PE (18:1) ( 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-Cap 
Biotinyl), and fluorescent PE (1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-
Carboxyfluorescein) were purchased from Avanti Polar Lpids, Inc. Alginate (ALG; low 
viscosity, ca. 60% mannuronic acid) was obtained from Pronova Biomedical (Norway).  
Poly (L-lysine) (PLL, MW > 300 kD) and all buffer salts are obtained from Sigma. 
Synthesis of monoacrylate-PC (AcPC, 1-palmitoyl-2-[12-(acryloyloxy)dodeca-noyl]-sn-
glycero-3-phosphocholine), monoacrylate-PE (AcPE, 1-palmitoyl-2-(12-
(acryloyloxy)dodecanoyl)-sn-glycero-3-phosphoethanolamine) and its biotin derivative 
(biotin-AcPE) have described previously (77, 94) . The synthesis of the terpolymer that 
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consists (3-acryloyl-3-oxapropyl-3-(N,N-dioctadecyl-carbamoyl)-propionate))6:(2-
hydroxyethyl acrylate)3:sodium styrene sulfonate1 (AOD6:HEA3:SS1) has been 
described elsewhere (96). 
5.3.2 Reconstitution of Tissue factor into Phospholipid vesicles 
TF was reconstituted within lipid vesicles as described in the literature with some 
modification (18, 177).Phospholipids (dissolved in chloroform) consisting of 79 mole% 
egg PC, 20 mole% brain PS, and 1 mole% biotin-cap-PE were dispensed in a glass test 
tube. The resulting solution was dried by N2, followed by high vacuum SpeedVac for 2 
hours. Fresh OG/HBS, buffer solution, containing 100mM n-octyl-β-D-glucopyranoside 
and HBS (20 mM Hepes, 100 mM NaCl, and 0.02% (w/v) sodium azide, pH 7.5), was 
prepared and added with vortexing to completely dissolve the dried lipid mixture. 
Sonication was occasionally necessary to dislodge any residual pellet at the bottom of the 
test tube. Once dissolved, the lipid mixture was kept at room temperature for subsequent 
relipidation of TF. TF was dissolved in the lipid mixture and HBSA, 0.1% (w/v) bovine 
serum albumin in HBS, added to produce a desired TF:lipid molar ratio, ranging from 
1:8000 to 1:160000, at a fixed lipid concentration of 5 mM. The whole mixture was 
mixed well and incubated for 30 min at room temperature. The sample was dialyzed (Mw 
cutoff: 12,000) at room temperature against three changes of HBS (24 hr each, for a total 
of 72 hr). Final TF concentrations ranging from 6 to 120 nM in 1mM lipid were prepared 
for surface samples. The relipidated TF was extruded 21 times each, through 0.6 µm and 
0.1µm polycarbonate filters (Avanti Polar Lipids, Inc.) and used for coating of test 
samples.  
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5.3.3 Fabrication of Tissue Factor Containing Membrane-Mimetic Surface 
Microscope glass slides (2.6 cm x 4.6 cm, Fisher) were cleaned and coated with 
biotin-functionalized membrane-mimetic thin film (molar ratio of AcPC: biotin-AcPE = 
90:10), followed by coating with streptavidin, as previously described (80). TF-coated 
surfaces were fabricated by immersing the entire glass slide in the TF-reconstituted lipid 
mixture on a rotating platform. The coating time was 30 min at room temperature, 
followed by rinsing extensively using deionized water. Fluorescent PE (fluorescein, 0.1 
mole% final) was doped within lipid vesicles (starting from removing chloroform step) 
for fluorescent microscopy studies.  
5.3.4 Continuous Flow Reactor Assays on Tissue Factor Containing Membrane-Mimetic 
Surface  
 
Surface TF bioactivity was characterized in terms of factor X activation and 
thrombin generation under flow conditions. 
Xa Generation—Surface TF-catalyzed factor X activation was investigated at shear rates 
of 50 sec-1 and 500 sec-1. A parallel plate flow system (0.6 cm (width) x 0.01 cm (height) 
x 3.6 cm (length), 22 µL volume) containing the coated sample was flushed with 20 mM 
Hepes buffer for 1 hours at γw  = 2000 sec-1 (flow rate of  1.24 mL/min). The reaction 
was started by perfusing the coated slides with a reaction mixture containing factor VIIa 
(10 nM, final), factor X (160 nM, final), and CaCl2 (5 mM, final) in Hepes buffer/BSA 
(10 mM Hepes + 140 mM NaCl + 0.1 wt% BSA, pH 7.5) (109). At pre-selected timed 
points, aliquots were withdrawn from perfusate at the reactor outlet and quenched in 
Hepes buffer/EDTA (20 mM Hepes + 150 mM NaCl + 50 mM EDTA + 0.1 wt% BSA, 
pH 7.5). Samples were assayed for Xa after adding S-2222 (0.2 mM, final). Xa 
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concentration was determined by monitoring the change in absorbance at 405 nm using 
UV-VIS spectrophotometer and calculating via a standard curve (see Appendix A). 
 
Thrombin Generation —Surface TF-initiated thrombin generation was investigated at 
shear rates of 50sec-1 and 500 sec-1.  The parallel plate flow system containing a coated 
test sample was flushed with 20 mM Hepes buffer for 1 hour at γw  = 2000 sec-1. The 
reaction was started by perfusing the surface with Hepes buffer/BSA (20 mM Hepes + 
150 mM NaCl, pH 7.4) (25, 172) containing coagulation factors (V, VII, VIIa, VIII, IX, 
X, prothrombin)  and 2 mM CaCl2 at 37oC (14, 26). The final concentrations of the 
proteins in the reaction were chosen to represent mean plasma values: 20 nM factor V, 10 
nM factor VII, 0.1 nM factor VIIa, 0.7 nM factor VIII, 90 nM factor IX, 160 nM factor X, 
and 1.4 µM prothrombin (14, 26). At pre-selected timed points, aliquots withdrawn from 
the perfusate at the reactor outlet were quenched in Tris-buffer/EDTA (50 mM Tris-HCl 
+ 150 mM NaCl + 20 mM EDTA, pH 7.4), and assayed by adding Spectrozyme TH 
(0.2mM final). Thrombin concentration was determined by monitoring the change in 
















5.4 RESULTS AND DISCUSSION 
5.4.1 Fluorescent Images of Lipid Vesicles Bound onto Membrane-Mimetic Films   
TF containing surfaces were fabricated by tethering TF reconstituted lipid vesicles, 
composed of 79 mol% phosphatidylcholine (PC), 20 mol% phosphatidylserine (PS), and 
1 mol% biotin- phosphatidylethanolamine (b-PE), to biotinylated membrane-mimetic thin 
films through biotin-streptavidin binding interactions. Doped with 0.1 mol% of 
fluorescein-labeled PE, immobilized lipid vesicles were visualized using fluorescent 
microscopy for initial characterization of the surface. 
Images (Figure 30) demonstrate that fluorescent intensity increases with increasing 
concentrations of biotin-PE, indicating that more vesicles adsorbed to those surfaces with 
increasing biotin-PE on glass substrates. While lipid vesicles appear to be evenly 
distributed on surfaces containing less than 10 mole% of biotin-AcPE, clustering of 


































Figure 30 The fluorescent images (20x) of 1mM lipid vesicle coated surfaces. 0.1 mol% 
FITC-doped lipid vesicles were coated on surface containing 0 mol% biotin-
AcPE/AcPC (control) (A), 5 mol% biotin-AcPE/AcPC (B), 10 mol% of 
biotin-AcPE/AcPC (C), and 50 mole% biotin-AcPE/AcPC (D) through biotin-









Such phenomena might be associated with microphase separation of the PC and 
biotinylated lipids, as well as incomplete vesicle fusion at high biotin-AcPE surface  
concentrations (80). In order to have well-distributed TF coated region, we proposed to 
utilize lipid composition of 10 mol% biotin-AcPE/90 mol% AcPC as our model platform 
for the following studies. 
 
5.4.2 Surface Activity of Tissue Factor Under Flow Conditions  
Since tissue factor is involved in a number of haemostatic reactions, we selectively 
investigate activation of factor X and generation of thrombin initiated by surface TF. 
Presumably, TF surface density ([TF]surface) is a function of relipidated TF concentration 
([TF]lipid) within biotinylated lipid vesicles (egg PC/brain PS/biotin-PE = 79/20/1) given 
the fixed biotin content of the lipid monolayer, which contains10 mol% biotin-AcPE. To 
determine TF surface density, we used radiolabeled TF, detected radioactivity from the 
coated surface, and converted to surface mass from specific activity. The details will be 
described in Chapter 6 (section 6.4.2). At this point, we apply the results which show 
[TF]surface ranging from 9 to 90 fmole/cm2 corresponding to 6 to 120 nM of TF within 
1mM lipid to represent TF surface content. The effect of [TF]surface on these two critical 
coagulation factors under flow conditions is presented in the following.   
 
Xa generation 
Kinetic data (Figure 31) reveal that Xa generation reaches a maximum level with a 
shorter lag period at the higher shear rate and the level is higher at lower shear rate. 
Times to reach maximum Xa generation are approximately 12 and 7 minutes at 50 and 
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500 sec-1, respectively. An exception was noted for the lowest [TF]surface of 9.4 
fmole/cm2, which takes 2 to 3 minute longer to reach the steady state. While the time to 
reach steady state Xa generation appears to be slow at a [TF]surface of 9.4 fmole/cm2, there 
is no significant shear effect on the time to reach steady state when TF density is greater 
than [TF]surface of  51.2 fmole/cm2. Steady state Xa generation as a function of TF density 
(Figure 32) shows steady state values increase with increasing TF density and tends to be 
saturated in the presence of high TF density.  Significantly, steady-state Xa generation 
plateaus at a [TF]surface of  51.2 fmole/cm2, indicating a transport-limit is reached.   
Activation of factor X as a function of TF surface density is analyzed in a similar 
fashion to activation of protein C described in Chapter 3. The relationship between rate of 
reaction and TF density was fit to the equation for a hyperbola to determine kinetic 
parameters: rate of reaction in the presence of saturated TF, Vmax E, and TF density 
required to reach half-maximal rates, K1/2E (Table 7). At 15.0 and 22.6 fmole of TF/cm2, 
the half-maximal activation rates of factor X were 0.45 and 1.13 pmole/(min·cm2) 
respectively, which are equivalent to 30.1 and 49.8 conversions per min per enzyme 
molecule at shear rates of 50 and 500 sec-1 respectively, as compared to 10.1 (500 sec-1) 
and 25.4 (500 sec-1) conversions per min per enzyme molecule at 88.6 fmol/cm2 TM, 
showing the excess catalytic capacity at high TF densities. According to the theoretical 
analysis of average transport rate limit (eq. (7), Chapter 3), the ratio of Vmax E at 500:50 
sec-1 is approximately 2.2 (5001/3:501/3), while experimental results show a ratio of 2.5, 

















































Figure 31 Factor Xa generation with various TF surface concentrations (9.4 (●) 27.3 (○) 
51.2 (■) 69.9 (□) 88.6 (▲) fmole/cm2) at shear rates of (A) 50 sec-1 and (B) 
500 sec-1. Each data point represents a mean value for five experiments (see 
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Figure 32  Steady state rate of factor Xa production as a function of TF surface 
concentration at shear rates of 50 (○) and 500 sec-1(●). Each data point 
represents a mean ± standard deviation (n = 5). Steady state rate of factor Xa 
generation (pmole/min/cm2) = steady state factor Xa generation (nM) x flow 




Table 7 Parameters of TF Density Titrations. The TF density plots (Lineweaver-Burk 
plot) of Figure 25 were fit to a hyperbola. The maximal factor Xa production 
rate (Vmax E) and the TF density resulting in half-maximal rate of reaction (K1/2 
E) are shown. Data represent mean ± standard deviation (n = 5). 
 
γw (sec-1) K1/2 E (fmole/cm2) Vmax E (pmole/min/cm2) 
50 14.96 ± 1.61 0.89 ± 0.10 








Thrombin generation  
Similar to characterizing factor X activation from surface TF, the effects of shear 
rates and TF surface density on surface TF-induced thrombin generation were 
investigated. Generally, thrombin generation started to accelerate within minutes of 
perfusion and steady state levels were reached at 10 and 5 minutes after starting the 
perfusion at shear rates of 50 and 500 sec-1, respectively. An exception was noted for the 
lowest TF surface density (9.4 fmole/cm2), which takes 2 to 3 minutes longer to reach 
steady state (Figure 33). Steady state thrombin concentrations were higher at lower shear 
rate, which was also observed for factor Xa generation. Thrombin generation increases 
with increasing TF surface density and plateaus when TF concentration is more than 51.2 
fmole/cm2 (Figure 32), which was also observed for factor Xa generation. Steady state 
levels of thrombin generation are 472.20 ± 35.24 nM and 190.37 ± 25.36 nM at shear 
rates of 50 and 500 sec-1, respectively. Since TF-initiated thrombin generation under flow 
conditions involves at least twenty kinetic rate constants (178) and also requires a 
consideration of transport properties of reactants and products towards and away from the 
catalytic surface, it is beyond the scope of this study to explore all of these potential 
factors. Nonetheless, these experimental results indicate that TF containing surfaces can 
be produced and exhibit prothrombotic activity for our intended antithrombogenic test 
system.   
Previous studies on thrombin generation under nonflow conditions (26, 178) show 
that a rapid thrombin production occurs within 1.5 minute and reaches the plateau after 2 
minutes of reaction with ~ 1.5 µM of thrombin generation. The slower thrombin response 
and lower level of thrombin generation from the current flow experiments demonstrate 
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the effect of shear rate and transport of reactants and products on surface enzymatic 
reactions related to blood coagulation. An in vitro flow study from van’t Veer et al. (179) 
has shown that TF surface activity on stimulated human umbilical vein endothelial cells 
can trigger activation of factor X as well as thrombin production by perfusion of 
coagulation protein mixture similar to current studies. Specifically, steady state rate of 
thrombin generation from a stimulated endothelial cell-coated surface was around 10 
pmole/min/cm2 at shear rate of 100 sec-1, while we observed around 6.8 pmole/min/cm2 
at shear rate of 50 sec-1 from the current TF-coated surface (the plateau in Figure 34B). A 
stimulated rate vascular smooth muscle cell-coated surface in an in vitro flow system 
(180) showed human factor Xa flux was approximately 0.14 pmole/min/cm2 at shear rate 
of 80 sec-1, while our studies showed that saturated rate of factor Xa generation was 
around 0.68 pmole/min/cm2 at shear rate of 50 sec-1. These demonstrate surface TF 
activity is cell-type specific and surface TF from our model system can exhibit 
comparable even greater activity than active cell surfaces. Although surface 
concentration of tissue factor expressed at vascular injury sites has not been well 
characterized, we speculate surface tissue factor activity on membrane-mimetic thin film 
to induce activation of factor X and thrombin generation from the current study may 
provide a potential model system for investigating blood coagulation on live cell 
membranes and its regulation using anticoagulants and/or inhibitors for future 
applications.  
We demonstrated surface bound TF is active due to its catalytic ability to initiate 
generation of Xa and thrombin. Previous studies (27) suggests that concentration of Xa is 
the rate-limiting component of prothrombinase complex formation and the ultimate 
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generation of thrombin activity. Since the involved reaction mechanisms intertwined with 
transport of substances makes thrombin generation under flow a complex issue, 




























































Figure 33 Thrombin generation with various TF surface concentrations (9.4 (●) 27.3 (○) 
51.2 (■) 69.9 (□) 88.6 (▲) fmole/cm2) at shear rates of (A) 50 sec-1 and (B) 
500 sec-1. Each data point represents a mean value for five experiments (see 
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Figure 34  (A) Thrombin concentration (nM) and (B) rate of thrombin generation 
(pmole/min/cm2) as a function of TF concentration within lipid vesicles at 
shear rates of 50 (●) and 500 (○) sec-1. Each data point represents a mean ± 





In summary, a TF containing membrane-mimetic thin film can be produced with 
predictable surface concentrations of TF. We demonstrated surface bound TF is active 
due to its ability to initiate generation of Xa and thrombin. We have utilized a parallel 
plate continuous flow reactor to investigate the effect of TF surface density on behavior 
of activation of factor X and thrombin generation at physiologic relevant shear rates. 
Factor Xa production increases with increasing TF surface density when surface 
concentration is less than 50 fmol/cm2, beyond which the catalytic capacity of TF is 
exceeded, indicating that reaction velocity will not increase because of a transport 
limitation. Similar responses of Xa and thrombin are consistent with the view that the 
generation of thrombin is dependent upon Xa.  Indeed, previous studies (27) suggests that 
concentration of Xa is the rate-limiting component of prothrombinase complex formation 
and the ultimate generation of thrombin activity.  
Recent studies have reported that physiologically active TF is found circulating in 
blood of healthy individuals either as a component of blood cells and microparticles or as 
a soluble plasma protein (181), it is speculated these forms of TF do not trigger blood 
coagulation because the activation threshold condition is not exceeded, and activated 
enzyme, such as factor VIIa, could safely circulate without initiating explosive 
coagulation. Substantial exposure of surface TF to blood due to vascular injury is largely 
responsible for thrombin generation. Trauma substantial enough to raise TF levels 
beyond the transition level would elicit a very strong response, primed by the interaction 
of the circulating factor VIIa with the newly exposed TF. That response would be 
localized to the immediate vicinity of surfaces on which the binding-site density was high. 
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Since surface density of TF from vascular injury site has not been reported, the 
current in vitro studies provide a strategy for generating TF-coated surface as a model to 













































   REGULATORY EFFECTS OF THROMBOMODULIN, HEPARIN, AND 
THROMBOMODULIN/HEPARIN COMPOSITE SURFACES ON TISSUE 






The ability to design blood contacting surfaces that limit tissue factor (TF)-induced 
thrombin generation by activating protein C and ATIII was evaluated in a continuous 
flow system. Tissue factor along with thrombomodulin (TM) and heparin was 
immobilized in a spatially distinct manner onto a planar surface as components of a 
membrane-mimetic film. Specifically, TF positioned over a 2 x 6 mm2 upstream region 
as a trigger for thrombin generation and TM and/or heparin positioned over the remaining 
downstream (34 x 6 mm2) portion of the test film. In the absence of TM and heparin, 
thrombin generation was investigated as a function of TF surface density at shear rates of 
50 and 500 sec-1.  At both shear rates, the limit of thrombin generation was attained at TF 
densities equal to or greater than 51.2 fmole per cm2. However, the lag time to reach 
steady state and the steady state concentration of thrombin were reduced at increasing 
shear rate. Peak ([T]max) and steady state ([T]ss) concentrations of thrombin were reduced 
by ATIII and in the presence of surface bound TM and/or heparin. Although ATIII alone 
reduced thrombin levels, this effect was significantly enhanced by surface bound TM and 
heparin. At shear rate of 50 sec-1, the steady state concentration of thrombin in the 
absence ATIII or protein C was approximately 29.8 ± 2.0 nM (mean ± standard deviation, 
n = 5).  In the presence of ATIII, but in the absence of surface bound TM or heparin, the 
steady state concentration of thrombin was profoundly reduced to 8.4 ± 0.7 nM.  
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Incorporating heparin or TM into a membrane-mimetic film reduced thrombin levels to 
6.3 ± 1.1 nM and 3.9 ± 1.0 nM, respectively. Compared to a TF surface in the presence of 
ATIII only, lowest levels of thrombin, which were reduced about three times, were 
observed when films contained both heparin and TM.  Similar responses were observed 
at 500 sec-1. These studies are the first to demonstrate the additive effect of surface bound 
heparin and TM as a combined interactive strategy to limit TF-induced thrombin 




































Tissue factor pathway has been commonly accepted as a major mechanism 
responsible for blood coagulation which is initiated by exposure of subendotheilial 
integral membrane protein tissue factor (TF) to blood due to vascular injury (14-16, 155). 
The procoagulant reaction starts with the binding of activated factor VII (factor VIIa) to 
TF to form VIIa-TF enzyme complex which activates the zymogens factor X and IX by 
limited proteolysis (182). Factor IXa combines with its cofactor factor VIIIa on the 
membrane surface to form a second complex that activates factor X. Once activated, 
factor Xa associates with its cofactor factor Va on a membrane surface to form 
prothrombinase, which converts prothrombin into thrombin (98, 183).The thrombin 
initially formed accelerates further thrombin generation by feedback activation of the 
procofactors factor V and factor VIII. Thrombin may also activate factor XI (184, 185), 
which, in turn, activates more factor IX.   
Thrombin stimulates platelets, which secrete their granule contents and aggregate, 
cleaves fibrinogen to generate the fibrin network, and activates the protransglutaminase 
factor XIII. The fibrin-platelet aggregate, stabilized by factor XIIIa-catalyzed cross-links, 
forms the haemostatic plug. Without regulatory systems of blood coagulation, amplified 
thrombin generation leading to overwhelmed blood clot formation would be detrimental 
due to severely constricted blood fluidity. 
Normal endothelium performs anticoagulant functions to balance thrombin generation 
by producing thrombin inhibitors, including endothelial surface-bound thrombomodulin 
(TM) and heparan sulfate (HS). TM functions as a critical regulator to trigger protein C 
activation. By binding to thrombin, TM converts procoagulant thrombin into 
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anticoagulant TM-thrombin complex which enhances activation of protein C. The 
product APC can exhibit its inhibitory effect on coagulation by proteolytically 
inactivating factor Va and factor VIIIa so that ultimate thrombin generation can be 
reduced. Moreover, previous studies showed that an individual suffering from thrombosis 
associated with a TM mutation leading to a defective protein (186) and the embryonic 
lethality in mice lacking the TM gene (187) identify the significance of TM as a natural 
anticoagulant.  
Heparan sulfate, a glycosaminoglycan, activates ATIII to catalyze the inhibition of 
thrombin and factor Xa. To date, heparin, a derivative of HS, has been largely used as an 
anticoagulant drug. According to ATIII-heparin binding mechanisms (120), sulfate 
groups on heparin pentasaccharide are essential to the high-affinity binding of ATIII. 
Extensive sulfation makes heparin a more potent catalyst to activate ATIII than HS. 
Heparin is also known to have a wide variety of biological actions independent of its 
anticoagulant effects, including interactions with endothelial cell growth factors (188), 
inhibition of smooth muscle cell proliferation (189), activation of lipoprotein lipase (190), 
suppression of aldosterone secretion, and interactions with platelets (191).  
Interactions among ATIII, heparin, and protein C pathway on regulation of 
coagulation were studied. The most significant observation was that coagulation time can 
be markedly prolonged in the presence of APC, ATIII, and heparin simultaneously 
compared to the effect by ATIII, APC, and heparin individually (192, 193). However, the 
molecular basis behind such phenomena remains indecisive. Hirahara et al. (192) found 
that the generation of prothrombinase was strongly suppressed by APC in the presence of 
heparin, leading to reduced thrombin generation. Petaja et al. (193) suggested that 
 119
synergistic effect of APC and heparin can enhance inhibition of thrombin generation by 
inactivation of factor V instead of Va. In contrast, Nicolaes et al. (194) suggested that 
APC-mediated inactivation of factor Va was enhanced by heparin on the basis on 
heparin-bound APC promoting association between factor Va and APC at position 
Arg306. Some previous studies (195, 196) even revealed thrombin inhibitors and heparin 
could compromise protein C activation by reducing affinity of thrombin for TM. 
In order to determine capacity of immobilized heparin and TM to inhibit surface TF-
initiated thrombin generation, we designed an in vitro model to mimic vascular 
implantation. Membrane-mimetic constructs containing TF, TM, and heparin were 
fabricated on a planar substrate (Figure 35) and investigated using a continuous flow 
system. Specifically, TF positioned over a 2 x 6 mm2 upstream region as a trigger for 
thrombin generation and TM and/or heparin positioned over the remaining downstream 
(34 x 6 mm2) portion of the test film. The surface systems are referred to as TF/TM, 
TF/Heparin, or TF/TM-Heparin. At shear rates of 50 and 500 sec-1, the surface was 
perfused with a protein mixture containing mean plasma concentrations of coagulation 
factors, along with physiologic concentrations of antithrombin and protein C when 
appropriate. In the absence of ATIII, TM or heparin, thrombin rapidly reached a steady 
state level of production ([T]TFss) which increased with increasing TF surface content. 
Significantly, [T]TFss was independent of TF surface density equal to or greater than 51.2 
fmole/cm2, which is possibly due to transport limitation effect on surface catalytic 
activity. After defining the upper limit of thrombin generation, we started to investigate 
the effect of surface anticoagulants on thrombin responses under the same flow 
conditions. 
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Acute initial thrombin generation was observed in the presence of ATIII, surface TM 
or heparin, indicating that ATIII and protein C pathway have no significant influence 
upon the initial phase of reaction. However, thrombin generation thereafter was reduced 
considerably, especially when the perfusate contained ATIII. Compared to steady state 
concentration of thrombin from TF surface with perfusate containing ATIII, [T]ss was 
further reduced with addition of surface TM and/or heparin. According to statistical 
analyses among TF+AT, TF/TM+AT, TF/Heparin, TF/TM-Heparin systems, surface TM 








































Figure 35  Schematic representation of immobilized thrombomodulin (TM), tissue factor 
(TF), and heparin on the basis of biotin functionalized polymeric phospholipid 
monolayer supported on an alkylated polyelectrolyte multilayer. Relipidated 






6.3 MATERIALS AND METHODS 
6.3.1 Materials  
Human coagulation factors V, VII, VIIa, IX, X, prothrombin, human antithrombin 
III, human protein C, and rabbit lung thrombomodulin (single chain containing NH2-
terminal hydrophobic domain, six EGF domains, one O-glycosylation rich domain, one 
transmembrane domain, COOH-terminal cytoplasmic domain, 74 kD, in 0.02 M Tris, 
0.15 M NaCl, pH 7.4 containing 0.05% lubrol PX) were obtained from Haematologic 
Technologies, Inc. Human coagulation factor VIII, tissue factor ( full length recombinant 
human tissue factor, TF, 43 kD, lyophilized from 0.01 M Tris, 0.15 M NaCl, pH 8.0 
containing 0.01% CHAPS and 200 mM mannitol), and Spectrozyme TH substrate for 
thrombin (H-D-hexahydrotyrosyl-L-alanyl-L-arginine-p-nitroanilide-diacetate salt) were 
obtained from American Diagnostica Inc. Eosin Y (EY, 5% in water), triethylamine 
(TEA), 1-vinyl-2-pyrrolidinone (VP) were obtained from Aldrich.  Nucleopore 
polycarbonate filters and Contrad 70 detergent were obtained from Fisher. Detergent OG 
(n-octyl-β-D-glucopyranoside) was obtained from Sigma. Chicken egg PC (L-α-
Phosphatidylcholine), porcine brain PS  (L-α-Phosphatidylserine, sodium salt), N-
Biotinyl Cap-PE (18:1) ( 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-(Cap 
Biotinyl), and fluorescent PE (1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-
(Carboxyfluorescein) were purchased from Avanti Polar Lipids, Inc. Alginate (ALG; low 
viscosity, ca. 60% mannuronic acid) was obtained from Pronova Biomedical (Norway).  
Poly (L-lysine) (PLL, MW > 300 kD) and all buffer salts are obtained from Sigma. 
Synthesis of monoacrylate-PC (AcPC,1-palmitoyl-2-[12-(acryloyloxy)dodeca-noyl]-sn-
glycero-3-phosphocholine), monoacrylate-PE (1-palmitoyl-2-(12-
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(acryloyloxy)dodecanoyl)-sn-glycero-3-phosphoethanolamine) and its biotin derivative 
(biotin-AcPE, mono-acrylPE-biotin) have described previously (77, 94) . The synthesis 
of the terpolymer that consists (3-acryloyl-3-oxapropyl-3-(N,N-dioctadecyl-carbamoyl)-
propionate))6:(2-hydroxyethyl acrylate)3:sodium styrene sulfonate1 (AOD6:HEA3:SS1) 
has been described elsewhere (96). Heparin (sodium salt, porcine intestinal mucosa, Mw: 
13,500-15,000) and streptavidin (Avidin, Streptomyces avidinii, Mw: 60 kDa) was 
obtained from Calbiochem. Synthesis of biotin-conjugated heparin was described in 
Chapter 4. 
6.3.2 Fabrication of Localized Tissue Factor Containing Membrane-Mimetic Surfaces. 
 
Microscope glass slides (2.6 cm x 4.6 cm, Fisher) were cleaned and coated with 
biotin-functionalized membrane-mimetic thin film (molar ratio of AcPC: biotin-AcPE = 
90:10), followed by coating with streptavidin as previously described (80). TF-coated 
surfaces were fabricated by dipping the glass slides vertically in a glass jar (2.6 x 2.6 cm2 
bottom area, Wheaton) containing 4.5 mL of a well stirred mixture of TF-constituted 
lipid vesicles (Chapter 5, section 5.3.2) (Figure 36).  The incubation time was 30 min at 
room temperature, followed by rinsing extensively using deionized water.  Fluorescent 
PE (fluorescein, 0.1mole% final) was doped within lipid vesicles for fluorescent 
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hematic representation for TF-coating process. Supporting substrates 
retreated with biotin-functionalized membrane-mimetic assemblies, 
ed by immobilization of streptavidin, then the streptavidin-coated 
es facing inwards were dipped into relipidated tissue factor mixture at 
emperature for 30 minutes. (B) The resulting localized TF-coated area 
). (Not to scale) 
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6.3.3 Determination of Tissue Factor Surface Density and Stability 
 Recombinant human tissue factor at a concentration of 0.1 mg/mL was radiolabeled with 
125I using Iodobeads (Pierce Chemical Co., Rockford, IL) according to the manufacture’s 
protocol. The concentration of radiolabeled TF was determined by a modification of the 
Bradford Protein Assay (Bio-Rad) using a TF standard curve.  Specific activity of the 
protein solution averaged 7.03 x 107 cpm/µg (3022 cpm/fmole). Cleaned supporting 
substrates (5x5 mm2 Si chip) were coated with membrane-mimetic thin film containing 
streptavidin (Chapter 5, section 5.3.3).  125I-TF and unlabeled TF were mixed to form 
1:30 molar ratio solution, and TF was then added to obtain the desired TF/lipid molar 
ratio (Chapter 5, section 5.3.2). The coated silicon chips were attached to glass slides and 
dipped into relipidated 125I-TF/unlabeled TF mixture, followed by rinsing extensively 
with deionized water prior to measuring surface radioactivity in a gamma counter. TF 
surface density (fmol/cm2) was calculated as {cpm/(specific activity x sample area)} and 
specific activity corrected for decay. Test samples were generated in six replicates for 
each TF/lipid molar ratio. For stability analysis, samples were stored in fresh PBS at 37 
°C and radioactivity was measured periodically after extensive washing in deionized 
water over a one-month period. 
6.3.4 Fabrication of Composite Tissue Factor/Thrombomodulin, Tissue Factor/Heparin, 
and Tissue Factor/Thrombomodulin-Heparin Containing Membrane-Mimetic Surfaces. 
 
TF/TM composite surface — Microscope glass substrates (2.6 cm x 4.6 cm, Fisher) 
were cleaned and coated with TM-incorporated biotin-functionalized membrane-mimetic 
thin film, followed by immobilizing streptavidin. TF-reconstituted lipid vesicles were 
tethered onto the above surfaces by dip-coating process (section 6.3.2).   
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TF/heparin composite surface — A membrane-mimetic thin film containing 
streptavidin was fabricated on a glass slide surface, followed by dip coating in relipidated 
TF mixture as described previously. After rinsing extensively, the TF-coated surface was 
then incubated with biotin-conjugated heparin (0.1 mg/mL) in PBST (50 mM NaH2PO4 
and 150 mM NaCl, pH 7.4) overnight at 4oC on a horizontal rotating platform, and rinsed 
with deionized water extensively. 
 
TF/TM-heparin composite surface—The coating procedure followed the order of 
immobilizing TM, TF, and heparin. Extensive rinsing with deionized water was 
performed between immobilization of each component. 
 
 All the above surface samples were stored in PBS (1X with 0.02% NaN3) at 4
o
C 
for the following flow studies and experiments were conducted 2 days after fabrication. 
6.3.5 Continuous Flow Reactor Assays on Immobilized Catalysts-Containing membrane-
mimetic surface: Effects of Anticoagulants on Thrombin Generation Triggered by TF 
 
TF-coated area (0.6 (W) x 0.2 (L) cm2) positioned at the upstream of the flow 
served as an inducer for thrombin generation. A parallel plate flow system (0.6cm (width) 
x 0.025cm (height) x 3.6cm (length), 54.9 µL volume) containing coated sample was 
flushed with 20 mM HEPES buffer for 1 hours at γw  = 2000 sec-1. Given the dimension 
of flow chamber and a shear rate of 50 sec-1, the residence times, defined as time spent by 
flow through exposed areas, were calculated (eq. (9) in Chapter 3) to be 0.94 sec for TF 
coated area and 16.06 sec for none-TF area, which simulates the same condition for a 40 
cm-long vascular graft (4mm i.d.) with a 2 cm-long injury. Residence times were 0.09 sec 
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for TF coated area and 1.61 sec for none-TF area at 500 sec-1. We determined the 
capacities of surface anticoagulants to inhibit TF-induced thrombin generation by 
conducting the following experiments. 
 
TF-Initiated Thrombin generation — Reaction was started by perfusing the surface with 
the reaction mixture HBS (20 mM Hepes + 150 mM NaCl, pH 7.4) containing 
coagulation factors (V, VII, VIIa, VIII, IX, X, prothrombin) and 2 mM CaCl2 at 37oC 
(Chapter 5, section 5.3.4). At pre-selected timed points, aliquots withdrawn from the 
perfusate at the reactor outlet were quenched by TBS/EDTA (50 mM Tris-HCl + 175 
mM NaCl + 20 mM EDTA, pH 7.4), and assayed after adding Spectrozyme TH (0.2 mM 
final) (25, 172). When the reaction mixture contained 2 µM of ATIII, aliquoted samples 
were withdrawn into TBS/EDTA containing Spectrozyme TH and assayed immediately 
for thrombin activity otherwise the measured thrombin concentration was not accurate 
due to rapid inactivation by ATIII (172). Thrombin concentration was determined by 
monitoring the hydrolysis of the substrate by the change in absorbance at 405 nm using 
UV-VIS spectrophotometer. Thrombin generation was calculated from a standard curve 
prepared using serial dilutions of human α-thrombin.  
 
Effect of Surface Bound TM on TF-Initiated Thrombin Generation—Reaction was started 
by perfusing TF/TM surface with the same reaction mixture containing 0.1 µM  protein C. 




Effect of Surface Heparin on Thrombin Generation Initiated by Surface TF— Reaction 
was started by perfusing TF/Heparin surface with the same reaction mixture including 
ATIII (2 µM, final). At pre-selected timed points, aliquots withdrawn from the perfusate 
at the reactor outlet were assayed by adding TBS/EDTA (50 mM Tris-HCl + 175 mM 
NaCl + 20 mM EDTA, pH 7.4) containing Spectrozyme TH (0.2 mM final).   
 
Effect of Composite TM/Heparin on Thrombin Generation Initiated by Surface TF— 
Reaction was started by perfusing TF/TM-Heparin surface with the same reaction 
mixture containing 0.1 µM protein C and 2 µM ATIII. Detection of thrombin generation 




























6.4 RESULTS AND DISCUSSION 
6.4.1 Lipid Vesicles Tethered onto Biotin-Functionalized Membrane-Mimetic Films 
Doped with fluorescent PE, immobilized lipid vesicles fabricated by the dip-coating 
process were examined by fluorescent microscopy for initial characterization. To assess 
the stability of immobilized vesicles, we conducted flow tests by exposing the coated 
surface to phosphate-buffered saline at a wall shear rate of 2000 sec-1 for 1 hour. 
Fluorescence imaging of test surfaces (Figure 37) demonstrates that there is a sharp 
boundary between vesicle-coated and uncoated regions and no discernible loss of vesicles 
after high shear flow.  
Previous studies have suggested that adhesion of lipid vesicles (with average 
diameter of 100 nm) doped with less then 1 mol% biotin appeared to reach saturation 
within a short time period (148, 197). The biotinylated phospholipid vesicles bind intact 
onto the streptavidin-coated surfaces without significant vesicle leakage or disruption 
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Figure 37  Fluorescent images (20x) of FITC-doped biotinylated lipid vesicles on Si 
coated with membrane-mimetic thin film (90/10 acrylate PC/biotin-acrylate 
PE) were taken before (A) and after (B) shear flow exposed to PBS at 2000 















6.4.2 Determination of Tissue Factor Surface Density   
125I-labeled TF was used to determine absolute surface concentration of TF on a 
planar substrate-supported membranes containing lipid composition of 10 mol% biotin-
AcPE/90 mol% AcPC. A linear relationship was observed between TF surface density 
and TF concentration reconstituted within vesicles (Figure 38). Stability of immobilized 
TF/lipid vesicle was studied by incubating samples in PBS at 37oC and measuring surface 
concentration periodically over a one month period. Generally, dramatic decrease in 
surface concentration was noted within the first week with little change thereafter up to 
28 days (Figure 39). The stabilized TF density ranges from 9.4 ± 3.9 fmole/cm2 to 88.6 ± 
7.5 fmole/cm2 (n = 6), corresponding to 6 nM to 120 nM TF reconstituted within lipid 
vesicles. Specifically, more dramatic decreases in surface concentration from TF 
concentration higher than 60 nM in vesicles were observed than other cases. We 
speculate that the decrease of TF concentration soon after the initiation of PBS incubation 
may be related to the loss of nonspecific binding of lipid vesicles. Notably, samples were 
removed from the bathing media on multiple occasions during the incubation period, 
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 Figure 38  Relipidated TF surface density as a function of TF concentration within lipid 
vesicles (1mM of egg PC/brain PS/ biotin-PE, 79:20:1 molar ratio). TF was 
radiolabeled with 125I and reconstituted into lipid vesicles. Surface 
concentration was determined after immobilizing onto streptavidin-
biotinylated polymeric membrane-mimetic constructs. The stability of this 
system was assessed in PBS at 37 °C over a 28-day period. Films were 
transferred to fresh PBS at indicated time points and radioactivity measured in 
a gamma counter. Each data point represents mean ± standard deviation (n = 















































Figure 39  Stability of relipidated TF surface density and based on membrane-mimetic 
thin films. The stability of this system was assessed in PBS at 37 °C over a 
28-day period. Note: a series of TF concentrations within lipid vesicles were 
prepared for immobilization: 6 nM (●),12 nM (○),30 nM (■), 60 nM (□), 90 
nM (▲), and 120 nM (∆). Each data point represents mean ± standard 












6.4.3 Surface Activity of Tissue Factor Under Flow Conditions: As a Source of Thrombin 
Generation From Upstream 
 
The rationale behind the design of immobilized TF surface is to mimic a focal 
vascular wall injury site. In order to design a realistic representation of an anastomotic 
site between a host artery and synthetic vascular graft, the residence times were 
calculated as a function of shear rate and size of a given test region (e.g. TF vs. none-TF 
domain). For example, coating one area of 2 (length) x 6 (width) mm2 with TF and the 
other of 34 (length) x 6 (width) mm2 without TF which is associated with a shear rate of 
50 sec-1 leads to residence times of 0.94 second and 16.06 seconds for TF-coated and 
none-TF coated areas, respectively. These residence times are equivalent to a 2 cm injury 
site followed by a 4mm i.d., 40 cm-long vascular graft. At shear rate of 500 sec-1, the 
residence times are one tenth of those at 50 sec-1.  
Thrombin generation induced by a series of TF surface densities was investigated at 
shear rates of 50 and 500 sec-1. Kinetics of thrombin generation (Figure 40) showed that 
the lag times to reach steady state concentrations of thrombin were 8-10 min and 4-6 min 
at shear rates of 50 sec -1 and 500 sec-1, respectively. Significantly, steady state thrombin 
levels (average 30.7nM and 12.7 nM at shear rates of 50 and 500 sec-1, respectively. 
Table 8) were attained at TF densities equal to or greater than 51.2 fmole per cm2 (Figure 
41), indicating that the transport of reactants and products towards and removal from the 
catalytic surface might play a crucial role in the overall reaction.   
Thrombin generation initiated by TF pathway under flow conditions shows distinct 
behavior from previous studies in static well-mixed models (26, 172, 178). While static 
models revealed identical saturated levels of thrombin generation in the presence of a 
wide range of TF concentrations, current flow studies showed that steady state thrombin 
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generation was dependent of TF surface density except more than certain surface content. 
After defining the saturated level of thrombin generation, we started to investigate the 
ability of surface TM and heparin to inhibit thrombin responses associated with the upper 







































































   
Figure 40 TF-induced thrombin generation at the reactor outlet over perfusion time as a 
function of surface TF concentrations (TF density: 9.4 (●) 27.3 (○) 51.2 (■) 
69.9 (□) 88.6 (▲) fmole/cm2) at wall shear rates of (A) 50 sec-1and (B) 500 
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Figure 41  Steady state level of thrombin generation as a function of TF surface density 
at wall shear rates of 50 sec  and 500 sec . -1 -1 Each data point represent a mean 
value ± standard deviation (n = 5).  The results show that thrombin generation 
becomes saturated in the presence of more than 50 fmole/cm2.  
 
 
Table 8 Steady state concentrations (mean ± standard deviation, n = 5) of thrombin at 
a series of TF surface densities.  
 
[TF] (fmole/cm2) Thrombin (nM), 50 sec-1 Thrombin (nM), 500 sec-1
9.4        18.31 ± 2.54 7.97 ± 1.07 
27.3        26.38 ± 1.38 10.63 ± 1.22 
51.2        29.76 ± 1.98 12.98 ± 1.69 
69.9        30.84 ± 3.24 13.24 ± 1.73 
















































































Figure 42 Rate of TF-induced thrombin generation at the reactor outlet over perfusion 
time as a function of surface TF concentrations (TF density: 9.4 (●) 27.3 (○) 
51.2 (■) 69.9 (□) 88.6 (▲) fmole/cm2) at wall shear rates of (A) 50 sec-1and 
(B) 500 sec-1. Each data point represent a mean value (n = 5). (see Table G2 in 
Appendix G). Note: rate of reaction = thrombin generation (Figure 40) x flow 
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Figure 43 Steady-state rate of thrombin generation as a function of TF surface density at 
wall shear rates of 50 sec-1 (●) and 500 sec-1 (○). Each data point represent a 
mean value ± standard deviation (n = 5).   
 
 
Table 9 Steady state rate of thrombin (T) generation (mean ± standard deviation, n = 
5) at a series of TF surface densities. Steady state rates of thrombin generation 
(pmol/min/cm2) in the presence of more than 50 fmole TF per cm2 are 2.75 ± 
0.25 and 11.77 ± 1.30 at shear rates of 50 and 500 sec-1 respectively  
 
[TF] (fmole/cm2) T (pmole/min/cm2), 50 sec-1 T (pmole/min/cm2), 500 sec-1
9.4 1.64 ± 0.23 7.14 ± 0.85 
27.3 2.18 ± 0.12 9.52 ± 1.14 
51.2 2.67 ± 0.27 11.63± 1.55 
69.9 2.76 ± 0.29 11.86± 1.44 





6.4.4 Effect of Surface Anticoagulants on Tissue Factor-Initiated Thrombin Generation 
Under Flow Conditions 
 
A tissue factor-immobilized membrane-mimetic thin film with TF surface density 
of 51.2 fmole/cm2, the threshold to induce transport limited thrombin generation, was 
used to investigate antithrombogenic capacity of surfaces containing TM and heparin. 
Based on the observed transport limit of TM-induced activation of protein C and  
heparin-catalyzed ATIII inactivation of thrombin, surface concentrations of TM and 
heparin were fixed at 1.35 pmole/cm2 (Ch 3, section 3.4.4) and 4.4 pmole/cm2 (Ch 4, 
section 4.4.6), respectively. 
 
Effect of Surface Bound TM on TF-Initiated Thrombin Generation 
 
The effect of surface TM on TF-initiated thrombin generation was studied by 
perfusion of a defined protein solution, which included protein C over test surfaces 
consisting of TF and TM over defined upstream and downstream regions, respectively. 
Thrombin responses were characterized by a rapid initial reaction, a transient peak, and 
gradual decay to a steady state level (Figure 44 & 45). Maximum ([T]max) and steady 
state ([T]ss) values of thrombin concentration are summarized in Table 10. When 
compared to test surfaces that did not contain TM, average [T]max and [T]ss were, 
respectively, 18% and 53% less at a shear rate of 50 sec-1 , and 16% and 45% less at a 
shear rate of 500 sec-1. Since the protein C pathway is not activated in the absence of 
thrombin, the capacity to reduce initial thrombin production is limited. These finding are 
consistent with other reports in which TM and TF were studied in a well mixed system of 
isolated vesicles (25). Thrombin decay in our system is likely due to the expected APC 














































Figure 44 Thrombin generation at the reactor outlet over perfusion time from TF (●) and  
TF/TM (○) surfaces TF positioned at the upstream at wall shear rates of (A) 
50 sec-1 (B) 500 sec-1. Each data point represents a mean value (n = 5) with a 
























































Figure 45 Rate of thrombin generation at the reactor outlet over perfusion time from TF 
(●) and TF/TM (○)surfaces with TF positioned at the upstream at wall shear 
rates of (A) 50 sec-1 (B) 500 sec-1. Each data point represents a mean value (n 
= 5) with a standard error less than 10%. Note: rate of reaction = thrombin 
generation (Figure 42) x flow rate / surface area of reactor ( = 0.6 (W, cm) x 
3.6 (L, cm) = 2.16 cm2). (see Table G2 in Appendix G) 
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Effect of Antithrombin (ATIII) on TF-induced Thrombin Generation 
 
Since physiologic concentration of ATIII ranges from 1.5 to 2.5 µM (152-154), we 
anticipated that ATIII would have a substantial inhibitory effect on thrombin activity. 
The effect of ATIII on TF-triggered thrombin generation (TF+AT), was studied using a 
protein mixture containing 2 µM of ATIII. 
Thrombin generation displayed a similar pattern to that of the TF/TM system with 
lower observed values for [T]max and [T]ss (Fig. 46 & 47, Table 10). When compared to  
[T]TF ss produced by test surfaces containing TF alone, average [T]max and [T]ss at shear 
rate of 50 sec-1 were 35% and 72% lower, respectively, while 29% and 65% lower at a  
shear rate of 500 sec-1. Moreover, average [T]max and [T]ss were approximately 15% and 
20% less than comparable values observed from the TF/TM system. 
The initial explosive thrombin generation was not reduced in the presence of ATIII, 
indicating ATIII is not an efficient inhibitor of TF:VIIa enzyme complex (200). Although 
ATIII alone is unable to influence the initiation phase of thrombin generation in the 
presence of low levels of TF:VIIa, ATIII is able to largely reduce even has a potential to 
completely inhibit thrombin activity afterwards (172). In addition, ATIII is also an 
inhibitor of factor Xa; with this effect occurring within minutes (172, 200, 201). 
Although factor Va can protect Xa from inactivation by ATIII (202, 203),  inactivation of 
















































Figure 46 Thrombin generation at the reactor outlet over perfusion time from TF (●), 
TF/TM (○), and TF+AT (■) surfaces with TF positioned at the upstream at 
wall shear rates of (A) 50 sec-1 (B) 500 sec-1. Each data point represents a 



























































Figure 47 Rate of thrombin generation at the reactor outlet over perfusion time from TF 
(●), TF/TM (○), and TF+AT (■) surfaces with TF positioned at the upstream 
at wall shear rates of (A) 50 sec-1 (B) 500 sec-1. Each data point represents a 
mean value (n = 5) with a standard error less than 10% (see Table G2 in 
Appendix G). Note: rate of reaction = thrombin generation (Figure 44) x flow 




Effects of ATIII and Surface Bound TM on TF-Induced Thrombin Generation 
 
The effect of ATIII and surface bound TM on TF-induced thrombin generation 
(TF/TM+AT) was studied using the patterned TF/TM surface, as described previously. 
The presence of TM further reduced thrombin generation when compared to the effect of 
ATIII alone (Figure 48 & 49). Specifically, average [T]max and [T]ss values were 
approximately 21% and 14% lower. 
 It has been noted that ATIII at physiological concentrations decreases the binding 
of thrombin to TM on endothelial cells and consequently reduces the production of APC 
(60, 204, 205). However, the rate of inactivation of thrombin by ATIII is stimulated 
several-fold by the presence of TM (206-208). Despite competitive binding of thrombin 
between ATIII and TM, we suspect that residual thrombin in the vicinity of the surface 
has sufficiently high affinity to TM to allow protein C activation to proceed. A reduction 
in thrombin levels is mediated by direct thrombin inactivation by ATIII, TM-mediated 
thrombin inactivation by ATIII, and protein C activation. Significantly, the presence of 





























































Figure 48 Thrombin generation at the reactor outlet over perfusion time from TF (●), 
TF/TM (○), TF+AT (■), and TF/TM+AT (□) surfaces with TF positioned at 
the upstream at wall shear rates of (A) 50 sec-1 (B) 500 sec-1.  Each data point 
represents a mean value (n = 5) with a standard error less than 10%. (see 




























































Figure 49 Rate of thrombin generation at the reactor outlet over perfusion time from TF 
(●),TF/TM (○), TF+AT (■), and TF/TM+AT (□) surfaces with TF positioned 
at the upstream at wall shear rates of (A) 50 sec-1 (B) 500 sec-1.  Data points 
represent mean values (n = 5) with a standard error less than 10%. (see Table 
G2 in Appendix G). Note: rate of reaction = thrombin generation (Figure 46) x 
flow rate / surface area of reactor (= 0.6 (W, cm) x 3.6 (L, cm) = 2.16 cm2). 
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Effect of Surface Bound Heparin on TF-induced Thrombin Generation 
 
The effect of surface bound heparin on TF-initiated thrombin generation 
(TF/Heparin) was studied using a protein mixture containing 2 µM ATIII. Test surfaces 
contained discrete upstream and downstream regions with TF and heparin, respectively. 
Average [T]max and [T]ss (Fig. 50, 51, Table 10) were reduced by 14% and 22%, 
respectively, when compared to concentrations observed in systems containing ATIII but 
without surface bound heparin. Interestingly, thrombin generation from the TF/TM+AT 
system was lower than that observed from TF/heparin + ATIII. This suggests that, TM 
may be more effective in inhibition of initial thrombin production than surface bound 
heparin.   
 It has been noted that the anticoagulant activity of heparin is a direct result of its 
ability to greatly (~1000-fold) accelerate the rate at which antithrombin reacts with 
thrombin (120). In our test system, ATIII has a dominant inhibitory effect on thrombin 
activity. The presence of surface bound heparin further reduces thrombin generation by at 
most 10-20%. We suspect that transport limitations associated with the diffusive flux of 




















































Figure 50 Thrombin generation at the reactor outlet over perfusion time from TF 
(●),TF/TM (○), TF + ATIII (■), TF/TM + ATIII (□), and TF/Heparin (▲) 
surfaces with TF positioned at the upstream at wall shear rates of (A) 50 sec-1 
(B) 500 sec-1.  Each data point represents a mean value (n = 5) with a standard 

























































Figure 51 Rate of thrombin generation at the reactor outlet over perfusion time from TF 
(●),TF/TM (○), TF + ATIII (■), TF/TM + ATIII (□), and TF/Heparin (▲) 
surfaces with TF positioned at the upstream at wall shear rates of (A) 50 sec-1 
(B) 500 sec-1. Each data point represents a mean value (n = 5) with a standard 
error less than 10% (see Table G2 in Appendix G). Note: rate of reaction = 
thrombin generation (Figure 48) x flow rate / surface area of reactor (= 0.6 




Effect of Combined Surface Bound TM and Heparin on TF-Induced Thrombin 
Generation 
The effect of combined surface bound TM and heparin on TF-induced thrombin 
generation (TF/TM-Heparin) was studied by perfusion of a protein mixture containing 
ATIII and protein C over test surfaces in which TF was deposited in an upstream region 
and TM and heparin largely confined to a downstream section. Kinetic data of thrombin 
responses are presented in Figure 52 and 53. 
Average [T]max and [T]ss values were reduced by 55% and 85% (Table 10), 
respectively, at both shear rates of 50 sec-1 and 500 sec-1 when compared to 
concentrations observed in test systems which did not contain either ATIII or surface 
bound TM or heparin. Moreover, we observed that thrombin generation was considerably 
lower when compared to systems containing ATIII with (13-15% reduction) or without 
(20-25% reduction) surface bound heparin.  
The combination of both surface bound TM and heparin appears to be the most 
efficient in inhibiting TF-induced thrombin generation. Indeed, heparin and activated 
protein C (APC) exhibit significant anticoagulant synergy in plasma (192, 193) due to 
three mechanisms: heparin enhancement of ATIII-dependent inactivation of thrombin 
and factor Va,  the inactivation of factor Va by APC, and the inactivation of factor V and 
Va enhanced by heparin and/or APC.  Average [T]max and [T]ss values (Figure 54) 
suggested that efficiency of thrombin inactivation is in the order of TF/TM-Heparin > 


















































Figure 52 Thrombin generation at the reactor outlet over perfusion time from TF 
(●),TF/TM (○), TF + AT (■),TF/TM + AT (□), TF/Heparin (▲), and TF/TM-
heparin (∆) surfaces with TF positioned at the upstream at wall shear rates of 
(A) 50 sec-1 (B) 500 sec-1. Each data point represents a mean value (n = 5) 


























































Figure 53 Rate of thrombin generation at the reactor outlet over perfusion time from TF 
(●),TF/TM (○), TF + ATIII (■), TF/TM + ATIII (□), TF/Heparin (▲), and 
TF/TM-heparin (∆) surfaces with TF positioned at the upstream at wall shear 
rates of (A) 50 sec-1 (B) 500 sec-1. Each data point represents a mean value (n 
= 5) with a standard error less than 10% (see Table G2 in Appendix G). Note: 
rate of reaction = thrombin generation (Figure 31) x flow rate / surface area of 
reactor (= 0.6 (W, cm) x 3.6 (L, cm) = 2.16 cm2). 
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Since physiologic level of ATIII has dramatic impact on thrombin generation from 
TF surface, we examined all systems containing ATIII in order to differentiate the effect 
on inhibition of thrombin generation in the presence of surface TM and heparin. 
Specifically, equality of mean values of [T]max and [T]ss among TF+AT, TF/TM+AT, 
TF/Heparin, and TF/TM-Heparin were statistically analyzed using the F test from the 
analysis of variance (ANOVA) (Appendix H) (209). The test results concluded that not 
all mean values of [T]max and [T]ss are equal. The probability of a type I error, which is 
probability of accepting the null hypothesis, is less than 0.001 according to F-test results. 
Then we further determined the significance of the presence of surface bound TM and/or 
heparin using the Tukey multiple comparison procedure (Appendix I) (209). This 
procedure is commonly used for pairwise comparison and is a preferred method to give 
narrower confidence limits than others such as Scheffé and Bonferroni procedures. For 
example, in Bonferroni procedure, one can form m simultaneous confidence intervals for 
an overall confidence level 1- α, leading to an individual level 1- α/m. Consequently, the 
half-width of confidence intervals is enlarged to cause wider confidence limits. 
Results of comprehensive analyses are summarized in Table 11. We found that the 
addition of surface bound TM induced a statistically significant (P < 0.05) reduction in 
both [T]max and [T]ss when compared to systems containing ATIII or heparin alone 
(Figure 54, 55). In contrast, the effect of adding surface bound heparin on [T]max and [T]ss 
was statistically insignificant (P < 0.2) when compared to systems, which already 
contained ATIII or surface bound TM. These results indicate that a membrane-mimetic 
film containing TM will likely have a greater antithrombogenic capacity than current 
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commercially available heparinized surface due to the capacity to actively inhibit 
thrombin generation rather than inactivate thrombin after it has already been produced. 
We found that the addition of surface bound TM induced a statistically significant 
reduction in both [T]max and [T]ss when compared to systems containing ATIII or heparin 
alone. In contrast, the effect of adding surface bound heparin on [T]max and [T]ss was 
statistically insignificant when compared to systems, which already contained ATIII or 
surface bound TM. These results indicate that a membrane-mimetic film containing TM 
will likely have a greater antithrombogenic capacity than current commercially available 
heparinized surface due to its capacity to actively inhibit thrombin generation rather than 








































Table 10  Summary of thrombin responses from a variety of surface systems, including 
maximum thrombin generation ([T]max, nM) and rate of reaction (RTmax, 
pmole/min/cm2), steady state thrombin generation ([T]ss, nM) and rate of 
reaction (RTss, pmole/min/cm2), and drop % of thrombin generation (mean 
value comparison of [T]max or [T]ss with respect to [T]TFss). Each data value 
for [T]max, RTmax, [T]ss, and RTss is presented as mean ± standard deviation (n 
= 5). 
 
50 sec-1 Surface Systems For Flow Studies 
 TF TF/TM TF+AT TF/TM+AT TF/Heparin TF/TM-Heparin 
[T]max 29.76 ± 1.98 24.55 ± 1.88 19.26 ± 1.73 13.86 ± 1.26 16.38 ± 0.92 12.94 ± 0.84 
 RTmax 2.67 ± 0.27 2.20 ± 0.17 1.77 ± 0.18 1.23 ± 0.15 1.45 ± 0.11 1.10 ± 0.08 
drop %  0 18 35 54 45 57 
[T]ss 29.76 ± 1.98 13.88 ± 1.95 8.45 ± 0.73 3.88 ± 1.03 6.29 ± 1.07 2.65 ± 1.16 
 RTss 2.67 ± 0.27 1.24 ± 0.18 0.75 ± 0.10 0.37 ± 0.06 0.62 ± 0.09 0.24 ± 0.06 
drop %  0 53 72 86 77 91 
 
500 sec-1 Surface Systems For Flow Studies 
 TF TF/TM TF+AT TF/TM+AT TF/Heparin TF/TM-Heparin 
[T]max 12.98 ± 1.69 10.98 ± 1.34 9.30 ± 0.98 6.59 ± 0.63 8.12 ± 0.89 5.74 ± 0.27 
RTmax 11.63± 1.55 9.84 ± 1.20 8.26 ± 0.92 5.75 ± 0.70 7.20 ± 0.90 5.10 ± 0.53 
 drop % 0 16 29 51 38 56 
[T]ss 12.98 ± 1.69 7.18 ± 0.87 4.59 ± 0.94 2.70 ± 0.46 3.36 ± 0.54 1.92 ± 0.53 
 RTss 11.63± 1.55 6.42 ± 0.78 4.11 ± 0.84 2.42 ± 0.41 3.01± 0.58 1.72 ± 0.49 


















































Figure 54 Thrombin responses at (A) peak ([T]max, nM) and (B) steady state ([T]ss, 
nM) levels from TF surfaces in the presence of ATIII only (TF+AT), surface 
heparin (TF/Heparin), surface TM (TF/TM+AT) and both surface heparin and 
TM (TF/TM-Heparin) at shear rates of 50 sec-1. P values are analyzed from 
comparisons between surfaces in the absence and presence of TM (TF+AT vs. 
TF/TM+AT and TF/Heparin vs. TF/TM-Heparin), and between surfaces in the 
absence and presence of heparin, (TF+AT vs. TF/Heparin and TF/TM+AT vs. 
TF/TM-Heparin). The error bars represent standard deviation (n = 5). 
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Figure 55 Thrombin responses at (A) peak ([T]max, nM) and (B) steady state ([T]ss, 
nM) levels from TF surfaces in the presence of ATIII only (TF+AT), surface 
heparin (TF/Heparin), surface TM (TF/TM+AT) and both surface heparin and 
TM (TF/TM-Heparin) at shear rates of 500 sec-1. P values are analyzed from 
comparisons between surfaces in the absence and presence of TM (TF+AT vs. 
TF/TM+AT and TF/Heparin vs. TF/TM-Heparin), and between surfaces in the 
absence and presence of heparin, (TF+AT vs. TF/Heparin and TF/TM+AT vs. 
TF/TM-Heparin). The error bars represent standard deviation (n = 5). 
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Table 11  Comparisons of transient peak ([T]max) and steady state ([T]ss) using 
ANOVA with Tukey multiple comparison procedure between test surfaces in 
the absence and presence of TM (TF+AT vs. TF/TM+AT and TF/Heparin vs. 
TF/TM-Heparin), and between test surfaces in the absence and presence of 
heparin, (TF+AT vs. TF/Heparin and TF/TM+AT vs. TF/TM-Heparin). 
Confidence intervals (C.I.) indicate whether the comparison of [T]max is 
significantly different or not for confidence coefficient of 95 percent. A value 
of P < 0.05 was used to define statistical significance. 
 
[T]max, 50 sec-1 TF+AT TF/TM-Heparin 
C.I. C.I. 
0.48 10.32 -0.81 2.65 TF/TM+AT 
p value < 0.04  p value < 0.2 
C.I. C.I. 
-0.21 5.98 0.36 6.52 TF/Heparin 
p value < 0.1  p value < 0.04 
 
[T]max, 500 sec-1 TF+AT TF/TM-Heparin 
C.I. C.I. 
0.194 5.220 -0.141 1.845 TF/TM+AT 
p value < 0.04 p value < 0.1 
C.I. C.I. 
-0.489 2.845 0.217 4.543 TF/Heparin 
 p value < 0.2  p value < 0.04 
 
[T]ss, 50 sec-1 TF+AT TF/TM-Heparin 
C.I. C.I. 
0.345 8.256 -0.390 3.413 TF/TM+AT 
p value < 0.04 p value < 0.2 
C.I. C.I. 
-0.073 2.958 0.527 8.020 TF/Heparin 
p value < 0.1 p value < 0.04 
 
[T]ss, 500 sec-1 TF+AT TF/TM-Heparin 
C.I. C.I. 
0.012 3.772 -0.187 1.739 TF/TM+AT 
p value < 0.05 p value < 0.1 
C.I. C.I. 
-0.270 2.733 0.027 2.846 TF/Heparin 





Effects of Mass Transfer on Thrombin Response In the Presence of Inhibitors 
 
According to the experimental conditions, the reactions occurring under flow 
involve more than twenty steps (Scheme I) (14, 106, 178). Concentrations and transport 
rates of the coagulation proteins to and from bulk fluid and a catalytically active surface 
can in principle be derived from various forms of mass balances according to Navier-
Stokes and continuity equations in mass transport coupled with reaction rates (210). 
Complete treatment of transport with surface reaction leads to an intractable set of 
nonlinear differential equations. Thus, we simplified our analysis using mass transfer 
coefficients and kinetic constants derived from previous studies (102, 103, 210-213) in 
order to interpret the results of our experimental studies.  
It has been recognized that the most cases of interest transport resistance resides 
entirely within a thin concentration boundary layer (the Lévêque regime) (210-213), 
Characteristically, the concentration changes within the boundary layer are much more 
significant than those taking place in the bulk. Generally, the concentration boundary 
layer thickness (δ) is dependent of time (t) and longitudinal distance (x) from inlet of the 
flow system. Since δ is related to mass transfer coefficient (kL: cm/sec), kL = D/δ (D: 
diffusion coefficient, cm2/sec), kL is also a function of x and t. At the time of initial 
reaction, for example, the activation of factor X by TF:VIIa complex near t = 0, there is 














TF + VIIa ↔ TF:VIIa (1) 
TF + VII ↔ TF:VII → TF:VIIa    (2) 
IX+TF:VIIa ↔ IX.TF:VIIa → TF:VIIa+IXa (3)  
X+TF:VIIa ↔ X.TF:VIIa → TF:VIIa+Xa (4)  
X + VIIIa:IXa  ↔  X:VIIIa:IXa → VIIIa:IXa + Xa  (5) 
IX + X a →  X a + IXa  (6) 
VIII + Xa →  Xa + VIIIa (7) 
V + Xa → Xa + Va  (8) 
V + IIa → IIa + Va  (9) 
VIII + IIa → IIa + VIIIa  (10) 
II + Va:Xa ↔ II:Va :Xa → Va:Xa + mIIa (11) 
mIIa + Va:Xa → Va.Xa + IIa  (12) 
VIIIa + IXa ↔ VIIIa:IXa  (13) 
Va+Xa ↔ Va:Xa  (14) 
ATIII + Xa ↔ ATIII:Xa → ATIII + Xai  (15) 
ATIII + IIa ↔ ATIII:IIa → ATIII + IIai  (16) 
H + ATII ↔ H:ATIII  (17) 
H:ATIII + Xa ↔H:ATIII:Xa → H:ATIII + Xai  (18) 
H:ATIII + IIa ↔ H:ATIII:IIa → H:ATIII + IIai  (19) 
IIa + TM ↔ IIa:TM  (20) 
PC + IIa:TM ↔ PC: IIa:TM → IIa:TM + APC  (21) 
APC + Va ↔ APC:Va → APC + Vai  (22) 
APC + VIIIa ↔ APC:VIIIa → APC + VIIIai (23) 
H + APC + V ↔ H:APC:V → H:APC + Vi  (24) 
 
Roman numeral numbers: coagulation factors, subscript i: inactive form, II: prothrombin, 
IIa: thrombin, APC: activated protein C, H: heparin, PC: protein C, TF: tissue factor, TM: 
thrombomodulin.  
 






However, immediately after the initiation of the reactive event, kL diminishes and 
δ increases rapidly and both reach steady state values, characteristic of a fully developed 
regime, within seconds (210). At this point, it is assumed that changes in kL and δ with 
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where L is length of the reactor (cm), γw is wall shear rate (sec-1), x is distance from inlet 
(cm), and D is diffusivity (cm2/sec). 
Since δ is relatively small within a few millimeters from the inlet of the reactor, 
mass transport resistance is less in those areas. This may explain why rapid TF-initiated 
reactions occur for thrombin generation. From the expression of δ as a function of x, 















In turn, given the geometry of the flow system and flow conditions, average mass 
transfer coefficient kL (= D/δav) can be obtained. The higher the shear rate, the larger the 
mass transfer coefficient, which will cause a more rapid surface reaction (less effect of 
diffusion) and shorter induction period for thrombin generation (211).  
In the classic Micahelis-Menten form, the Micahelis constant (Km) represents the 
inherent kinetic property of an enzyme. However, in the case of immobilized enzymatic 
reactions under flow, an apparent Michaelis constant (Kmapp) is used to replace Km in the 
Michaelis-Menten equation, so as to incorporate transport effects. Specifically, Laidler et 
al. (102, 103) suggested that the apparent Michaelis constant vary with the reciprocal 
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cubic rot of the flow rate, indicating that Kmapp is smaller at higher shear flow and 
consequently the rates of reaction is larger. 
Net thrombin production is the result of a mass balance involving the transport of 
relevant coagulation proteins to/from reactive surface, reaction kinetics including 
activation of factor X by TF, positive feedback reactions catalyzed by tenase (IXa:VIIIa 
complex) and prothrombinase (Xa:Va complex), and negative feedback reactions 
including direct inactivation by antithrombin either alone or catalyzed by surface bound 
heparin, and surface bound TM-induced protein C activation. The general expression 








where [P0] and [P] are the protein concentrations in the bulk and at the surface, 
respectively, kL is the mass transfer coefficient and RP is the rate of enzymatic reaction. 
Model simulations of thrombin dynamics (211, 212) for common pathway of coagulation 
in the presence of antithrombin have revealed rapid initial thrombin generation, followed 
by transient maximum and subsequent steady state at a slightly lower level than the peak 
thrombin generation. These results are similar to our experimental observations with the 
exception that surface bound TM and heparin reduce both peak and steady state thrombin 
concentrations. The TM effect appears greater than heparin, although as complementary 
negative feedback systems the combined effect of both factors had the greatest impact.  






A vascular injury site was mimicked by fabricating membrane-mimetic assemblies 
containing tissue factor on a planar supporting substrate. Relipidated TF vesicles were 
tethered onto a membrane-mimetic thin film by a dip-coating process. Thrombin 
generation initiated by TF with surface density ranging from approximately 9 to 90 
fmole/cm2 was investigated by perfusion of a coagulation protein mixture over test 
surfaces at shear rates of 50 sec-1 and 500 sec-1. Our results showed that thrombin 
production was initially rapid and then reached a steady state level. Steady state thrombin 
generation did not significantly increase in the presence of TF density more than 51.2 
fmole/cm2, indicating a transport limiting effect in the reaction. This TF surface density 
was selected to investigate effect of surface bound TM and heparin on thrombin 
production under flow. 
 In the presence of surface anticoagulants, kinetics of thrombin generation featured a 
rapid induction phase and a transient maximum that was followed by a gradual decrease 
to a steady state level. Initial thrombin production could not be completely inhibited, 
which is likely a result of minimal transport resistance for surface bound TF-mediated 
extrinsic coagulation pathway activation. However, peak and steady state values of 
thrombin were decreased by ATIII and surface bound heparin and TM. At physiologic 
concentrations of ATIII, thrombin activity was profoundly inhibited. Nonetheless, surface 
bound TM and heparin appear to have the potential to completely shut down thrombin 
generation. In particular, surface bound TM was superior to heparin in reducing thrombin 
generation. Admittedly, limitations of an experimental approach, which utilizes an 
artificial plasma protein solution, include the presence of existing natural inhibitors in 
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plasma or blood that could compromise the anticoagulant capacities of surface bound TM 
and heparin.  For example, heparin can be inhibited by platelet factor 4 or potentially 
cleaved by endogenous heparanases and two serpins, α1-antitrypsin and the protein C 
inhibitor (PCI) are capable of inactivating APC. Of interest, PCI-catalyzed inhibition of 



























Over the years, a substantial amount of research in designing nonthrombogenic 
surfaces has been performed to improve the biocompatibility of synthetic materials in 
contact with blood. Pharmacologically active compounds have been recognized and 
incorporated on surfaces as a design approach. Specifically, heparinization of artificial 
surfaces has been shown to be a successful strategy to prevent thrombus formation. For 
example, covalent bonding of nitrite-degraded heparin onto membrane oxygenators and 
tubings has made it possible to maintain a long-lasting extracorporeal circulation without 
systemic heparinization (53). It has been reported that the thrombogenic collagen 
becomes more thromboresistant in the presence of immobilized heparin (215). However, 
studies in animal or human models have demonstrated that heparin fails to prevent 
thrombosis (83, 216, 217) possibly due to the ineffectiveness of heparin/antithrombin III 
in preventing thrombin-induced platelet deposition. In addition, the findings of heparin 
limiting the spread of thrombus from the site of occlusion, lowering embolism recurrence, 
and reduceing mortality after prolonged treatment have been disputed (218). These have 
motivated us to design other potent antithrombogenic agent-immobilized surfaces.  
There is growing evidence that the transmembrane protein thrombomodulin (TM) 
triggering the protein C pathway represents the major anticoagulant mechanism that is 
operative in both normal and injured blood vessels under physiologic conditions in vivo 
(84), which led to immobilization of TM as a antithrombogenic system. Several 
investigators have described the direct immobilization of thrombomodulin onto 
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polymeric surfaces in order to generate thromboresistant materials for blood contacting 
applications (54-59, 85, 86). Although these studies confirm that substrate bound TM has 
the potential to limit thrombus formation on synthetic surfaces, reduction in TM 
bioactivity was observed as evident by protein C activation rates, which were three orders 
of magnitude less than those when TM is evaluated as a component of either lipid 
vesicles or the endothelial cell surface. This emphasizes the importance of lipid 
membrane as an essential cofactor for protein bioactivity, leading to the design of 
membrane-mimetic systems incorporating biological substrates that can exhibit activities 
to mimic the functions of physiological regulators for blood coagulation.  
In order to create membrane-membrane assemblies, we have developed an in-situ 
polymerization strategy using monoacrylate phospholipids as a means of stabilizing a 
self-assembled lipid monolayer on an alkylated surface supported by a hydrophilic 
polymeric cushion (77, 94, 219), and such a system showed limited thrombus formation 
and neointimal hyperplasia short term in vivo assays (77). Therefore, we believe that the 
inherent strength of a membrane-mimetic based approach is the capacity to incorporate 
within these systems a variety of physiologically significant processes relevant to the 
control of both blood coagulation and endothelial regeneration.  
We observed TM-incorporated membrane-mimetic systems lipid membrane can 
exhibit bioactivity in vitro by catalyzing protein C activity. Significantly, surface bound 
TM was functional at physiologic shear rates and its activity was exceeded in the 
presence of high surface content due a transport-limiting effect. Surface TM activity 
showed at least short term stability in human plasma. Although stability of the surface 
bound TM has been confirmed, decrease in surface TM catalytic efficiency was noticed. 
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We suspect this is related to reduced membrane mobility and direct photoinactivation 
(79). In addition, activity of TM may be reduced due to limited molecular mobility and 
photoinactivation within the planar lipid membrane since immobilization of TM involves 
photopolymerization of acrylated lipids (79). 
 Since anticoagulant synergism of heparin and protein C pathway has been suggested 
(192-194), we designed a heparinized surface based on membrane-mimetic systems in 
order to incorporate with TM. Surface bound heparin is active by facilitating thrombin 
inactivation by antithrombin (ATIII). In a similar fashion to surface TM activity under 
flow, we observed surface heparin activity reached a limit in the presence of high surface 
content. Although stability of surface heparin was not exclusively examined, we assume 
the system was stabilized by the high affinity of biotin-streptavidin binding. In addition, 
surface heparin was resistant to high shear flow in short term. However, we do not 
exclude the possibility of loss of surface streptavidin due to competitive binding of 
biotinylated heparin in free from. We consider conducting long-term stability tests for the 
future work. 
Based on the similar membrane-mimetic systems, tissue factor (TF) was incorporated 
to serve as a trigger for thrombin generation (15, 16). At shear flow conditions, we 
observed surface TF was functional by catalyzing factor Xa and thrombin generation. 
This provides a strategy to investigate antithrombogenic capacities of surface TM and 
heparin. Significantly, reduction in thrombin generation was observed in the presence of 
surface anticoagulants, demonstrating the potential to create an actively antithrombogenic 
surface. However, the major drawback of this system is that initial rapid thrombin 
production can not be effectively inhibited, which is similar to previous studies in static 
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models (14, 172, 200). This may lead to platelet (220) as well as coagulation protein 
activation when the surface is exposed to blood. In addition, other blood elements 
including natural inhibitors of anticoagulants may compromise the surface 
antithrombogenicity. More discussion comes in the following section when the model 
systems are investigated under blood flow.   
There are certain important issues that need attention especially when applying the 
model surface in vivo. In order to investigate flow effect on surface enzyme activity, we 
approximated in vivo conditions by applying two shear rates of 50 and 500 sec-1 to 
simulate the conditions in vein and artery, respectively. Although the shear rates for the 
current in vitro systems are similar to most blood vessels in the human circulation, such 
as femoral artery and carotid (221), there is a broad range of shear rate outside these two 
values because physiologic wall shear rates can be lower than 50 sec-1 in larger vein, raise 
up to 1600 sec-1 in arteriole (221), or even extremely high more than 40,000 sec-1 in 
atherosclerotic vessels (222, 223). In addition, the hydrodynamic properties of the current 
in vitro system do not strictly apply to hemodynamic in the circulation for various 
reasons. Blood is not a homogeneous Newtonian fluid, and the velocity profiles are 
affected by flow rate and hematocrit. In the microcirculation, deviations from the 
parabolic profile are related to the effect of the erythrocytes on the flow. Given the shear 
conditions in the current in vitro systems, the entrance length is less than 1% of the total 
reactor length so that shear flow is considered to be fully developed over the whole flow-
exposed area. For blood flow in vivo, the entrance length can be large enough so that it 
exceeds the lengths available before bifurcation occurs, leading to a non-fully developed 
flow condition. This explains why entrance effects are more operative in the aorta and 
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most of the major arteries than smaller vessels due to the larger Reynold’s number and 
the vessel diameter. With increasing Reynold’s number, particularly larger than the 
critical number ~ 2100, the stability of the flow decreases, resulting in turbulent flow due 
to the high energy dissipation associated with greater momentum losses from the random 
velocity fluctuations. 
Moreover, instead of being unidirectional in vitro, flow is pulsatile and affected by 
branching and vessel curvature in vivo, where inertial effects result in the production of 
secondary flows having radial components, and sometimes in flow separation and eddy 
formation, which are likely present at aortic T-branches, at the carotid bifurcation, at the 
heart valves, and downstream of vascular stenoses. All these affect the transport of blood 
elements to interact with its contacting surface due to prolonged residence times and 
hence mechanisms of surface reactions.   
Effects of blood elements including blood cells and inhibitors also limit the activity 
of surface anticoagulants. At increasing shear forces, inward migration of erythrocytes to 
the axis of the flow resulting in outward movement of platelets to the vessel wall occurs, 
which may explain that platelets play an important role in arterial thrombus formation 
(221, 224). In venous thrombus formation, fibrin and fibrin-trapped erythrocytes are the 
predominant thrombus building blocks. Platelets and leukocytes also provide 
procoagulant surfaces for local thrombin generation by assembling coagulation proteins 
and thereby amplifying coagulation activity on their surface (225-227). In addition, 
natural inhibitors of anticoagulants may compromise surface antithrombogenicity of the 
model system. For example, protein C inhibitor (PCI) inactivates activated protein C as 
well as the thrombin-thrombomodulin complex (113, 114). Homocystein, a sulfur 
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containing amino acid in plasma, can inactivate the cofactor activity of thrombomodulin 
by reducing the disulfide-bond rich epidermal growth factor-like structures of 
thrombomodulin (115). Heparin can be inhibited by platelet factor 4 or potentially 
cleaved by endogenous heparanases and two serpins, α1-antitrypsin. Moreover, PCI-
catalyzed inhibition of APC can be enhanced when APC binds to heparin or heparan 
sulfate (214). 
It has been suggested that the presence of the erythrocytes at volume concentration 
more than 40% considerably disturbs the transport of proteins and other blood cells. In 
flowing blood, the collisions between the blood cells induces a way of solute mixing, 
resulting in dispersion or effective diffusion coefficients which are two to three orders of 
magnitude greater than those due to Brownian motion and this mixing motion becomes 
the major mechanism for permitting cells and possibly certain larger proteins to interact 



















The use of synthetic materials for treatment of vascular disease is limited to larger 
diameter grafts due to the frequency of occlusion observed at diameters less than 5mm. It 
is recognized that the adverse events leading to the failure of vascular prostheses are 
related to maladaptive biological reactions at the blood-material and tissue-material 
interface. For example, many grafts occlude due to anastomotic restenosis, a condition 
caused by the maladaptive response to the implant and generated by the uncontrolled 
healing of the injured vessel. The ability of implanted materials to be compatible to the 
surrounding tissues and living cells is critical to the long-term patency of the implants. 
Among the approaches for improving the performance of the grafts, we postulate that 
biologically active membrane-mimetic assemblies, which are sufficiently robust for 
medical implant applications, can provide platforms for the presentation of biomolecular 
constructs that would exhibit antithrombogenic properties. In addition, such model 
materials may also assist in defining the extent to which the flow regime influences the 
catalytic efficiency of immobilized surface anticoagulants.  
In attempt to test the hypothesis that membrane-mimetic films containing biologically 
functional regulators of the coagulation pathway can limit surface induced thrombus 
formation, we designed a system to determine the antithrombogenic capacities of 
immobilized surface anticoagulants, thrombomodulin and heparin. In the process, an in 
vitro equivalent of an in vivo vascular injury site was created that could be investigated 
under physiologic arterial and venous flow conditions. Test surfaces were fabricated and 
 174
characterized on planar supporting substrates including borosilicate glass and silicon 
wafers and flow studies were conducted using a parallel plate flow chamber. 
The first step was to fabricate and characterize TM-containing membrane-mimetic 
surface. Fabrication of the construct involved layer-by-layer assembly of a 
polyelectrolyte multilayer containing poly-L-lysine and alginate, followed by coating of a 
terpolymer that consists (3-acryloyl-3-oxapropyl-3-(N,N-dioctadecyl-carbamoyl)-
propionate))6:(2-hydroxyethyl acrylate)3:sodium styrene sulfonate1 (AOD6:HEA3:SS1) to 
present a hydrophobic alkylated basal layer on top of which TM-reconstituted acrylate 
phosphatidylcholine (AcPC, 1-palmitoyl-2-[12-(acryloyloxy) dodeca-noyl]-sn-glycero-3-
phosphocholine) lipid vesicles (600 nm diameter) were fused to form lipid monolayer and 
subsequently stabilized by in situ polymerization. In the absence of surface TM, the 
membrane-mimetic surface constructs have been characterized by water contact angle 
measurement, infrared spectroscopy, scanning electronic microscopy, and ellipsometry. 
Films containing surface bound TM were characterized in a similar manner. In addition, 
surface TM density and catalytic activity under flow conditions were defined. TM surface 
content was quantified using 125I-labeled TM and was found to be linearly correlated to 
the TM concentration in the lipid vesicle mixture used for membrane fusion: 6 to 300 nM 
of TM within 1.2 mM lipid vesicles lead to surface concentrations ranging between 66 to 
1350 fmole/cm2. 
  Flow studies demonstrated that TM induced activation of protein C reached a 
maximum at surface TM concentrations greater than 800 fmole per cm2, indicating there 
is transport limitation on  surface enzymatic reaction. The persistence of TM activity was 
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investigated by incubating test films in human plasma at 37oC with periodic testing up to 
three months. Durable surface bound TM activity was observed. 
In addition to incorporating TM into our model platform, we designed to 
accommodate a heparin containing membrane-mimetic system. In order to fabricate the 
heparinized surface, heparin was chemically modified by conjugation of biotin and 
anchored on a streptavidin functionalized membrane-mimetic surface which was 
composed of AcPC and biotin-conjugated AcPE (1-palmitoyl-2-(12-
(acryloyloxy)dodecanoyl)-sn-glycero-3-phosphoethanolamine-biotin). Surface 
concentration of heparin was characterized using 3H-labeled heparin and found to be 
directly related to the surface density of biotin-conjugated AcPE. Surface heparin activity 
was investigated by perfusion of a solution containing equal molar of thrombin and 
antithrombin at 30 nM. This study revealed that the steady state rate of thrombin 
inactivation could not be significantly increased beyond that obtained for surface 
composed of 4.4 pmole of heparin per cm2, corresponding to 10 mol% of biotin-
containing membrane-mimetic thin film.  
In order to determine the relative capacity of surface bound TM and heparin to inhibit 
thrombin, we fabricated tissue factor-coated surfaces which triggered thrombin 
generation as a mimic of vascular injury. Briefly, TF was reconstituted into lipid vesicles 
(100 nm diameter) composed of 79 mole% egg PC (L-α-Phosphatidylcholine), 20 mole% 
brain PS (L-α-Phosphatidylserine), and 1 mole% biotin-PE ( 1,2-Dioleoyl-sn-Glycero-3-
Phosphoethanolamine-N-Cap Biotinyl) which were tethered on a streptavidin 
functionalized membrane-mimetic surface. Prior studies had confirmed that films 
composed of 10 mol% of biotin-conjugated AcPE and 90 mol% of AcPC displayed 
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optimal activity of both surface TM and heparin in terms of protein C activation and 
thrombin inactivation, respectively. 
In a similar fashion to heparinized and TM-coated surfaces, surface concentration of 
TF was determined using 125I-labeled TF and was found linearly correlated to relipidated 
TF concentration: 6 to 120 nM TF/lipid vesicles (molar ratio of TF to liposome ranges 
from 1:8000 to 1: 160000) yielding in 9 to 90 fmole/cm2 of TF surface density after 4 
weeks of stability testing under static conditions in PBS at 37 °C. Surface bound TF was 
active due to its catalytic ability to initiate generation of factor Xa and thrombin under 
flow conditions. Both rates of factor Xa and thrombin generation were saturated at 
surface concentrations of TF equal to or greater than 50 fmole per cm2. Similar responses 
of factor Xa and thrombin indicate that the thrombin generation is possibly dependent 
upon activation of factor X. 
The final phase of our investigations focused on the antithrombogenic capacities of 
TM and heparin bound on surface alone and in a combined system. TF, TM and/or 
heparin (the implanted graft) were patterned on test surfaces with TF positioned at the 
upstream of flow. The TF–coated area was created using a dip-coating process. In the 
presence of TM, peak thrombin generation was reduced by 16% with an overall 50% 
reduction in steady state thrombin production.  
A profound effect on thrombin inactivation was observed at physiologic 
concentrations of antithrombin. Without surface bound TM, peak thrombin 
concentrations were reduced by more than 30% and steady state levels decreased by more 
than 65%.  With the addition of TM, peak values were reduced by more than 50% and 
steady state levels by 80%.  Notably, thrombin inactivation was not significantly 
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influenced in the presence of surface heparin whether alone or in combination with TM. 
Nevertheless, thrombin production from TF/TM-heparin surface was the lowest among 
all test systems. Peak thrombin concentrations were reduced by 55% and steady state 
levels by 85%. 
In addition to incorporating TM and heparin, the current membrane-mimetic system 
provides a platform that can potentially accommodate more biologically functional 
substances that improve antithrombogenicity of the surface. We believe that such surface 
modification strategies will help in the design of more robust materials for improving the 
















CHAPTER 9   
 
 




In this thesis, we addressed the issues dealing with biomaterials, biomolecular 
engineering, surface enzymatic reaction, and transport phenomena. Following the present 
work, we are looking forward to not only improving the performance of the model 
surface construct but also expanding its applicability to medical implants. 
In the process of fabricating membrane-mimetic assemblies, formation of lipid 
monolayer, via vesicle fusion and in situ photopolymerization, on alkylated 
polyelectrolyte multilayer can retain the stability for at least short-term period.   
Since most of the data presented in this thesis are results of empirical studies, we are 
looking forward to doing mathematical modeling based on the experimental conditions to 
not only validate the experimental results, but also simulating what can not be 
experimentally achieved, especially for detailed spatial and temporal dynamics of 
reactants and products involved in surface reactions under flow conditions. According to 
the flow studies on surface catalytic activity (immobilized TM, heparin, and TF), 
experimental results only revealed the product responses at the outlet of the flow reactor, 
including protein C activation, thrombin inactivation, and thrombin generation, 
representing the product concentrations in the bulk phase. Under flow conditions, surface 
enzymatic reaction which is generally assumed to occur only within the boundary layer 
of the reactive surface involves not only intrinsic kinetics between substrates and surface 
enzyme, but also transport of substrates to the catalytic sites and products removed from 
the surface. Mathematical simulation can assist to analyze dynamic behavior of reactants 
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and products within the boundary layer, which is extremely difficult to characterize 
experimentally.   
As for TF-coated surface, we were focusing on making a TF functionalized system so 
that it can at least exhibit enzymatic activity. However, relipidated TF tethered on the 
membrane-mimetic assemblies needs to be further characterized, including size of lipid 
vesicles, surface structure, and stability of TF activity. Although the similar construct has 
been reported  (148) that biotinylated lipid vesicles can bind intact on streptavidin 
functionalized surface, it is not yet clear that this technique can be applied to all lipids. 
We suggest using laser light scattering to determine vesicle size, ellipsometry to 
determine the thickness of anchored lipid vesicle layer, atomic force microscopy to 
examine the surface structure, and extensive flow studies on stability of TF activity. 
Through these scrutinized characterization process, we can have more consolidate 
understanding of such a system and further utilized for more applications such as 
incorporating more functionalized macromolecules for desired performances. 
 Ultimately, we are looking forward to successfully apply the current system to 
commercially available synthetic vascular grafts such as expanded poly-
tetrafluoroethylene (ePTFE). Investigating graft performance using ex vivo models such 
as venous-arterial shunt studies or in vivo models by graft implantation for studies of 

















Activated Protein C 
 
A series of concentrations (ranging from 5 nM to 100nM) of activated protein C 
were prepared by diluting 1µM of APC in Tris-BSA (20mM Tris-HCl + 100 mM 
NaCl + 0.1 wt% BSA, pH 7.5) . The assay was conducted by adding 100 µL of each 
diluted APC to 200µL of Tris-BSA containing Spectrozyme PCa substrate (0.2 mM, 
final concentration) and monitoring absorbance change over time continuously at 405 
nm for approximately 5 minutes. The standard curve was generated by plotting [APC] 






































Figure A1  Standard curve of activated protein C. A linear relationship between [APC] 
(nM) and rate of absorbance change (dA/min) was observed: [APC] (nM) = 




A series of concentrations (ranging from 2 nM ~ 100nM) of Factor Xa were 
prepared by diluting 1µM of factor Xa in HBSA (10 mM Hepes buffer + 140 mM 
NaCl + 0.1 wt% BSA, pH 7.5) . The assay was conducted by adding 16 µL of each 
diluted factor Xa to 384 µL of HBSA containing S-2222 substrate (0.2 mM, final 
concentration) and monitoring absorbance change over time continuously at 405 nm 
for approximately 5 minutes. The standard curve was generated by plotting [Xa] (nM) 















































Figure A2  Standard curve of factor Xa. A linear relationship between [Xa] (nM) and rate 





A series of concentrations (ranging from 2 nM to 500nM) of thrombin were 
prepared by diluting 5 µM of thrombin in Hepes buffer/BSA (20 mM Hepes + 150 
mM NaCl, pH 7.4). The assay was conducted by adding 16 µL of each diluted factor 
Xa to 384 µL of Hepes buffer/BSA containing Spectrozyme TH substrate (0.2 mM, 
final concentration) and monitoring absorbance change over time continuously at 405 
nm for approximately 2 minutes. The standard curve was generated by plotting 















































Figure A3  Standard curve of thrombin. A linear relationship between [thrombin] (nM) 
and rate of absorbance change (dA/min) was observed: [thrombin] (nM) = 









In order develop an expression to compute steady state rate of reaction for diffusion 






























yvvz   (2) 
 
The appropriate boundary conditions at the surface and in the bulk fluid are: 
 
B.C. 1: C = C0      at   z = 0 (at entrance) for all y (3)  
 
B.C. 2: C = 0        at y = ±B for all z (4) 
                                B.C. 3: C = C0 everywhere but at y ≈ ±B   (5) 
 
By introducing a coordinate system (x) emanating from the wall and for half the 
symmetrical reactor, we have: 
     x + y = B 




























































subject to the boundary conditions 
 
At the entrance: C = C0      at   z = 0, x > 0  (3)  
 
       At the wall: C = 0      at x = 0 for all z (4) 
For very thin layers near the wall, the bulk flow appears far away, so we write for short 
penetration: 
                                                           C  C0   at x  ∞, z > 0   (5) 
 
The symmetry of the boundary conditions suggests a combination of variable approach. 
The similarity exists in the governing equation: 
3
max2~ xvzDB  


















































































































































































xv ηηη  
 
   0)('3)(" 2 =+ ηηη ff
 
with boundary conditions: 
 
    f = C0      at η = ∞ (z = 0 or x  ∞) 
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a , b = 0 
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Finally, average rate of reaction is expressed as a function of shear rate, length of flow 






























































The steady state concentration of product, [P]diff, at the outlet of the parallel plate reactor 






































Table C  APC generation (nM) as a function of perfusion time at a series of TM surface 
concentrations (fmole/cm2). Each data point represents the mean ± standard 
error (n = 5). 
 
50 sec-1 TM surface concentration (fmole/cm^2) 
Time (min) 1351 764 488 344 162 82 66 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
5 4.50 ± 0.16 3.14 ± 0.16 7.75 ± 0.63 7.98 ± 1.00 2.24 ± 0.41 2.66 ± 0.32 1.51 ± 0.12 
15 17.99 ± 1.23 12.06 ± 1.01 17.32 ± 0.39 15.66 ± 0.90 16.66 ± 1.25 6.45 ± 0.59 5.06 ± 0.49 
25 28.60 ± 1.31 22.19 ±0.80 23.43 ± 0.63 21.61 ± 0.87 22.78 ± 0.38 16.75 ± 0.71 12.34 ± 0.42 
35 31.34 ± 1.15 28.72 ± 0.90 27.41 ± 0.59 24.44 ± 0.77 23.00 ± 0.77 18.65 ± 1.41 14.15 ± 1.32 
45 34.64 ± 1.18 32.35 ± 1.21 30.25 ± 0.93 26.07 ± 1.58 23.60 ± 0.93 19.41 ± 0.81 13.23 ± 1.39 
55 33.44 ± 1.34 32.60 ± 0.89 30.21 ± 0.94 27.58 ± 0.79 21.56 ± 0.86 18.06 ± 0.89 12.99 ± 0.56 
65 33.38 ± 1.22 32.00 ± 1.01 30.17 ± 0.85 27.55 ± 0.62 22.49 ± 0.88 18.82 ± 0.65 13.32 ± 1.18 
75 34.28 ± 1.25 31.57 ± 0.82 30.56 ± 1.13 26.77 ± 1.70 22.28 ± 0.94 19.07 ± 1.52 13.12 ± 1.19 
85 33.81 ± 1.28 30.92 ± 0.98 31.00 ± 0.66 27.36 ± 1.40 22.72 ± 0.60 18.63 ± 0.89 13.64 ± 1.25 
95 34.70 ± 1.12 31.87 ± 0.94 29.78 ± 1.04 26.78 ± 1.45 22.59 ± 1.01 18.14 ± 1.40 12.55 ± 1.20 
500 sec-1 TM surface concentration (fmole/cm^2) 
Time (min) 1351 764 488 344 162 82 66 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
1 2.72  ± 0.30 4.29 ± 0.51 3.14 ± 0.50 2.38 ± 0.50 1.82 ± 0.46 1.24 ± 0.31 1.28 ± 0.25 
3 8.15 ± 1.03 8.16 ± 1.51 9.70 ± 0.72 8.01 ± 0.76 6.50 ± 0.63 3.88 ± 0.65 3.32 ± 0.35 
5 12.62 ± 1.75 11.49 ± 1.12 12.19 ± 0.97 10.46 ± 0.64 7.06 ± 0.84 5.22 ± 0.58 3.98 ± 0.51 
7 12.71 ± 2.06 12.45 ± 1.22 11.66 ± 1.43 9.97 ± 0.84 7.15 ± 0.83 4.85 ± 0.56 3.64 ± 0.79 
9 12.85 ± 1.85 12.09 ± 1.45 12.91 ± 1.04 9.72 ± 1.12 7.21 ± 0.59 4.76 ± 0.53 3.94 ± 0.32 
11 11.74 ± 2.01 11.78 ± 1.42 13.05 ± 1.29 9.74 ± 1.35 6.93 ± 0.44 5.14 ± 0.29 3.71 ± 0.56 
13 12.21 ± 2.05 12.73 ± 1.49 12.49 ± 1.66 10.89 ± 0.73 6.43 ± 0.44 4.92 ± 0.59 3.75 ± 0.53 
15 11.99 ± 2.13 11.87 ± 1.10 10.88 ± 1.15 9.65 ± 0.95 7.18 ± 0.77 4.99 ± 0.30 3.61 ± 0.83 
17 12.39 ± 1.90 12.04 ± 1.35 12.43 ± 1.16 10.28 ± 0.65 7.40 ± 0.41 4.72 ± 0.50 3.68 ± 0.23 



















To purify the compound, a commercial kit called ImmunoPure® Immobilized 
Monomeric Avidin (Pierce) was used. The principle of the kit is using immobilized 
polymeric forms of avidin with strong binding characteristics to biotinylated molecules. 
In brief, these high affinity biotin-binding sites are first blocked with a biotin-containing 
buffer. Biotin molecules are eluted from the monomers with a glycine solution revealing 
only the reversible binding sites. The biotinylated molecule of interest may then be 
applied to the support for purification and then eluted by ligand competition using a 
biotin-containing buffer. 
Materials: 
Monomeric Avidin Column containing 2 ml of settled gel (support: 4% beaded agarose 
supplied as a 50% slurry, i.e., 4 ml of 50% slurry is equivalent to 2 ml of settled gel) with 
binding capacity ≥1.2 mg biotinylated BSA/ml settled gel. BupH™ Phosphate Buffered 
Saline (PBS) (0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2 when reconstituted with 
500 ml of sterilized deionized water). Biotin Blocking and Elution Buffer (200mL 2 mM 




1. Equilibrated kit components to room temperature. 
2. Washed column with 8 ml PBS, followed by adding 6 ml Biotin Blocking and Elution 
Buffer to block any non-reversible biotin binding sites. 
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3. Removed biotin from the reversible binding sites by adding 12 ml Regeneration 
Buffer, followed by washing column with 8 ml PBS. 
4. Placed at least twelve 12 x 75mm test tubes in a rack. Place the Monomeric Avidin 
Column in a tube and add 2mL biotinylated heparin (2mg/mL) by applying solution 
to the center of the disc. 
5. When the entire sample has passed through the disc, 0.25 ml PBS was added to force 
sample completely into the gel bed.  
6. Allowed the biotinylated heparin to incubate (cap the bottom and then the top of the 
column) in the column for 30min.  
7. Placed column in a new tube and added 2.0 ml of PBS. Repeated PBS additions until 
a total of six 2.0 ml fractions have been collected. Samples were monitored by 
measuring the absorbance of the fractions at 280 nm (use PBS to obtain a baseline 
value). When absorbance value returns to baseline, non-bound protein has been 
removed (Figure D1 A). 
8. Biotin Blocking and Elution Buffer was added to elute the bound biotinylated 
molecule, and collected at least six 2.0 ml fractions. Measure the absorbance of each 
fraction at 280 nm (Figure D1 B) and reserve the fractions of interest for further 
analysis, including dialysis and HABA assay to assure optimal binding capacity. 
9. Regenerated the column by washing two times with 4 ml Regeneration Buffer, 
followed by washing column with 5 ml of PBS and stored the column at 4oC for 
future use.  
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According to step 7 & 8, results from monitoring the desired eluted compound from 





































































PBS w ash f# 1
PBS w ash f# 2
PBS w ash f# 3
PBS w ash f# 4
PBS w ash f# 5




















biotin block w ash f# 1
biotin block w ash f# 2
biotin block w ash f# 3
biotin block w ash f# 4
biotin block w ash f# 5
biotin block w ash f# 6
Figure D1 The UV-VIS scanning results demonstrate (A) the complete 
heparin in avidin column after washing with PBS (step 7) an
the bound compound after washing with Biotin Blocking and
(step 8). For PBS washing, non-bound material was complete
the third fraction collection (f#3). As for recovery of the biot
the avidin column, scanning curves almost overlap with that 
blocking buffer after collecting fraction #5 (f#5), indicating t
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Table E1  Factor Xa generation as a function of perfusion time at a series of TF surface 
concentrations (fmole/cm2). Each data point represents the mean ± standard 
error (n = 5). 
50 sec-1 [TF] (nM) reconstituted within lipid vesicles 
Time (min) 6 30 60 90 120 
0 0.00 0.00 0.00 0.00 0.00 
2 2.04 ± 0.09 4.19 ± 0.36 5.11 ± 0.42 4.58 ± 0.63 6.29 ± 0.36 
4 3.92 ± 0.14 6.86 ± 1.07 13.91 ± 0.06 16.85 ± 0.86 21.44 ± 3.39
6 8.89 ± 0.66 24.08 ± 1.34 28.00 ± 2.39 38.08 ± 2.72 41.73 ± 3.88
8 15.59 ± 1.04 35.99 ± 1.67 45.60 ± 0.97 51.14 ± 0.65 50.77 ± 2.76
10 21.26 ± 1.08 43.14 ± 1.96 49.19 ± 1.78 50.07 ± 2.03 49.84 ± 1.18
12 24.10 ± 1.87 43.59 ± 2.61 48.51 ± 1.19 53.41 ± 2.37 54.87 ± 4.70
14 25.63 ± 2.04 43.85 ± 0.80 51.88 ± 1.64 51.52 ± 0.73 45.96 ± 1.21
16 25.45 ± 2.39 42.06 ± 1.89 53.69 ± 2.55 50.55 ± 3.60 53.80 ± 2.68
18 24.26 ± 1.56 42.00 ± 1.65 46.53 ± 3.60 53.99 ± 0.97 51.78 ± 4.19
20 23.28 ± 1.64 40.92 ± 2.30 51.80 ± 2.68 53.82 ± 2.68 44.63 ± 1.20
22 23.08 ± 1.43 44.98 ± 1.58 53.12 ± 2.12 48.12 ± 1.98 52.76 ± 3.17
24 24.99 ± 1.72 42.21 ± 1.58 53.12 ± 2.12 49.78 ± 3.23 49.35 ± 2.01
500 sec-1 [TF] (nM) reconstituted within lipid vesicles 
Time (min) 6 30 60 90 120 
0 0.00 0.00 0.00 0.00 0.00 
1 0.59 ± 0.04 1.27 ± 0.19 1.78 ± 0.04 1.71 ± 0.14 2.21 ± 0.17 
2 1.01 ± 0.07 2.41 ± 0.10 3.76 ± 0.13 4.35 ± 0.35 4.63 ± 0.78 
3 1.38 ± 0.21 4.17 ± 0.63 5.98 ± 0.71 7.87 ± 0.69 8.63 ± 0.92 
4 2.44 ± 0.28 7.61 ± 0.30 9.54 ± 0.35 10.49 ± 1.07 11.97 ± 0.82
5 3.12 ± 0.51 8.25 ± 0.42 10.04 ± 0.50 11.86 ± 0.73 10.71 ± 0.51
6 4.24 ± 0.31 9.35 ± 0.53 11.31 ± 1.25 10.66 ± 1.07 9.51 ± 0.78 
7 4.82 ± 0.25 9.46 ± 1.18 11.39 ± 1.42 12.50 ± 0.75 11.35 ± 0.52
8 4.78 ± 0.35 9.18 ± 0.64 11.11 ± 1.25 11.53 ± 0.71 10.95 ± 0.35
9 5.54 ± 0.40 8.42 ± 0.63 11.82 ± 0.54 9.83 ± 1.05 11.55 ± 0.33
10 4.88 ± 0.45 9.31 ± 1.13 11.20 ± 1.00 11.17 ± 0.35 10.59 ± 0.25
12 5.56 ± 0.52 8.77 ± 0.56 10.86 ± 0.72 11.69 ± 0.77 11.11 ± 0.40












 Table E2  Thrombin generation as a function of perfusion time at a series of TF surface 
concentrations (fmole/cm2). Each data point represents mean ± standard error 
(n = 5). 
 
50 sec-1 [TF] (nM) reconstituted within lipid vesicles 
Time (min) 6 30 60 90 120 
0 0.00 0.00 0.00 0.00 0.00 
2 17.40 ± 0.67 23.39 ± 1.57 25.00 ± 2.68 25.63 ± 2.72 28.56 ± 3.37 
4 20.64 ± 2.92 31.16 ± 3.38 40.20 ± 2.67 20.11 ± 1.87 50.00 ± 4.32 
6 48.89 ± 4.57 155.93 ± 12.98 194.36 ± 11.62 201.54 ± 10.19 224.52 ± 18.79
8 136.62 ± 8.25 241.13 ± 17.23 316.26 ± 18.85 280.02 ± 12.65 335.01 ± 19.61
10 195.69 ± 14.70 350.27 ± 31.79 400.53 ± 22.14 408.60 ± 13.16 383.15 ± 16.41
12 218.94 ± 18.85 375.17 ± 24.26 484.33 ± 15.81 440.40 ± 19.49 492.43 ± 25.30
14 256.57 ± 21.64 368.73 ± 27.43 443.73 ± 26.32 463.70 ± 25.18 478.30 ± 15.81
16 266.14 ± 18.57 415.42 ± 23.62 495.42 ± 28.46 480.42 ± 19.49 432.20 ± 18.97
18 209.28 ± 13.38 400.67 ± 35.16 470.67 ± 22.14 460.56 ± 15.81 505.29 ± 12.65
20 246.91 ± 16.54 372.49 ± 22.38 472.49 ± 22.14 444.91 ± 22.14 479.39 ± 25.77
22 269.58 ± 20.82 410.40 ± 26.23 490.40 ± 25.30 471.80 ± 26.44 448.40 ± 19.49
24 209.13 ± 15.40 396.62 ± 30.45 476.62 ± 22.14 495.20 ± 31.29 476.48 ± 18.06
500 sec-1  [TF] (nM) reconstituted within lipid vesicles 
Time (min) 6 30 60 90 120 
0 0.00 0.00 0.00 0.00 0.00 
1 11.71 ± 1.58 31.22 ± 2.52 54.44 ± 4.04 70.66 ± 3.81 78.72 ± 6.58 
2 29.67 ± 3.16 59.73 ± 6.05 89.21 ± 7.62 118.73 ± 9.09 133.34 ± 10.06
3 49.15 ± 4.52 110.32 ± 11.38 160.43 ± 12.56 172.80 ± 13.12 168.32 ± 12.58
4 55.03 ± 4.72 145.00 ± 13.63 177.28 ± 16.32 185.71 ± 16.62 201.92 ± 17.11
5 65.23 ± 6.34 153.25 ± 9.49 198.71 ± 13.87 195.49 ± 10.34 191.92 ± 20.44
6 65.36 ± 5.28 160.24 ± 12.38 195.90 ± 18.32 186.52 ± 18.01 205.84 ± 14.57
7 84.73 ± 8.92 154.44 ± 13.02 181.12 ± 19.49 197.83 ± 12.87 204.97 ± 11.88
8 59.53 ± 6.10 148.33 ± 10.54 197.78 ± 12.32 184.10 ± 13.03 188.92 ± 18.31
9 78.96 ± 6.56 148.88 ± 13.73 171.96 ±15.25 201.81 ± 22.16 185.71 ± 12.66
10 66.84 ± 5.87 159.42 ± 14.74 192.30 ± 18.84 181.88 ± 19.16 197.57 ± 14.16
12 71.33 ± 6.78 163.51 ± 17.08 182.50 ± 15.77 188.72 ± 13.21 193.97 ± 14.66























Table F1  Tissue factor surface density (fmole/cm2) as a function of TF concentration 
(nM)a within lipid vesicles (1mM of egg PC/brain PS/ biotin-PE, 79:20:1 
molar ratio). Stability of TF coated surface was assessed by incubating the 
sample with PBS at 37 °C over a 28-day period. The samples were transferred 
to fresh PBS at indicated time points and radioactivity measured in a gamma 
counter. Each data point represents mean ± standard deviation (n = 6). 
 
TF (nM)a Day1 Day 3 Day 7 Day 14 Day 28 
6 15.34 ± 5.95 11.71 ± 3.91 9.97 ± 4.29 9.21 ± 3.13 9.40 ± 4.64 
12 28.70 ± 8.17 20.91 ± 7.86 19.26 ± 8.32 16.04 ± 6.54 15.56 ± 7.63 
30 54.22 ± 7.81 38.42 ± 6.90 31.37 ± 6.87 26.19 ± 5.55 27.28 ± 6.06 
60 108.62 ± 13.72 83.97 ± 14.17 66.08 ± 12.48 57.39 ± 10.23 51.16 ± 9.86 
90 150.75 ± 13.02 115.18 ± 8.33 86.07 ± 10.24 73.29 ± 5.21 69.88 ± 8.65 




























Table G1 Thrombin generation (nM, mean ± standard error, n = 5) vs. perfusion time for 
a variety of composite surfaces including TF, TF/TM, TF/heparin, and 
TF/TM-heparin systems. 
 
50 sec-1  
Time (min) TF TF/TM TF+ ATIII TF/TM + ATIII TF/Heparin TF/TM-Heparin 
0 0 0 0 0 0 0 
0.5 1.23 ± 0.14 0.73 ± 0.06 1.12 ± 0.15 1.05 ± 0.10 0.93 ± 0.07 0.82 ± 0.08 
1 1.81± 0.14 1.67 ± 0.19 1.84 ± 0.21 2.36 ± 0.19 1.86 ± 0.24 1.92 0.21 
2 6.32 ± 0.33 4.48 ± 0.33 4.96 ± 0.29 5.80 ± 0.47 6.78 ± 0.37 3.68 ± 0.34 
4 18.66 ± 1.44 21.80 ± 0.82 17.28 ± 0.73 13.49 ± 0.55 15.52 ± 0.35 10.64 ± 0.79 
6 29.68 ± 1.06 24.55 ± 0.84 19.26 ± 0.88 13.86 ± 0.72 16.38 ± 0.56 12.94 ± 0.38 
8 31.25 ± 2.17 24.48 ± 0.82 18.61 ± 0.47 12.93 ± 0.57 15.04 ± 53 10.33 ± 0.47 
10 31.83 ± 1.51 21.72 ± 1.00 16.35 ± 0.55 11.74 ± 0.48 13.25 ± 0.44 8.71 ± 0.40 
15 29.97 ± 2.42 17.66 ± 0.86 14.58 ± 0.59 8.67 ± 0.52 11.36 ± 0.63 6.38 ± 0.52 
20 29.80 ± 2.15 15.24 ± 0.85 12.31 ± 0.69 6.52 ± 0.47 9.23 ± 0.55 4.69 ± 0.32 
25 30.76 ± 2.15 14.35 ± 1.11 10.73 ± 0.67 5.05 ± 0.37 7.39 ± 0.52 3.30 ± 0.39 
30 32.00 ± 2.04 13.88 ± 0.87 8.49 ± 0.69 4.50 ± 0.36 6.37 ± 0.55 2.73 ± 0.26 
35 30.11 ± 2.51 13.58 ± 1.13 8.16 ± 0.37 3.58 ± 0.11 6.30 ± 0.40 2.38 ± 0.18 
 
500 sec-1  
Time (min) TF TF/TM TF+ ATIII TF/TM + ATIII TF/Heparin TF/TM-Heparin 
0 0 0 0 0 0 0 
0.5 1.16 ± 0.12 1.10 ± 0.11 1.36 ± 0.18 1.25 ± 0.18 0.86 ± 0.10 0.99 ± 0.09 
1.5 8.16 ± 0.31 8.31 ± 0.31 7.13 ± 0.36 5.67 ± 0.41 6.25 ± 0.31 4.32 ± 0.26 
2.5 12.73 ± 0.58 10.96 ± 0.44 9.30 ± 0.46 6.59 ± 0.35 8.12 ± 0.45 5.74 ± 0.28 
3.5 13.22 ± 1.05 10.59 ± 0.27 8.58 ± 0.50 5.74 ± 0.32 7.38 ± 0.34 5.08 ± 0.44 
4.5 13.70 ± 0.64 10.98 ± 0.60 8.34 ± 0.50 5.55 ± 0.18 7.13 ± 0.33 4.72 ± 0.45 
6 13.45 ± 0.56 10.49 ± 60 7.43 ± 0.48 5.24 ± 0.17 6.09 ± 0.33 4.18 ± 0.20 
8 13.19 ± 1.12 8.34 ± 0.63 6.60 ± 0.63 4.33 ± 0.30 5.34 ± 0.26 3.68 ± 0.22 
10 13.60 ± 1.10 7.82 ± 0.56 5.66 ± 0.32 3.64 ± 0.32 4.79 ± 0.28 2.74 ± 0.25 
12 12.41 ± 1.22 8.04 ± 0.28 4.92 ± 0.23 3.20 ± 0.40 4.37 ± 0.41 2.33 ± 0.23 
14 13.48 ± 0.53 7.59 ± 0.34 4.76 ± 0.36 2.73 ± 0.21 3.72 ± 041 1.99 ± 0.25 
16 13.14 ± 0.44 7.09 ± 0.44 4.37 ± 0.47 2.59 ± 0.21 3.21 ± 0.19 1.76 ± 0.09 
 













Table G2 Rate of thrombin generation (pmole/min/cm2, mean ± standard error, n = 5) 
vs. perfusion time for a variety of composite surfaces including TF, TF/TM, 
TF/heparin, and TF/TM-heparin systems. 
 
50 sec-1  
Time (min) TF TF/TM TF+ ATIII TF/TM + ATIII TF/Heparin TF/TM-Heparin 
0 0 0 0 0 0 0 
0.5 0.110 ± 0.013 0.065 ± 0.006 0.100 ± 0.013 0.094 ± 0.009 0.084 ± 0.007 0.074 ± 0.007 
1 0.162 ± 0.013 0.150 ± 0.017 0.165 ± 0.019 0.212 ± 0.017 0.166 ± 0.022 0.173 ± 0.019 
2 0.566 ± 0.029 0.401 ± 0.030 0.445 ± 0.026 0.520 ± 0.042 0.607 ± 0.033 0.330 ± 0.030 
4 1.672 ± 0.130 1.953 ± 0.074 1.548 ± 0.066 1.209 ± 0.050 1.391 ± 0.031 0.953 ± 0.071 
6 2.659 ± 0.095 2.199 ± 0.075 1.774 ± 0.079 1.229 ± 0.065 1.454 ± 0.050 1.099 ± 0.034 
8 2.800 ± 0.195 2.193 ± 0.074 1.667 ± 0.042 1.159 ± 0.051 1.348 ± 0.047 0.925 ± 0.042 
10 2.851 ± 0.135 1.946 ± 0.090 1.464 ± 0.050 1.052 ± 0.043 1.187 ± 0.039 0.781 ± 0.036 
15 2.685 ± 0.217 1.582 ± 0.077 1.306 ± 0.053 0.777 ± 0.047 1.018 ± 0.056 0.571 ± 0.047 
20 2.670 ± 0.193 1.365 ± 0.077 1.103 ± 0.062 0.584 ± 0.043 0.827 ± 0.049 0.420 ± 0.029 
25 2.755 ± 0.190 1.286 ± 0.099 0.962 ± 0.060 0.453 ± 0.033 0.662 ± 0.047 0.295 ± 0.035 
30 2.867 ± 0.183 1.243 ± 0.078 0.850 ± 0.062 0.403 ± 0.033 0.571 ± 0.049 0.245 ± 0.023 
35 2.697 ± 0.225 1.216 ± 0.101 0.731 ± 0.033 0.231 ± 0.010 0.475 ± 0.036 0.213 ± 0.016 
 
500 sec-1  
Time (min) TF TF/TM TF+ ATIII TF/TM + ATIII TF/Heparin TF/TM-Heparin 
0 0 0 0 0 0 0 
0.5 1.037 ± 0.103 0.989 ± 0.101 1.220 ± 0.166 1.119 ± 0.165 0.773 ± 0.091 0.887 ± 0.080 
1.5 7.308 ± 0.282 7.442 ± 0.275 6.387 ± 0.321 5.077 ± 0.368 5.600 ± 0.276 3.867 ± 0.236 
2.5 11.408 ± 0.515 9.817 ± 0.392 8.261 ± 0.411 5.751 ± 0.313 7.198 ± 0.402 5.096 ± 0.249 
3.5 11.847 ± 0.938 9.483 ± 0.240 7.683 ± 0.446 5.146 ± 0.287 6.611 ± 0.307 4.554 ± 0.390 
4.5 12.277 ± 0.573 9.840 ± 0.537 7.469 ± 0.445 4.968 ± 0.162 6.391 ± 0.265 4.225 ± 0.401 
6 12.053 ± 0.501 9.400 ± 0.540 6.656 ± 0.431 4.691 ± 0.152 5.460 ± 0.292 3.744 ± 0.181 
8 11.814 ± 1.004 7.475 ± 0.562 5.914 ± 1.271 3.875 ± 0.266 4.780 ± 0.237 3.301 ± 0.198 
10 12.180 ± 0.982 7.008 ± 0.504 5.072 ± 0.568 3.260 ± 0.288 4.292 ± 0.250 2.454 ± 0.222 
12 11.117 ± 1.096 7.203 ± 0.254 4.404 ± 0.290 2.865 ± 0.355 3.911 ± 0.369 2.084 ± 0.206 
14 12.072 ± 0.478 6.798 ± 0.302 4.268 ± 0.320 2.448 ± 0.184 3.329 ± 0.365 1.786 ± 0.224 
16 11.770 ± 0.395 6.349 ± 0.398 3.918 ± 0.418 2.319 ± 0.186 2.872 ± 0.173 1.576 ± 0.085 
 











F Test for Equality of [T]max and [T]ss means among TF+AT, TF/TM+AT, 




It is customary to begin the preliminary analysis of whether all the mean values of 
[T]max and [T]ss among the test systems containing ATIII are equal before pairwise 
comparison. The hypotheses we consider are” 
H0: all mean values are equal 
Ha: not all mean values are equal 
The test statistic is F test based on analysis of variance (ANOVA). When F is larger than 
its distributed form, F (1- α; r -1, nT – r), we conclude Ha. Since we have four systems, 
there are four mean values (n = 5). Therefore, r and nT are equal to 4 and 20, respectively. 
For 95 percentile (α = 0.05) of F distribution, F (0.95; 3, 16) is less than F (0.95; 3, 15), 
which is equal to 3.29. Mean values of [T]max and [T]ss at shear rates of 50 sec-1 and 500 
sec-1 were statistically analyzed using ANOVA model and the results were computed by 
MINITAB (Release 13.1). All F values are much larger than F (0.95; 3, 16), so we 
conclude Ha.  Results of ANOVA computed by MINTAB are shown below: 
[T]max at 50 sec-1
Analysis of Variance 
Source     DF        SS        MS        F        P 
Factor      3    120.58     40.19    26.28    0.000 
Error      16     24.47      1.53 
Total      19    145.05 
                                   Individual 95% CIs For Mean 
                                   Based on Pooled StDev 
Level       N      Mean     StDev  ---+---------+---------+---------+--- 
TF+AT       5    19.263     1.727                           (----*----)  
TF/Heparin  5    16.380     0.916                (----*---)  
TF/TM+AT    5    13.860     1.263      (---*----)  
TF/TM-Hep   5    12.942     0.837  (----*---)  
                                   ---+---------+---------+---------+--- 






[T]ss at 50 sec-1 
Analysis of Variance 
Source     DF        SS        MS        F        P 
Factor      3    100.04     33.35    32.70    0.000 
Error      16     16.32      1.02 
Total      19    116.36 
                                   Individual 95% CIs For Mean 
                                   Based on Pooled StDev 
Level       N      Mean     StDev  ----+---------+---------+---------+-- 
TF+AT_1     5     8.457     0.728                          (---*---)  
TF/Heparin  5     6.291     1.073                 (---*---)  
TF/TM+AT    5     3.882     1.028        (---*--)  
TF/TM-Hep   5     2.645     1.159   (---*--)  
                                   ----+---------+---------+---------+-- 




[T]max at 500 sec-1
Analysis of Variance 
Source     DF        SS        MS     F        P     
Factor      3    37.635    12.545    22.58    0.000 
Error      16     8.888     0.555 
Total      19    46.523 
                                   Individual 95% CIs For Mean 
                                   Based on Pooled StDev 
Level       N      Mean     StDev  -------+---------+---------+--------- 
TF+AT_2     5     9.295     0.979                          (----*----)  
TF/Heparin  5     8.117     0.888                  (----*----)  
TF/TM+AT    5     6.588     0.634        (----*----)  
TF/TM/Hep   5     5.736     0.269   (---*----)  
                                   -------+---------+---------+--------- 





[T]ss at 500 sec-1 
Analysis of Variance 
Source     DF        SS        MS        F        P 
Factor      3    19.142     6.381    15.29    0.000 
Error      16     6.678     0.417 
Total      19    25.820 
                                   Individual 95% CIs For Mean 
                                   Based on Pooled StDev 
Level       N      Mean     StDev  ----------+---------+---------+------ 
TF+AT_3     5    4.5876    0.9365                         (----*----)  
TF/Heparin  5    3.3558    0.5444               (----*----)  
TF/TM+AT    5    2.6958    0.4607         (----*-----)  
TF/TM-Hep   5    1.9198    0.5328   (----*----)  
                                   ----------+---------+---------+------ 













To test whether the presence of surface TM causes significant difference in 
transient peak values of thrombin generation between TF+AT and TF/TM+AT at shear 
rate of 50 sec-1, the hypotheses for comparison of [T]TF+AT max and [T]TF/TM+AT max are  
Ho : µ of [T]TF + AT max =  µ of [T]TF/TM+AT  max    (µ: mean value)
 
Ha : µ of [T]TF + AT max ≠  µ of [T]TF/TM+AT  max 
 
The pairwise confidence limits are expressed as  
 
D ± Ts{D} 
where 
 







   
 MSE: error mean square = SSE/(nT – r), r = 2 for two levels of factor 
 
(SSE: error sum of squares, nT = n1 + n2) 
 
T = q (1-α; r; nT –r)/(21/2)  
 
q: the required percentile of the studentized range distribution 
 
Data from each case has five replicates, meaning that n1 = n2 = 5. For confidence 
coefficient of 95 percent (1- α = 0.95), q (0.95; 2; 8) = 3.26, so we obtain T = 2.31. From 
the calculated MSE, which is 11.41, s{D}is equal to 2.14, leading to Ts{D} = 4.92. 
Therefore, the confidence limits are 5.40 ± 4.92 and confidence interval falls between 
0.48 and 10.32. Since confidence interval does not include 0, conclusion Ha is reached, 
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meaning the difference between the maximum thrombin generation from TF+AT and that 
from TF/TM+AT is statistically significant. 
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